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Amyloid proteins feature in neurodegenerative diseases and functionally throughout many organisms. 
Furthermore, due to their structural properties, amyloid proteins have been developed as materials in 
biotechnology. This raises the question of what makes disease-related amyloid proteins toxic. β- 
amyloid 1-42 (Aβ42) is a self-assembling protein that goes through many structural changes before 
forming the extracellular plaques characteristic of Alzheimer's disease. We have studied the 
conformational changes of the Aβ42 peptide over time by combining a range of biophysical 
approaches including circular dichroism, and Thioflavin T fluorescence with Transmission Electron 
Microscopy. Aβ42 assembly is compared to a novel, rationally-designed, assembly- resistant Aβ42 
peptide variant (vAβ42), as well as the two main Aβ42 controls, Aβ reversed (Aβ42-1) and Aβ 
scrambled (AβS). The vAβ42 differs in sequence by only two amino acids, however, does not self-
assemble or form β-sheet structures, unlike Aβ42-1 and AβS which both display a high propensity to 
form amyloid. All three variants of Aβ42 were non-toxic in primary hippocampal cultures, 
highlighting the importance of primary sequence in determining the toxic nature of an amyloid 
protein. Furthermore, the structure and toxicity of the naturally functional amyloid protein, 
GNNQQNY, and the designed functional amyloid peptide, FEFKFEFKK (F9), have also been 
characterised. These show immediate assembly into mature fibrils, do not form intermediary species 
and are not cytotoxic. Together, this data suggests the ability to form oligomers and the time spent in 
this conformation is a requirement of amyloid toxicity. To further investigate the link between size, 
conformation and toxicity, we compared the cytotoxicity and internalisation of oligomeric, fibrillar 
and sonicated fibres of Aβ42 in primary hippocampal neurons using immunolabelling and live cell 
imaging. As expected, the oligomeric Aβ42 was highly neurotoxic in hippocampal cultures, however 
fibrillar and sonicated fibrils did not have the same effect. Finally, the necessity of internalisation in 
mediating cytotoxicity was investigated and showed a certain threshold of intracellular accumulation 
must be met to induce cytotoxicity. Overall, our data suggests primary sequence, the resultant self-
assembly and intermediary species formed, and intracellular accumulation are vital in determining the 
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Chapter 1: Introduction 
1.1 Protein Folding, Chaperones and Proteostasis 
1.1.1 Folding and misfolding 
The way in which genetic information has been described to 'flow' from DNA to RNA and gene 
encoded proteins has been known for almost 60 years and is now referred to as the central dogma of 
molecular biology (Crick, 1970; Crick, 1958). It was already known by this time that amino acids 
condense into long polypeptide chains formed by covalent links whilst being translated on the 
ribosome. Crick proposed that subsequent folding is simply a result of the order of the amino acids. 
More in depth structural work by Pauling and Corey revealed the three-dimensional structure formed 
from the folding of these polypeptide chains was vital in the ability of the protein to perform its 
function. The three-dimensional shape is formed via α-helices and β-sheet secondary structures which 
are metastable (Pauling et al., 1951; Pauling & Corey, 1951). In 1961, Anfinsen and colleagues 
reported that bovine pancreatic ribonuclease could be reduced to an unfolded, randomly coiled 
polypeptide chain made up of eight cysteine residues, which under optimal conditions could 
completely reform the disulphide bonds. This led to the conclusion, supporting Crick, that information 
of the native secondary and tertiary structure is contained within the amino acid sequence itself 
(Anfinsen et al., 1961) and no external factors are required. Furthermore, Anfinsen suggested the idea 
that the final fold of the protein would be one that was the most thermodynamically stable. This is 
known as the thermodynamic hypothesis (Anfinsen, 1973).  
In 1968, Levinthal put forward that there were simply far too many structural options for a protein to 
search for within a short time frame and that the folding process must be directed. This has become 
known as Levinthal's paradox and although he stated it would be logical to suggest the protein would 
fold to a final state of lowest free energy and highest stability, this is not always the case. The paradox 
has since been addressed and it has been established that the folding process does not require a 
number of fixed steps of specific partially folded states, but instead an unpredictable search of the 





partially folded proteins, different residues within the primary amino acid sequence can interact. Of 
importance, due to native interactions between the amino acids being more stable than the non-native 
interactions, only a very small number of conformational possibilities are explored before the correct 
one is reached. This concept is known as the 'new view' of protein folding which also ventures into 
the idea of energy landscapes and funnels. These have been used to describe the free energy for the 
polypeptide backbone and its conformational properties; as the polypeptide gets closer to reaching its 
natively folded state, there are fewer conformational possibilities. Essentially, this means that there is 














Figure 1.1. Energy landscape of protein folding and misfolding. The left hand sided 
(dark blue) shows the conformations ‘funnelling’ to the native state via intramolecular 
bonds. The right hand side (light blue) shows the conformations leading to amyloid 





As proteins are in a dynamic equilibrium between unfolded and partially folded states, and there being 
more than one route to reaching the native state, the energy landscape has unsystematic fluctuations as 
various conformations are sampled.  As well as folding into their native states, proteins can also 
misfold. This misfolding results in the protein adopting a non-native state and can be due to a number 
of factors (e.g. pH, temperature). Figure 1.1 is a representation of the energy funnel of protein folding 
and misfolding.  
The aggregates formed during misfolding will be discussed in detail in the 'Amyloid proteins' 
sections. Briefly, proteins can misfold and adopt a specific structure termed amyloid. This is a highly 
ordered and stable structure made from polymeric assemblies of normally soluble proteins. Amyloid 
proteins form rod-like fibrils which display a characteristic cross-β structure pattern by X-ray fibre 
diffraction (Serpell, 2000). Intermediary species formed on the way to these fibrils include oligomers 
and protofibrils (Eliezer, 2012).  
It is thought that protein folding is a product of nucleation-condensation where a small number of 
essential residues form a 'folding nucleus' and the remainder of the structure can then condense 
around this (Nolting et al., 1997).  This has been the conclusion drawn from many studies exploring 
mechanisms by which proteins fold; there is first the collapse of the hydrophobic regions into the 
centre of the molecule which then leads to the formation of stable secondary structures. These regions 
can then guide subsequent folding leading to a three-dimensional structure stabilised by covalent 
bonds. The process of folding is rate limited by intermediates with a strong secondary structure but 
lack a defined tertiary structure. These motifs are formed during the later stages of folding where 
intermediates are in equilibrium with fully unfolded proteins and can only very slowly be converted to 
their native conformation (Gething & Sambrook, 1992).  
Although in vitro studies have provided fundamental understandings of protein folding, in vivo, the 
process of protein folding is more complicated. In vivo assays developed to monitor the formation of 
disulphide bonds in secretory proteins as a measure of protein folding, found that these disulphide 





that disulphide bond formation occurs at a faster rate than can be achieved in vitro and the folding is 
occurring in a more favourable condition (Freedman et al., 1984). As the folding of proteins in cells is 
a highly controlled process, it is not surprising that a number of molecular chaperones work together 
to ensure various stages of folding are completed successfully. These chaperones do not speed up the 
process of folding but rather increase the efficiency by which it occurs; for example by protecting 
exposed regions of partially folded proteins against inappropriate interactions in the highly crowded 
environment of the cell (Ellis, 2001). There are also folding enzymes present in the cell which 
catalyse the formation of disulphide bonds or proline cis-trans isomerisation (Braakman & Hebert, 
2013). Peptidylprolyl isomerases are important examples of catalysts increasing the rate of 
isomerisation involving proline residues (Dobson, 2004).   
1.1.2 Molecular chaperones and proteostasis 
Molecular chaperones have a key role in ensuring that proteins do not misfold; increased levels of 
these chaperones have been detected during cell stress (Jolly & Morimoto, 2000), highlighting their 
importance. A molecular chaperone is defined as any protein involved in interacting or stabilising 
another protein in order to reach its functionally active conformation (Hartl et al., 2011). Molecular 
chaperones are often referred to as stress proteins or heat shock proteins (HSP) which are categorised 
according to size (e.g. HSP70, HSP90 etc). These proteins facilitate protein folding via ATP- and 
cofactor-regulated binding release cycles (Hartl et al., 2011). There is also a 'quality control' 
mechanism involving a number of glycosylation and deglycosylation steps in the endoplasmic 
reticulum to prevent proteins from misfolding. Finally, folded and unfolded proteins can be 
recognised and targeted for degradation by the ubiquitin-proteasome system (UPS) pathway 
(Kaufman, 2002). These numerous pathways of ensuring correct protein folding maintains the optimal 
homeostasis within a cell and is known as proteostasis. This is shown in Figure 1.2 where chaperone 
pathways, UPS system and autophagy, an intracellular degradation system (Mizushima, 2007),  are 





Despite the process of protein folding in cells being highly controlled and efficient there is a 
possibility of proteins folding into a non-native state, giving rise to what are known as protein 
misfolding diseases.   
 
 
The pathological hallmarks of several of these diseases involves the deposition of insoluble amyloid 
fibrils which are formed from proteins that would under normal conditions be soluble.  It had been 
thought for many years that only a select few proteins with sequence specific motifs for the amyloid 
core could form these fibrils. However, it is now clear that the ability to form amyloid it is most likely 
a generic feature common to all polypeptide chains (Chiti et al., 1999) and under the right conditions, 
almost all proteins can form amyloid (Dobson, 2003). 
Figure 1.2. Proteostasis network. This is the integration of chaperones involved in the folding of 
new proteins and the remodelling of misfolded protein states and disaggregation. The UPS and 






As all amyloid fibrils share very similar morphology, despite having different precursor peptide or 
proteins, it is thought that the formation of amyloid fibrils is driven by the destabilisation of the native 
structure into a partially unfolded conformation. This may allow for interactions that would otherwise 
not be possible in the tightly packed tertiary structure of the protein. Intrinsically disordered proteins, 
which are natively unfolded (e.g. alpha-synuclein), are thought to fibrillise by first stabilising a 
partially folded conformation. It can therefore be argued that the structural transition of a natively 
folded protein into amyloid fibrils requires a partially folded conformation as a prerequisite (Uversky 
& Fink, 2004). As partially and unfolded proteins often exist in equilibrium with the native state 
under normal physiological condition, this could act as a pool of proteins that can facilitate the 
misfolding of proteins into amyloid (Soldi et al., 2005). As with proteins in their native state, there are 
many interactions that govern the formation of amyloid. These include hydrophobic, aromatic and 
electrostatic interactions as well as hydrogen bonding  (Marshall et al., 2011). Unlike the native state 
where hydrophobic regions are buried within the folded protein, in misfolded proteins these are often 
exposed, leading to aggregation (Hartl & Hayer-Hartl, 2009) and formation of amyloid fibrils. The 
core of amyloid fibrils are stabilised by interactions with the main polypeptide backbone chain and as 
this main chain is common to all polypeptides, it is not surprising that the morphology of fibrils 
formed from varying amino acids are so similar (Dobson, 2004). Furthermore, these amyloid fibrils 
are thought to be kinetically trapped and at the lowest energy conformation (Chiti & Dobson, 2006).  
In the last 20 years, advances have been made in understanding the folding process of proteins of 
differing sizes; small proteins (less than 100 amino acids) fold in a cooperative two state transition 
where only the native and denatured states are highly populated, and larger proteins (with more than 
100 amino acids) fold via intermediate states that can act as stepping stones to the native state 
(Brockwell & Radford, 2007). It is interesting that many misfolded proteins form intermediates such 
as oligomers in the assembly process to amyloid fibrils, similar to those seen in native state folding 
(Jahn & Radford, 2005).   
The mechanisms of protein folding and misfolding has been important in helping us understand basic 





disease-related misfolded proteins. It has also provided a new therapeutic approach in these diseases; 
facilitating the folding of proteins to their native state (targeting molecular chaperones for example) 
could reduce the number of misfolded proteins to either slow or stop the progression of disease 
pathology (Cohen & Kelly, 2003).   
1.2 Amyloid proteins 
1.2.1 Structure and definition 
The term amyloid, derived from the Latin amylum meaning starch, was first coined in 1854 by 
Rudolph Virchow to describe the lardaceous waxy deposits in brain tissue that exhibited positive 
staining following addition of iodine and sulphuric acid (Riek & Eisenberg, 2016). From this 
observation, Virchow concluded these inclusions to be primarily composed of carbohydrates. It was 
Friedreich and Kekule that later, in 1959, demonstrated the high nitrogen content of these amyloid 
deposits and began to think of these as proteins rather than carbohydrates. They concluded that the 
positive staining of iodine seen by Virchow was due to proteoglycans (Sipe & Cohen, 2000).  
In 1959 Cohen and Clakins showed that amyloid was fibrillar in structure by transmission electron 
microscopy (TEM) (Cohen & Calkins, 1959). Our understanding of amyloid structure has since 
greatly evolved with advancing technology. Tinctorial properties of amyloid proteins, suggestive of a 
fibrillary structure, includes the specific binding to Congo Red (Puchtler & Sweat, 1965) which 
produces an apple green birefringence when visualised between cross polarisers using a light 
microscope (Rambaran & Serpell, 2008). Fluorescence in the presence of Thioflavin T (ThT) dye is 
also characteristic of amyloid proteins and suggests fibrillogenesis (Vassar & Culling, 1959). Low 
atomic resolution techniques including electron microscopy (EM) and atomic force microscopy 
(AFM) have revealed amyloid fibres to be generally between 60-120Å long, often twisted and 
unbranched (Petkova et al., 2006; Rambaran & Serpell, 2008; Sumner Makin & Serpell, 2004).  
As amyloid proteins are inherently ordered and highly repetitive, it is possible to use X-ray fibre 
diffraction (XRFD) in order to gain insight into the molecular structure. XRFD reveals a cross-β 





β-sheet ribbons which extend along the fibre axis (Morris & Serpell, 2012). This gives rise to two 
characteristic diffraction signals; a sharp reflection on the meridian at 4.7-4.8 Å and a signal on the 
equator at approximately 10Å (Jahn et al., 2010). This pattern was first pioneered by William Astbury 
who obtained a XRFD pattern from a poached egg white.  
 
Figure 1. 3. Cross-β structure of Aβ42 fibrils (50μM incubated for 3 days, prepared in 20mM phosphate 
buffer pH 7.4) Scale bar shown at 0.5μm. X-ray Fibre diffraction pattern taken from (Serpell et al., 1999). 
The fibres display a sharp reflection on the meridian at 4.7-4.8 Å and a signal on the equator at 
approximately 10Å characteristic of amyloid proteins. 
 
This cross-β structure is common to both disease-related and functional amyloids and is responsible 
for the highly stable nature of amyloid proteins (Figure 1.3).   
Cryo-electron microscopy (cryo-EM) and single particle processing of amyloid fibres have also 
revealed that a single mature fibre is composed of protofilament subunits. For example, fibrils made 
up of the SH3 domain of phosphatidylinositol-3’-kinase, are comprised of four protofilaments around 
the central core (Fowler et al., 2006).  The number, orientation and substructure of protofilaments 





giving rise to a number of structures formed by one protein. This is known as amyloid polymorphism 
and has been shown in a number amyloidogenic proteins using techniques including cryo-EM, AFM 
and solid state nuclear magnetic resonance (ssNMR). One example is the 20-29 fragment and 
amyloidogenic core of the 37aa human islet amyloid polypeptide (hIAPP) known as amylin. ssNMR 
has revealed amylin can simultaneously assemble into two categories of fibres distinguishable by the 
alignment of the β-strands in either an anti-parallel or parallel configuration (Madine et al., 2008). It 
has been suggested that the number and orientation of the protofilaments within an amyloid fibre is 
guided by the packing of the regions of the polypeptide chain that are not involved with the formation 
of the cross-β core. A non- disease related example is the Pme117 repeat domain of melanosomes 
which act as templates for the deposition of melanin. Pme117 is polymorphic suggesting functionality 
does not necessarily mean one unique structure (Hu et al., 2011). 
The cross-β sheet motif is made up of two tightly packed repetitive β-sheets adhered by interdigitation 
of the side chains; this is known as the ‘steric zipper’ (Nelson et al., 2005). Cross-β structures can be 
separated into various categories dependent on the orientation and surface interactions of these β-
sheets; they can be parallel, anti-parallel, packed face-to-face or face-to-back, both sheets facing the 
‘up’ direction or opposite ‘up-down’ directions. These various possibilities have given rise to eight 
classes of steric zippers (Sawaya et al., 2007). This structural information has been possible to 
uncover due to a combination of X-ray diffraction (Morris & Serpell, 2012) and advances in ssNMR 
where amyloid proteins containing isoptically labelled amino acids are recombinantly expressed and 
once fibrils are formed, resonances can be detected. 
In a parallel arrangement of β-sheets, the strands can be either in-register or out-of-register. In most 
amyloid proteins, including β-amyloid (Aβ), the β-strands are generally in register (Landreh et al., 
2016). In-register β-sheets are stacked directly on top of each other, forming hydrogen bonds to 
adjacent strands. In an out-of-register arrangement, β-strands either wrap around an axis to form a β-





One way in which the cross-β structure provides such stability, is through the parallel N-H. . .O=C 
hydrogen bonds formed between the backbone amide groups. These point up and down the β-sheets 
due to the polar nature of the hydrogen bonds (Riek & Eisenberg, 2016). These hydrogen bonds 
polarise one another and as a result, reach a cooperative energy of formation (Tsemekhman et al., 
2007). van der Waals forces, increase in entropy from the release of water molecules (Gazit, 2002) 
and interactions between the side chains also all contribute to the stability of the fibrils. For example, 
the aromatic side chain Tyr, associates with the β-sheets via π-π stacking (Marshall & Serpell, 2009). 
It has been suggested that this π -stacking is largely driven by entropy; as ordered water molecules are 
released from the aromatic rings during intermolecular interactions, the overall entropy of the 
thermodynamic structure is increased. Other side chains, including Asn, Gln and Ser, can form 
hydrogen bonds called ladders also adding an additional level of stability to the fibre (Kurt et al., 
2017; Tsai et al., 2006).  
The insolubility and heterogeneity of amyloids has meant it is extremely difficult to achieve 
crystallisation which would otherwise provide structural information of high atomic resolution. 
Additionally, the twisted architecture of amyloid fibrils further complicates this. To overcome this 
problem, the shortest fragments retaining the amyloidogenicity of full length proteins were sought out. 
This was first achieved in the Sup35 yeast prion protein with the sequence GNNQQNY and it was 
confirmed this domain assembled into structures meeting all criteria for an amyloid protein. 
Furthermore, based on the dehydrated β-sheets observed, it was suggested that amyloid forming units 
may be short segments of full length proteins that are exposed by partial unfolding (Balbirnie et al., 
2001).  
Another example of a solved amyloid crystal structure is the 99 residue β2-microglobulin, which 
makes up the non-covalently linked light chain of class 1 human leukocyte antigen. It is a disease-
related amyloid, where the deposition of fibrils in the musculoskeletal system leads to the 
development of dialysis related amyloidosis. Three segments of the sequence are found to form 
amyloid fibrils in isolation; Ser20 to Lys41, Asp59 to Thr71, Pro72 to Met99. However in depth 





determinant of amyloid formation (Ivanova et al., 2004) Crystallisation studies have determined this 
fragment to serve as a hinge loop that folds into a two stranded antiparallel β-sheet (Domanska et al., 
2011). Interestingly, there have been over 80 different solved crystal structures displaying a seven-
stranded β-sandwich fold that is typical to IgG superfamilies (Berman et al., 2000; Trinh et al., 2002).  
There are now over 100 atomic resolution solved structures related to 15 disease associated amyloid 
proteins, based on short segments of the full length protein (Eisenberg & Sawaya, 2017). All 
presented a steric zipper structure. Although the information provided from these crystal structures 
have helped progress our understanding of amyloid proteins, and in some cases provide us with some 
insight into the misfolding mechanism, it is also limited. As no crystal structure has been solved for a 
fragment longer than seven residues and not the full length of proteins, it is entirely possible that the 
structures represent the spines of a single polymorph.   
The definition of an amyloid, or the criteria required for a protein to be classified as an amyloid, is a 
debated topic. In 2014, it was put forward that a protein must be deposited as insoluble ridged fibrils 
(roughly 10nm in diameter) in the extracellular space of organs as a result of protein misfolding to be 
defined as an amyloid. There are however, intracellular deposits observed e.g. α-synuclein Lewy 
bodies (Serpell et al., 2000). Furthermore, the fibril must bind to Congo red and display green 
birefringence when viewed by polarised light as well as exhibit a cross-β diffraction pattern by XRFD 
when isolated from tissues (Sipe et al., 2014).  Due to advances in solid phase protein synthesis, it is 
possible to use synthetic peptides that have been previously termed to be ‘amyloid-like’. Here, we will 










1.2.2 Amyloid assembly 
The ability of form amyloid fibrils under suitable conditions is conserved amongst many peptides and 
proteins. This is despite differences in primary sequences and has been attributed to an inherent 
property of the polypeptide backbone chain (Dobson, 2003). Techniques such as XRFD and NMR 
spectroscopy have been essential in determining the structure and morphology of mature amyloid 
fibrils. There has been a considerable effort made to understand the assembly process of amyloid 
proteins. This is especially due to the identification of the oligomeric species, which are formed on the 
pathway to amyloid fibrils, as being neurotoxic in many neurodegenerative diseases (Gadad et al., 
2011). 
The way in which proteins can misfold to form amyloid has been discussed in Protein folding and 
misfolding (Section 1.1.1); briefly, there is the unfolding of the native form into a partially folded 
state that allows for interactions that would otherwise be unable to occur due to the tightly packed 
three-dimensional native conformation (Uversky & Fink, 2004). The inherent flexibility of the 
partially unfolded intermediate is crucial in forming the core cross-β structure characteristic of 
amyloid. It is believed that unfolded/partially folded monomers leads first to the assembly of small 
nuclei which then assemble into pre-fibrillar species (protofibrils) and mature into fibres (Serpell, 
2000). 
The mechanism of amyloid assembly is thought to be via nucleated polymerisation (Ferrone, 1999). 
There is first the nucleation phase where the monomer precursor is either in an unfolded, partially 
folded or natively folded state and undergoes usually unfavourable self-association (Roychaudhuri et 
al., 2009). For amyloid formation, this nucleus has to template the bonding pattern of the fibre spine. 
The nuclei formed are thought to be in a pre-equilibrium with monomers and once formed, can either 
disassemble back into monomers or proceed to the next series of events leading fibril formation 
(Wetzel, 2006). The fate of the nuclei is concentration dependent; it has been suggested that at least 
three to four molecules of the monomeric protein must simultaneously expose their amyloidogenic 





has been formed, there is a very rapid formation of fibrils by the addition of monomers. This is known 
as the elongation phase. Fibril formation in this way is known as primary nucleation. There are also, 
secondary nucleation pathways that also lead to the formation of fibrils. Monomers can bind to pre-
formed aggregates to form a new nuclei for fibril formation (Knowles et al., 2014) in a mechanism 
called surface catalysed secondary nucleation (Knowles et al., 2014).  This is shown by Figure 1.4.  
 
 
The formation of amyloid fibrils can be monitored by ThT dye fluorescence, which displays a 
sigmoidal growth curve (Figure 1.5). There is a lag phase, which correlates to the time it takes to 
reach critical concentration of nuclei to elongate; growth phase where the conversion of peptides into 
amyloid fibres is at its greatest; and finally a plateau where the concentration of soluble protein for 
Figure 1. 4. Schematic representation of fibril formation by primary and secondary pathways. In primary 
nucleation, soluble monomeric forms of protein generate oligomers which have the potential to form 
amyloid fibrils. Secondary nucleation greatly enhances fibril formation where aggregates are able to grow 
by further addition of the protein. Secondary nucleation also includes fragmentation, where new fibril ends 






elongation has been depleted or reached an equilibrium (Arosio et al., 2015). Addition of fragmented 
preformed fibrils results in the lag phase being entirely or partially bypassed, serving as evidence of 
secondary nucleation pathways (Xue et al., 2008).   
 
 
1.3 Disease-related amyloid proteins  
1.3.1 Amyloid in disease 
The deposition of amyloid fibrils in the body related to disease is known as amyloidosis. Although not 
all misfolded protein diseases are related to amyloid deposition, cystic fibrosis for example (Fraser-
Pitt & O'Neil, 2015), there are a number of diseases that present amyloidosis. The presence of 
amyloid proteins in disease is not limited to one type of disease; this is seen in neurodegenerative 
diseases such as Alzheimer’s disease (AD), Spongiform encephalopathies and Parkinson’s disease, as 
well as non-neuropathic localised diseases such as Type II diabetes and pituitary prolactinoma. 
Figure 1. 5. Sigmoidal ThT aggregation curve of Aβ42 (50 μM prepared in 10mM HEPES buffer pH 
7.4). In the lag phase, there is generation of nuclei which are needed for the rapid elongation phases 
where amyloid fibril generation is occurring. Finally, there is a plateau reached and conversion of 






Amyloid deposition is also seen in systemic amyloidosis. In this class of disease, amyloid is deposited 
in tissues as insoluble structures that can sometimes replace cells. For example, in lysozyme 
amyloidosis a majority of the kidney is replaced by amyloid deposits (Marshall et al., 2014).  
Table 1.1 provides some examples of amyloid related diseases (Chiti & Dobson, 2006). 
In vitro, it is possible for almost any native protein to misfold into amyloid under suitable conditions, 
although these may not be physiologically relevant (e.g. low pH or high concentrations) (Dobson, 
2003). Within cells, however, there are many regulatory mechanisms that maintain correct protein 
folding. When there are incidences of misfolding proteins, the cell attempts to maintain normal 
homeostasis and prevent toxicity. For example, it has been shown that the promyelocytic leukaemia 
(PML) protein and the small ubiquitin-like modifier (SUMO) dependent ubiquitin ligase RNF4, bind 
together to identify and degrade misfolded proteins. The PML identifies misfolded proteins via a 
substrate recognition site which in turn conjugates the protein with SUMO ligases. The misfolded 
proteins are then ubiquinated by the RNF4 ligase (Guo et al., 2014). When the cell is overwhelmed by 
the amount of misfolded protein or can no longer sufficiently clear the accumulation of misfold 
protein, there is often cell death (Marshall et al., 2004).  
Amyloid proteins are known to be both disease-related as well a functional; there are over 40 
identified amyloidogenic proteins associated with various diseases as well as at least 12 non-
pathogenic amyloid proteins that are exploited for their strength and resistance to degradation (Riek & 
Eisenberg, 2016).  This raises the question of 'what makes an amyloid protein toxic?’ In order to 
investigate this, the disease-related model being used is β-amyloid 1-42 (Aβ42), the deposition of 








Disease Misfolded protein Precursor Native structure 
Neurodegenerative disease   
Alzheimer’s disease Amyloid β Unfolded 
Parkinson’s disease α-synuclein Unfolded 
Amyotrophic lateral sclerosis 





#Familial British Dementia ABri Unfolded 
Familial Danish Dementia Adan Unfolded 
Systemic amyloidosis    
AL amyloidosis 
Immunoglobulin light chains or 
fragments 
All-β 




Localised diseases   
Type II diabetes  Islet amyloid polypeptide Unfolded 
Atrial amyloidosis  Atrial natriuretic factor Unfolded 
Pulmonary alveolar amyloidosis Lung surfactant protein C Unknown 







1.3.2 Misfolded Aβ and Alzheimer's disease: The amyloid cascade hypothesis 
AD is a post developmental neurodegenerative disease characterised by a progressive decline in 
cognitive ability (McKhann et al., 2011). There are two broad types of AD; familial AD which 
approximately 5% of all cases, and sporadic AD cases which account for the remaining 95% of all 
AD cases (Kepp, 2017). Pathological hallmarks of the disease include extracellular plaques and 
intracellular neurofibrillary tangles, the components of which are Aβ and tau respectively (Hardy & 
Higgins, 1992).  These pathological hallmarks were first identified by Alois Alzheimer over a century 
ago and are still used as the basis of post mortem diagnosis (Sommer, 2002).   
There has been a strong correlation seen between the degree of tauopathy and cognitive decline seen 
in AD patients. A significant, but much weaker and inconsistent correlation is seen between the level 
of cognitive decline and deposition of Aβ (Wilcock & Esiri, 1982). Despite this, as Aβ was first 
sequenced from the meningeal blood vessels of AD and Downs’s syndrome patients and was 
identified as the main component of neuritic plaques, this deposition was postulated to be the first 
pathogenic event in AD (Hardy & Selkoe, 2002). The identification and cloning of the Amyloid 
Precursor Protein (APP) found on chromosome 21, the trisomy of which is a causative factor for 
Down’s syndrome (Roper & Reeves, 2006), has been instrumental in understanding the production of 
Aβ. There are several lengths of Aβ produced from the processing of APP, with Aβ42 identified as 
being the major species found in amyloid plaques deposited in AD.  
Due to this, a major focus has been put on Aβ for the role it plays in AD. There are however, normal 
physiological roles that have been suggested for this protein when it is not misfolded. Soluble Aβ, 
predominantly Aβ1-40, has been reported to be involved in the modulation of synaptic function, 
neuronal growth and survival as well as protection against oxidative stress (Bishop & Robinson, 
2004). Furthermore, clearance, transport and degradation of Aβ maintains the non-toxic, physiological 
Aβ concentration. It is therefore only when there is an overwhelming accumulation of misfolded 





The last two decades have heavily focused on the Amyloid Cascade Hypothesis. This presumes Aβ 
deposition, particularly the oligomeric species formed on the pathway to amyloid fibrils (McLean et 
al., 1999), to be the causative factor of neurodegeneration.  
Mutations found in the presenilin (PSEN) 1, 2 and APP genes, all of which are heavily involved in the 
elevated production of Aβ, have been the most compelling argument for the amyloid cascade 
hypothesis. Additionally, the ε4 allele of the apoplioprotein E (APOE) has been identified as strongest 
genetic risk factor of both early and late onset AD and is implicated in Aβ metabolism (Carter, 2005; 
Corder et al., 1993; Farrer et al., 1997). As a consequence of elevated Aβ production and deposition, a 
cascade of events is initiated, including tau pathology and synaptic dysfunction which lead to eventual 
neuronal loss (De Strooper & Karran, 2016)  
 






There are, however, a number of arguments raised against this hypothesis which have led to 
questioning the importance of Aβ in AD. Figure 1.6 is a summary of the updated amyloid cascade 
hypothesis, trying to address some of these criticisms. Firstly, there is a low correlation seen with the 
amount of amyloid deposition and cognitive decline seen in AD patients. However, a strong 
correlation is seen with the elevated levels of soluble Aβ and the level of neurodegeneration (McLean 
et al., 1999).  It has also been argued that the hypothesis is too neuro-centric and does not consider the 
other cell types that are involved in the pathogenic process. For example, it has been reported that the 
binding and activation of the formyl peptide receptor-like 1 (FPRL-1) receptor by Aβ could be 
responsible for the accumulation and activation of microglia resulting in an inflammatory response. 
Interestingly, the same study reported that Aβ formed a fibril forming complex with FPRL-1 
following prolonged exposure and the internalisation of this complex was rapid (Cui et al., 2002). Aβ 
also binds to the receptor for advanced glycation end products (RAGE) which allows for transport 
across the blood brain barrier (BBB). The interaction of Aβ with RAGE induces oxidative stress, the 
activation of microglia and subsequent cell death (Chen et al., 2007; Deane et al., 2003; Yan et al., 
2009).  
It is becoming apparent that the linearity of the cascade is a simplification of the reality by which Aβ 
can facilitate eventual neuronal death. Furthermore, the cascade is quantitative, suggesting that 
targeting Aβ quantity should slow down or halt the progression of disease.  However, therapeutic 
agents developed to lower the levels of Aβ produced, such as Semagacestat which is a gamma 
secretase inhibitor, have not been successful (Karran et al., 2011). This may be explained by the 
findings that mutations found in presenilin-1 component of the gamma secretase complex, do not 
increase the amount of Aβ produced, but promotes cleavage of APP to release longer length (>42 aa), 
more hydrophobic fragments. This is attributed to the destabilisation of the gamma secretase complex 
(Chavez-Gutierrez et al., 2012).  Although the levels of shorter Aβ produced may be reduced, the 
production of these more amyloidogenic fragments could be a nucleation point and seed further the 
production of misfolded Aβ. Therefore, the mutations in AD are more related to the quality of the Aβ 





Another criticism of the amyloid cascade hypothesis is the relationship between Aβ and tau. The two 
are found in different locations within the brain and follow a different progression in the brain, 
suggesting the two pathologies are independent of each other (Braak & Braak, 1995). However, it is 
possible that the oxidative stress caused by Aβ may initiate tau translocation and downstream 
deleterious events. This effect is not specific to Aβ and has also been seen to be induced by glutamate 
demonstrating tau can respond in this way to any oxidative stress inducing event (Alavi Naini & 
Soussi-Yanicostas, 2015).  Furthermore, tau tangles have been found to be common in both AD and 
non-AD brains and are already present in early life (Braak & Del Tredici, 2011b).  
Despite the controversy surrounding the amyloid cascade hypothesis, Aβ undoubtedly plays an 
important role in AD. The mechanisms by which Aβ leads to toxicity have been extensively studied 
and it is widely accepted that the oligomeric species is the primary neurotoxic culprit (McLean et al., 
1999; Stroud et al., 2012; Walsh et al., 2002a).  There are number of proposed mechanisms of Aβ 
oligomer toxicity. These include receptor mediated toxicity, cell membrane disruption related toxicity 
and intracellular accumulation mediated toxicity. It is likely that Aβ oligomers can mediate their 
effects in an array of pathways and that once downstream effects have been triggered, there is 
neurotoxicity.    
1.3.3 An alternative to the amyloid cascade hypothesis: The three phases of AD 
Recently it has been suggested that there are three phases of AD; the biochemical, cellular and clinical 
phase (Figure 1.7). This has been explained in depth by De Strooper and Karran (De Strooper & 
Karran, 2016). Briefly, during the biochemical phases there is the abnormal aggregation of Aβ, tau 
hyperphosphorylation and the generation of oligomeric species of both these proteins. There is also 
the propagation and transmission of these proteins as well as the interaction with a several other 
proteins and membranes leading to disruption of normal cell signalling and functioning.  The order of 
these events is not yet understood; it is possible that impaired proteostasis leads to misfolding of 
proteins or vice versa. These events are not thought to be irreversible or overwhelming, however 





there is progression to the cellular phase. The cellular phase is extremely complex and spans over two 
decades which may explain the ‘silent’ phase of AD. It is during this phase that the compensation 
mechanisms become irreversible mechanisms and disrupt brain homeostasis. This phase is not 
specific only to neurons; a failing neurovascular system, astroglia, microglia and oligodendrocytes are 
all involved. When there is no longer the ability to maintain normal homeostasis in the brain, the 
clinical phase is initiated. These three phases are thought to be in a feedback/feedforward mechanism 
between cells which eventually leads to dementia (De Strooper & Karran, 2016).  
This view not only provides explanations for gaps found in the amyloid cascade hypothesis, but also 
appreciates that there are numerous cell types that must also be involved in the pathogenic process. 
Although an emphasis is placed on the inflammatory response and irreversible compensatory 
mechanisms within the cellular phase of AD, Aβ is suggested to be the trigger for subsequent cell 
death in the biochemical phase.  
 
 







1.4 Amyloid Precursor Protein (APP) and Aβ production  
1.4.1 APP structure 
 
 
The APP protein was first cloned and identified as the precursor to Aβ, 30 years ago (Kang et al., 
1987). Located on chromosome 21, APP is a member of a family of conserved type I transmembrane 
proteins that also includes APP-like proteins (APLPs) 1 and 2 (Zheng & Koo, 2011). Although all 
three proteins share a vastly similar structure with a large extracellular domain linked via a single pass 
transmembrane domain to a smaller cytoplasmic region, only APP contains the domain encoding Aβ 
(Muller et al., 2017). Undergoing extensive differential splicing at exons 7, 8 and 15, APP has at least 
eight different isoforms which vary by 400 amino acids in length (Sandbrink et al., 1996).  The 
isoform most abundant in neuronal cells is APP695, with APP751 and APP770 (named according to 
their amino acid length) being highly expressed in most tissue (Kang & Muller-Hill, 1990) and have 
almost 90% more expression in glial cells rather than neurons (Rohan de Silva et al., 1997). Figure 1.8 
shows the structure of APP770 (adapted from (Dawkins & Small, 2014)). It is therefore accepted that 
APP expression is  regulated by cell-specific transcription (Menendez-Gonzalez et al., 2005). APP751 
and APP770 isoforms contain the Kunitz Protease Inhibitor (KPI) domain which is lacking from the 
APP695 isoform. This KPI domain is 56 amino acids long and is homologous to the Kunitz family of 
Figure 1. 8. APP structure. There is a N-terminal Signal Protein (SP) after which the E1 domain is found. 
This is comprised of the heparin binding domain 1 and a copper binding domain. The Kunitz protease 
inhibitor is found in the APP751 and APP770 only. The E2 domain also has a heparin binding domain as 





serine protease inhibitors which have the function of inhibiting peptidases. The role of the KPI 
domain has been reviewed (Menendez-Gonzalez et al., 2005) and is involved with forming stable 
enzyme complexes with trypsin (Oltersdorf et al., 1989), regulation of neuronal connections (Kido et 
al., 1990) and also in learning and memory (Conboy et al., 2005). Furthermore, the levels of APP 
containing this KPI domain has been shown to be increased in AD patients (Preece et al., 2004) 
suggesting either a role or consequence of disease progression.  
The structure of APP has been extensively studied and several possible physiological functions of this 
protein have come to light as a result. As mentioned above, APP has a large extracellular domain with 
a cysteine-rich growth factor like domain after which there is a zinc binding domain. Together these 
are referred to as the E1 domain. Next, an acid rich domain which contains aspartic and glutamic 
acids, followed by the KPI rich region for APP751 and APP770. There is then the region termed E2, 
consisting of another cysteine-rich growth factor like domain, zinc and copper binding domains and 
finally a carbohydrate domain where the N-glycosylation site can be found (Coulson et al., 2000). The 
crystal structures of both E1 and E2 domains have been solved (Dahms et al., 2010; Wang & Ha, 
2004) and this has provided considerable detail regarding the interactions occurring at or between the 
different domains. Briefly, on the cell surface, this structure of APP allows it to form 
homo/heterodimers. Heparin binding in particular is thought to heavily influence  dimerization (Xue 
et al., 2011). These interactions occur in the E1 region by the N terminal cysteine-rich growth factor 
as well as the copper binding domain (Soba et al., 2005). Disulphide bridges forming a loop in this 
region have been shown to be critical for the stability of the homodimer at residues 91-111 (Kaden et 
al., 2008). This N-terminal dependent dimerization has been shown to be both critical and sufficient 
whereas the C-terminal does not seem to be initially required for this process. However, although the 
N-terminal is a prerequisite to dimer formation, the C-terminal domain is needed to link two APP 
dimers together and form larger oligomeric species (Scheuermann et al., 2001).  
Independently, cis-dimerisation, that is dimerisation between two monomers of APP within the same 
membrane of a single cell, is facilitated through the juxtamembrane/transmembrane (JT/TM) via cross 





molecules.  In this JT/TM region, there are three glycine (GxxxG) motifs, one of which is within the 
Aβ domain. There is also the presence of a GxxxA motif in the APP TM domain (but on a different 
interface) and as there have been observations that glycine shows compatibility with α-helices in lipid 
bilayers, it is possible that dimersation of APP where GxxxG/GxxxA motifs mediated by two 
different interfaces could regulate cleavage of APP (Khalifa et al., 2010). Mutations introduced into 
APP to alter the glycine motifs to alanine residues have resulted in less APP dimerization, and less 
APP processing resulting in a reduced Aβ42 production (Munter et al., 2007). On the other hand, 
studies have reported an increase in APP dimerization by introducing cysteines at the JT/TM which 
has led to the increase in amyloid formation. (Scheuermann et al., 2001). Therefore, cis- dimerization 
is thought to affect APP functioning (Eggert et al., 2009) although it is not yet entirely understood.  
Trans-dimerisation, between monomers in the plasma membrane of different cells, can occur with not 
only two APP monomers but also with APP-APLP1/2 monomers. This is possible due to the E2 
region of APP being able to dimerise in an antiparallel orientation and interestingly, this dimerization 
is reversible suggesting that once APP reaches the cell surface, the cis dimers may be able to 
dissociate and re-associate as trans dimers with APP on the surface of nearby cells and thus 
facilitating cell-cell adhesion (Wang & Ha, 2004). This has been shown to be particularly important in 
synaptic function (Soba et al., 2005). 
1.4.2 APP Processing 
APP can be processed in either the amyloidogenic or non-amyloidogenic pathways (Figure 1.9); a 
deciding factor is the co-localisation of APP with various secretases which in turn, is dependent on the 
distribution of APP. Full length APP is synthesised and dimerises in the endoplasmic reticulum 
(Scheuermann et al., 2001) and is then subject to a number of post translational modifications as it is 
transported by the Golgi/trans-Golgi network. As APP matures through a constitutive secretory 
pathway, it acquires a tyrosine sulphate and a phosphate as well as N- and O-linked carbohydrates 
(Weidemann et al., 1989). APP can be transported to the cell surface in trans-Golgi network derived 





(Groemer et al., 2011). However, the majority of APP is found in the Golgi network.  The production 
of Aβ occurs in several intracellular organelles and as such, the increased delivery of APP to the cell 
surface favours the non-amyloidogenic pathway. APP residing in acidic compartments such as the 
endosomes favours the amyloidogenic processing pathway and thereby the increased levels of Aβ 
(Muller et al., 2017). 
APP is first cleaved either by α-secretase in the non-amyloidogenic pathway, or by β-secretase in the 
amyloidogenic pathway. In the non-amyloidogenic pathway, this leads to the release of sAPPα which 
is essentially a large ectodomain of APP as well as a membrane-associated C-terminal fragment 
(CTF) consisting of 83 amino acids (C83).  In the amyloidogenic pathway, it is APP cleavage by the 
β-secretases at the N-terminal of Aβ that begins the release of Aβ. The two products of this β-
secretase processing are sAPPβ and a CTF consisting of 99 amino acids (C99). The excision of Aβ 
from APP, however, requires the sequential cleavage by both β- and γ-secretase.  
γ-secretase acts in both the amyloidogenic and non-amyloidogenic pathways by cleaving the 
membrane-tethered CTFs. The C83 and C99 fragments are cleaved by γ-secretase in a number of 
steps beginning with an endolytic cut at the ε site which frees the C terminal APP intercellular domain 
(AICD). In the non-amyloidogenic pathway, there is the release of the non-toxic p3 peptide whereas 
in the amyloidogenic pathway, the C99 fragment is internalised and further processed by γ-secretases 
at several sites to produce fragments of Aβ of varying length (Chen et al., 2017). This sequential 
cleavage has been shown to take place every three residues along the α-helical face of the 
transmembrane domain of APP (Takami et al., 2009). The Aβ39-42 peptides released as a result of 
amyloidogenic cleavage contain 28 residues of the extracellular domain and 11-15 residues of the 
transmembrane domain of APP. A schematic representation of APP processing in both pathways is 








Figure 1. 9. APP processing. In the Non-Amyloidogenic pathway, APP is first cleaved by α-secretase 
within the Aβ sequence releasing sAPPα. This is then cleaved by γ-secretase which releases the p3 
fragment. In the Amyloidogenic pathway, β-secretase cleavage of APP at the Aβ terminus releases sAPPβ. 








Figure 1. 10. α-secretase structure. Non-Amyloidogenic APP processing is mediated by a number of 
proteases, mainly from the ADAM family. These are membrane bound consisting of several extracellular 
domains.  
 
There has been extensive research into each of the secretases in order to better understand their modes 
of action and develop therapeutics against them with the overall aim of decreasing Aβ production. 
This approach would address the mechanism of disease pathogenesis rather than target downstream 
effects of pathogenesis. α-secretase (Figure 1.10) processing of APP is mediated by members of the A 
disintegrin and metalloproteinase domain proteins (ADAM) and of these, ADAM 9, 10, 17 and 19 are 
the enzymes most likely to be involved (Asai et al., 2003), particularly ADAM10. The cleavage site 
of α-secretases is within the Aβ domain at Lys16-Leu17 bond. As this processing of APP does not 
result in the production of toxic Aβ, it has been less focused on as a therapeutic target in AD. 
However, enhancing the non-amyloidogenic pathway of APP processing is now becoming more 
popular due to the combination of the physiological benefits of the sAPPα (Habib et al., 2017; 
Mockett et al., 2017)  as well as the disappointing results of targeting secretases in the amyloidogenic 
pathway.  
1.4.4 β-secretases 
The β-secretases (Figure 1.11), which are aspartic proteases, involved in the production of Aβ are 
BACE (beta-site amyloid precursor protein cleaving enzyme 1 and -2 (BACE1 and BACE2). BACE1 
is the major β-secretase in the brain and acts at the β-site, whereas BACE2 acts within the Aβ domain 
making it a competitor to α-secretase cleavage. However, it is not thought to be a major contributor to 
APP processing. Both are produced as precursor proteins in the endoplasmic reticulum and have 





made up of 518 amino acids. As β-secretases are aspartic proteases, their prodomain which aids in 
protein folding, is removed by furin-like proprotein convertases in the Golgi compartments and 
thereby producing active enzymes (Yan, 2017).  From the Golgi, BACE1 is transported to endosomes 
where the acidic environment favours the processing of APP in the amyloidogenic pathway. The 
transportation is due to the interactions of BACE1 with Golgi localised ϒ-ear-containing ADP 
ribosylation factors (ARF) binding proteins, known as GGA protein (von Einem et al., 2015) . The 
interaction occurs between the C-terminal DXXLL motif on BACE1 and the VHL domain of the 
CGA proteins (Kandalepas & Vassar, 2014). Intracellularly, the localisation of BACE1 can also be 
regulated by Ritculon/Nogo family members; these negatively regulate BACE1 translocation to the 
endosome. Overexpression of reticulon proteins has been shown to keep BACE1 in the endoplasmic 
reticulum and therefore decrease the amount of Aβ produced (Shi et al., 2017).  Other examples of 
BACE1 trafficking regulatory proteins include sorting nexin 6 (Okada et al., 2010) and sortilin (Finan 
et al., 2011).  
The docking of BACE1 into the lipid bilayer has been suggested to be a crucial step for APP 
processing and this is facilitated by the S-palmitoylation on four Cys residues found on the junction of 
the transmembrane and cytosolic domains. This leads to increased activity of the enzyme (Cordy et 
al., 2003). However, there is also evidence suggesting that this lipid localisation and palmitoylation 
does not increase the activity of the β-secretase (Vetrivel et al., 2009) suggesting that BACE1 
processes APP in both lipid raft and non-lipid raft environments. 
  
Figure 1. 11. β-secretase structure. BACE1 is a membrane bound enzyme responsible for cleaving APP at 
the β-site.  
 
BACE1 plays an essential role in, and is the rate limiting factor in Aβ production and therefore it has 





dependent on the luminal orientation of the BACE1 active site which is correctly positioned to cleave 
APP, and this is highly sequence specific (Cole & Vassar, 2007). The aspartates hydrolyse peptide 
bonds following a general acid-base mechanism where the Asp228 is the base activating a bridging 
catalytic water molecule, and the Asp32 is the acid protonating the carbonyl group on the substrate 
(Ellis et al., 2016). The activated water molecule nucleophilically attacks the scissile-bond carbonyl 
and the resultant intermediate is stabilised by hydrogen bonds. There is then the decomposition of the 
scissile C-N bond with which there is a proton transfer from the Asp32. On top of this catalytic site is 
the Tyr68-Glu77 β-hairpin loop which acts as the 'flap' controlling substrate exposure and solved 
crystal structure suggest that this flap can change from open to closed conformation at room 
temperature (Shimizu et al., 2008).  
Overexpression (Lee et al., 2003) or downregulation (Cai et al., 2001) of BACE1 activity results in 
increased or decreased APP processing and Aβ production respectively. The cleavage sites of BACE1 
on APP are between Met671 and Asp672 (β-site) and between Thy681 and Gln682 (β'site). Cleavage 
at the β-site generates the C99 fragment and cleavage at the alternative site results in the C89 
fragment, both of which are then cleaved by γ-secretase to produce Aβ11-XX or Aβ1-XX 
respectively.  A recent study has emphasised the importance of BACE1 cleavage site selection in the 
production of Aβ and subsequent pathogenesis (Zhang et al., 2017).  A mutation of APP that causes 
recessively inherited AD, A673V, which occurs at position 2 of Aβ has been shown to shift the 
BACE1 cleavage from Glu11 to Asp1 which resulted in the increased levels of C99 and Aβ 
production. Furthermore, the Aβ produced seems to be more aggregation prone than the wild type 
(Zhang et al., 2017). The dimerisation of the mutant and wild type APP was also seen as was the 
increased lysosomal degradation of the mutant APP and inhibition of γ-secretase cleavage. Of note, 
other mutations in this site reduced C99 production and were shown to be protective e.g. Icelandic 
A673T mutation. Together the results suggest A673 is involved in APP processing and could be a 
possible therapeutic target in some cases of AD. More importantly, this study highlights the fact that 
BACE1 cleavage site selection is crucial in the production of Aβ. Furthermore, it has been observed 





(Coulson et al., 2010). Due to the crucial role BACE1 plays in the production of Aβ, several BACE1 
inhibitors have been developed and entered clinical trials with the hope of decreasing the amount of 
Aβ produced in the amyloidogenic pathway and the subsequent pathology that follows.  







Following β-secretase, the subsequent cleavage of APP is by γ secretase (Figure 1.12). This is an 
aspartyl protease comprised of four subunits; a catalytic domain comprised of presenilin-1 and 
presenilin-2 (PS1/2), the substrate receptor nicastrin, PEN2 which acts as an enhancer of activity and 
finally anterior pharynx defective (APH-1) which is thought to be the stabilising subunit (De Strooper 
et al., 2012). Mutations in PS1 are well documented in familial AD. Although the crystal structure of 
the complex has not yet been solved, PS1 is known to have nine transmembrane (TM) helices with the 
aspartyl residues needed for autoproteolysis found in TM6 and TM7. This autoproteolyic cleavage is a 
result of full complex formation and occurs within the cytosolic loop domain between these two TM 
domains to generate N- and C-terminal fragments which results in the active form of γ-secretase being 
released. It has been known for over ten years that the active site of γ-secretase resides in a catalytic 
pore that is filled with water (Sato et al., 2006a). TM1, 6, 7 and 9 are thought to make up this core and 
face the hydrophilic environment of the catalytic pore. Studies investigating the spatial arrangement 
Figure 1. 12. γ-secretase structure. This secretase is made up of four proteins; nicastrin, APH-1, 






of PS1 have shown that distance between the cytosolic sides of TM4 and 7 correlates with Aβ42 
production in particular; cross-linking experiments altering this distance by manipulating the 
flexibility of TM4 to make it shorter resulted in lowered Aβ42 levels and increasing this distance 
leads to the increased amount of Aβ production (Tominaga et al., 2016). The substrate binding model 
demonstrates that TM2 and 6 are close to TM9 and involved in forming the substrate binding site. 
This displays the conformational flexibility that would be expected of 'gate doors' for substrates to 
reach the catalytic pore. The hinge region of this pore has been identified as loop1 (position of which 
is between aa 106-131) which cooperates with the C-terminus of PS1 in order to regulate substrate  
gating and recognition (Somavarapu & Kepp, 2016). Cryo-EM has also provided insights into the 
importance of the interactions between the other subunits forming the full γ-secretase complex; the 
nicastrin subunit has been shown to be important as a substrate recruiter. Once a substrate has been 
bound, the subunit has been speculated to align the nicastrin pocket and the catalytic pore of PS1 and 
thus facilitating the cleavage of the substrate (Zoltowska & Berezovska, 2017), in this instance the 
C99 fragment of APP. PS1 cleavage is between the Leu40 and Val50 which leads to an array of Aβ 
peptides of varying length, all spaced by three amino acids, indicating two different α-helices on C99 
from which Aβ49,46,43 and 40 (one subset) and Aβ48,45,42 and 38 (second subset) are produced 
(Olsson et al., 2014). Together, this demonstrates that the structure and conformation of the γ-
secretase complex strongly dictates the type of Aβ produced. Over a 150 AD linked mutations have 
been identified in the genes encoding PS1/2, which shift the ratio of Aβ produced in favour of Aβ42 
by altering the overall biochemical quality of the γ-secretase complex and its interaction with APP 
(De Strooper et al., 2012). Considering this, γ-secretase has also been the focus of much therapeutic 
development for treatment of AD. 
1.4.6 Therapies targeting secretases 
Although these secretases provide a good starting point as therapeutic targets in developing drugs for 
AD patients, there have been many hurdles encountered which have not yet been resolved. Firstly, 
both BACE1 and PS1 have other substrates aside from their respective APP fragments and the 





involved in the cleavage of neuregulin-1 is necessary for regulating myelination (Willem et al., 2006) 
and γ-secretase cleavage of the Notch receptor is critical in the maintenance of stem cells (Yu et al., 
2008). Many inhibitors targeting γ-secretases have been unsuccessful when it comes to clinical trials 
due to side effect related incidences of skin cancer and a decline in cognitive functioning e.g. 
Semagacestat (Doody et al., 2013) (Eli Lilly) and Avagacestat (Coric et al., 2015) (Bristol-Myers-
Squibb). BACE1 inhibitors are showing to be slightly more promising, however, BACE null mice 
showed impaired neuronal phenotypes (Hu et al., 2010), complete BACE1 inhibition can lead to 
severe side effects and as such there needs to be a threshold established beyond which the BACE1 
inhibition levels cannot pass. Aside from the side effects, there is also the issue of therapeutics that 
can cross both the BBB and cell membranes. There is a vast amount of literature investigating the 
successes and failures of secretase inhibitors as therapeutics. These have been reviewed extensively 
(Bachurin et al., 2017; Cummings et al., 2017; Evin, 2016; Extance, 2010; Karran & Hardy, 2014; 
Mangialasche et al., 2010; Selkoe, 1994; Selkoe & Hardy, 2016). 
1.5 Mechanisms of oligomer toxicity 
Although the link between oligomers and toxicity has been established for many years, the 
mechanism for this toxicity is still unclear. One reason oligomers are thought to be cytotoxic is due to 
their exposed hydrophobic region, which under normal conditions would be buried, being able to 
interact with cellular components and exert cell dysfunction (Cheon et al., 2007).  
Oligomers are formed by numerous disease-related amyloid proteins including Aβ42 and α-synuclein, 
which suggests a similar structural feature. This was consolidated by the development of the 
conformation specific A11 antibody, which binds to all oligomers regardless of the precursor protein 
(Kayed et al., 2003). It has therefore been proposed that these similar structures must also share 
commonality in mechanisms of cytotoxicity.  
As this thesis focuses heavily on the disease-related Aβ42 protein, the proposed mechanisms of Aβ42 






1.5.1 Receptor-mediated Aβ toxicity 
A number of receptors have been implicated in Aβ mediated toxicity. This is then thought to lead to 
downstream synaptic dysregulation and eventual neurodegeneration. Figure 1.13 (De Strooper & 
Karran, 2016) summarises the many proposed receptor mediated mechanisms of Aβ oligomer 
toxicity.  
The evidence for the involvement of each of these receptors has been somewhat confusing. For 
example, Aβ oligomers have been suggested to induce nerve growth factor (NGF) receptor mediated 
neuronal death via the p75 neurotropin receptor (p75NTR). This was shown to be true for Aβ-derived 
diffusible ligands (ADDLs) which are a class of oligomers, and that neuronal death is mediated by a 
death domain found in the cytoplasmic portion of the receptor (Bothwell, 1996; Yamamoto et al., 
2007). Another study, however, showed that this same receptor promotes cell survival in the presence 
of Aβ oligomers and in fact, toxicity was independent of the p75TR receptor altogether (Costantini et 
al., 2005) 
There has also been extensive research into the N-methyl-D-aspartate receptor (NMDAR) dependent 
Aβ disruption of long term potentiation. This is thought to affect several downstream pathways of the 
NMDA receptor which have been extensively reviewed (Yamin, 2009). 
Disruption of the Wnt signally pathway is also thought to be a mechanism of Aβ toxicity. Oligomers 
have been shown to bind to the Frizzled cysteine-rich domain in the Wnt-binding site and thereby 
inhibit Wnt signalling altogether. As this is critical for cell-cell communication, disruption by 
oligomers in this way is detrimental to the cell (Magdesian et al., 2008). Recent studies, however, 
have suggested that this disruption can be overcome (Shruster et al., 2011) 
The cellular prion protein has also been put forward as a receptor of Aβ oligomers (Salazar & 
Strittmatter, 2017). The specific binding of Aβ oligomers to cellular prion proteins has been identified 
in human COS cells as well as primary neurons and mutations to remove these prion proteins was able 





recovery has also been shown in mouse models (Gimbel et al., 2010). Therefore, it seems extremely 
likely that at least some oligomer toxicity is mediated by binding to cellular prion proteins.  
A brief overview has been given of the vast literature surrounding receptor-mediated toxicity of 
oligomers. It is most likely that oligomers are extremely promiscuous and bind to several receptors to 
disrupt downstream pathways. As oligomers are formed in several proteins on the process to forming 
amyloid fibres, it seems the structure of these oligomers plays a role in their promiscuity.  
 
 







1.5.2 Cellular membrane disruption by oligomers 
One of the more prominent mechanisms for Aβ oligomer induced neurodegeneration, is channel 
formation and disrupted calcium homeostasis (Glabe & Kayed, 2006). This is known as the 'channel 
hypothesis'. The formation of channels into lipid bilayers by oligomers, referred to as amyloid pores, 
has been shown by several groups (Bode et al., 2017; Meleleo et al., 2013; Serra-Batiste et al., 2016). 
As a result of this, elevated calcium levels were monitored in the cytosol. There is a strong suggestion 
that Aβ incorporated into the membrane to form pores, leads to subsequent aggregated Aβ 
accumulating on the membrane (Williams & Serpell, 2011). It is also entirely possible Aβ shares 
toxicity mechanisms similar to those displayed by antimicrobial or antifungal peptides; free radical 
formation is an example of how channel formation can lead to cell disruption (Kayed & Lasagna-
Reeves, 2013).  
More recently, it has been proposed that this 'channel hypothesis' is not responsible for cellular 
membrane mediated oligomer toxicity. It is more to do with membrane permeabilisation caused by 
oligomers which is independent of channel formation; the oligomers increase the permeability of the 
membrane and penetrate the cell resulting in leakage of calcium (Bucciantini et al., 2004). It has also 
been shown that oligomers, regardless of primary sequence, increase the conductance of the cell 
membrane and thereby leads to the depolarisation of the plasma membrane with detrimental effects 
(Kayed et al., 2004) . Increased conductance in this way can lead to ion homeostasis dysfunction as 
well as signal disruption. One way in which the integrity of the bilayer is disrupted by oligomers, is 
thought to be the spreading apart of the lipid head groups and therefore thinning of the bilayer and 
lowering the permeability (Kayed & Lasagna-Reeves, 2013). 
1.5.3 Accumulation of intracellular oligomers 
In AD, Aβ is deposited extracellularly as plaques which are made up of amyloid fibrils. There is 
however, Aβ accumulation intracellularly and this is thought to precede the formation of extracellular 
deposits (Skovronsky et al., 1998). The internalisation of Aβ will be discussed in a later chapter 





are thought to internalise into the cell. For example, the scavenger receptor for advanced glycation 
end products (RAGE) is thought to be one method of internalisation in both neurons and microglia. 
This interaction between RAGE and Aβ can cause oxidative stress as well as the activation of the 
nuclear factor-к B thereby inducing the macrophage colony-stimulating factor (Verdier & Penke, 
2004; Yan et al., 1998).  
Not all intracellular Aβ is accumulated by internalisation. Cell themselves produce Aβ and it is not yet 
understood if part of the intracellular accumulation is due to Aβ not being secreted after generation or 
if secreted Aβ is simply taken back up into the cell. Assembly of oligomers from intracellular 
monomers remains unclear, however one hypothesis is that this could be result of Aβ interactions with 
other intracellular proteins. For example, the accumulation of GM1 in early endosomes supports the 
notion that this ganglioside could induce Aβ oligomerisation (Yuyama et al., 2008). There is also the 
action of molecular chaperones; for example, the chaperone prefoldin which captures and delivers 
denatured proteins to another chaperone, chaperonin. This interaction between Aβ oligomers and 
prefoldin may prevent further aggregation by stabilising the oligomer (Sakono & Zako, 2010).  
A fundamental understanding of mechanisms leading to toxicity is still lacking. One mechanism is 
thought to be by inhibiting the normal function of the proteasome and de-ubiquinating enzymes 
(Almeida et al., 2006). Accumulation of oligomers in mitochondria has also been related to disrupted 
enzyme activity of the respiratory chain complexes III and IV resulting in reduced oxygen 
consumption and cellular dysfunction (Caspersen et al., 2005). There is also substantial evidence to 
suggest intracellular accumulation of Aβ leads to synaptic dysfunction (Bayer & Wirths, 2010). 
The mechanisms by which oligomers exert their toxicity is likely to be vast and far reaching. Amyloid 
oligomers show a high level of affinity and interactions with numerous proteins and receptors which 
lead to cellular dysfunction. The clearance of these misfolded proteins has been previously discussed 
and it seems that oligomer toxicity occurs when this clearance or degradation becomes inefficient. 





chaperones, or simply that the cell cannot cope with the level of protein aggregation insult 
accumulating over time.  
A key point to take from this, however, is that the effects of the oligomeric species are not specific to 
primary sequence and therefore indicate structure and/or size as a mediator of toxicity.  
1.6 Non-pathogenic amyloid proteins 
1.6.1 Functional amyloid proteins in living organisms 
Although a large focus of amyloid research has centred on disease-related proteins, there are a number 
of amyloid proteins identified as being non-pathogenic and functional. These functional amyloid 
proteins are found in a range of organisms from humans to bacteria (Table 1.2). 
In humans, functional amyloid has been found to be involved in a number of physiological processes. 
Proteins can exploit the ability to form amyloid in order to perform function.  For example it has been 
found that peptide hormone storage (Maji et al., 2009), pigmentation (Fowler et al., 2006) and cell 
responses to stress (Audas et al., 2016) all heavily involve amyloid proteins.  
Peptide hormones are stored in an amyloid conformation within secretory granules, these amyloid 
fibrils then dissociate upon release when exposed to the correct pH (Maji et al., 2009). This reversible 
amyloidogenicity is tightly controlled and allows for the peptide hormones to be stored at high 
concentrations before being released as functional monomers (Maji et al., 2009).  
Pmel17 is the glycoprotein essential in the biogenesis of melanosomes, which are the organelles of 
pigment cells where melanins are synthesised and stored. These organelles have been found to be 
loaded with fibrillar amyloid (Fowler et al., 2006). Pmel17 is known to lyse into two fragments during 
the biogenesis of melanosomes; one of which is the Mα fragment whilst the other, Mβ, is rapidly 
degraded. It is the Mα fragment that self-assembles into fibres and forms the core the mature 
melanosomes. The assembly process of Mα has been highly characterised (Fowler, 2006) and has 
been found to be extremely rapid. This suggests forming fibrils rapidly sequesters any intermediary 





Upon severe environmental insult such a heat shock or acidosis in cells, there is the expression of A-
bodies. These have been defined as rIGSRNA-seeded nuclear foci which contain proteins possessing 
the characteristic properties of amyloid. These A-bodies act as stores for proteins until the stressors 
are removed, after which they disassemble. Many proteins have been identified as being able to form 
A-bodies, including those involved in cell cycle progression and DNA synthesis. This allows the cells 
to enter a dormant state and survive the stressors being placed on the cell (Audas et al., 2016).  
Functional amyloid proteins are also found in other organisms. For example, the propagation of the 
amyloid HET-S prion protein has been postulated to be an important factor in fungi signal 
transduction (Daskalov et al., 2015). In Saccharomyces cerevisiae, a type of yeast, a Sup35p fragment 
(GNNQQNY) is a translation termination factor that ensures the cessation of protein synthesis at 
nonsense (stop) codons (Kushnirov et al., 2000). Sup35p formation of amyloid prevents translation 
termination and thereby results in stop codon read through as well a C-terminal extension. This is 
critical in generating phenotypic diversity which is most likely due to an altered proteome (Bertram et 
al., 2001; Fowler et al., 2007). The Sup35p amyloid formation is prion-like and allows for the 
transmission of genetic information; the cytoplasmic amyloid is reversible  and heritable leading to a 
particular phenotype being passed from mother to daughter cells upon division (Fowler et al., 2007) in 
an epigenetic, non-Mendlian manner. 
More recently, the formation of hydrogels has been identified in nuclear pore complexes. One 
example is the hydrogel formed from the ‘amyloid-like’ β-sheet rich FG repeat domain of the 
nucleoporin NSp1 protein. This hydrogel has sieve like permeability to allow the entry of nuclear 
transport receptor but exclude the entry of large, inert macromolecules (Ader et al., 2010). The study 
further highlighted the importance of β-sheet structures maintaining the permeability barrier of 
nuclear pores.  
Understanding how these proteins form amyloid in a rapid, reversible and non-toxic manner will 





of functional amyloid proteins, using lessons learnt from their assembly process, we may establish 
'rules' that determine how to avoid the toxic nature of disease-related amyloid proteins. 
Bacteria Protein Reference 
Gram negative bacteria Curli (Chapman et al., 2002) 
Streptomyces coelicolor Chaplins (Wasmer et al., 2008) 
Staphylococcus aureus Bap 
Modulin 
(Taglialegna et al., 2016) 
(Zheng et al., 2017) 
Klebsiella pneumoniae Microcin E492 (Arranz et al., 2012) 
Fungi Protein  
Saccharomyces cerevisiae Sup35 (Balbirnie et al., 2001) 
Podospora anserine HET-s (Maddelein et al., 2002) 
Candida albicans Als adhesin (Otoo et al., 2008) 
Fungi spp. Hydrophobins (Morris & Sunde, 2013) 
Plants  Protein  
Algae spp. Macroalgal adhesive (Mostaert et al., 2006) 
Hevea brasiliensis Rubber Elongation Factor (Berthelot et al., 2016) 
Animal- Mammals and insects Protein  
Human Pmel 17 
Protegrin-1 
Human defensin 6 
(Fowler et al., 2006) 
(Jang et al., 2011) 
(Chu et al., 2012) 
Spider Spidroin (Slotta et al., 2007) 
Mice  CPEB3 (Fioriti et al., 2015) 





In general, functional amyloid proteins are thought to be non-toxic, however, there are a few rare 
instances where this is not the case. Examples of this include antimicrobial peptides, including 
Protegrin-1 found in humans, where cytotoxicity is induced by membrane disruption through channel 
formation (Jang et al., 2011). Interestingly, Aβ has been shown to be an antimicrobial peptide in its 
functional amyloid form (Soscia et al., 2010).  Another example is the human defensin which is found 
at the gut mucosa and binds with a high affinity to the surface of bacteria to 'trap' them in a net-like 
structure thereby stopping further invasion (Chu et al., 2012). These examples illustrate the tight 
regulation displayed by functional amyloid proteins which exploit their cytotoxic nature only when 
necessary. This is not the case for disease-related amyloid proteins where pathology is linked to 
protein misfolding and no regulation of toxicity. 
1.6.2 Regulation of toxicity 
There are several ways in which functional amyloid proteins regulate their (lack of) toxicity. The 
rapid nature in which amyloid is formed by these proteins often means the formation of the 
intermediary oligomeric species is either by-passed or the kinetics of assembly are rapid enough, so 
toxicity is minimised. (Fowler et al., 2006).  Examples of this are seen with Pmel 17 (Fowler et al., 
2006) as well as the Sup35 yeast prion protein (Wang et al., 2007). This is also seen with the amyloid 
silk spidroin protein, produced in spiders, which rapidly forms insoluble amyloid in response finely 
controlled series of pH drop, salt gradients finalised by spinning (Kenney et al., 2002). Furthermore, 
Curli, formed by bacteria, encodes its own protective mechanism within in the CsgA subunit, to 
prevent the formation of oligomeric species. This is achieved by inhibition of aggregation propensities 
(Wang et al., 2010). The ability to form oligomers and the time spent in this aggregation state, may be 
a determinant of toxicity and this is minimised in functional amyloid proteins. 
The location of functional amyloid proteins may also play a part in toxicity regulation. Functional 
amyloid proteins are often confined to specific compartments (Berson et al., 2003) and are therefore 





the membrane surface (Swasthi & Mukhopadhyay, 2017). Controlling the temporal location of 
amyloid proteins in this way, may protect other parts of the cell from cytotoxicity. 
Finally, the use of molecular chaperones to inhibit the formation of amyloid may prevent toxicity. 
Molecular chaperones are essential for maintaining normal cell proteostasis, it is therefore 
unsurprising they play a role in regulating amyloid toxicity.  For example HSPs are involved in 
binding to hydrophobic regions and transiently blocking aggregation (Hartl et al., 2011). Furthermore, 
the HSP70 and HSP40 have been shown to break down amyloid into 'seeds' to accelerate the 
formation of fibrils and avoid oligomer formation (Rikhvanov et al., 2007). 
1.7 Exploiting amyloid: Nanomaterials 
Amyloid proteins can be thought of as a natural nanomaterial due to their unique properties. Firstly, 
under suitable conditions, almost any peptide has the ability to form amyloid (Dobson, 2004). 
Secondly, amyloid proteins are highly stable and have high mechanical strength (Smith et al., 2006). 
In fact, the stability and strength of amyloid fibrils is comparable to that of steel and silk (Smith et al., 
2006). The nucleation dependent polymerisation and ability to accelerate amyloid formation using 
seeds (Xue et al., 2009) also makes amyloid proteins extremely attractive as bionanomaterials. 
Amyloid properties can also easily be manipulated by altering primary sequences and functional 
groups can be conjugated to amino acid side chains (Mankar et al., 2011). Furthermore, amyloid 
proteins can also form complex networks of gels and films. (Aggeli et al., 1997). Therefore, amyloid 
has been exploited as a bionanomaterial for applications discussed below.  
1.7.1 Applications in biotechnology – Cell culture scaffolds 
One of the recent exploitations of amyloid proteins is the formation of hydrogels. Hydrogels are 
formed from amyloid fibrils which, above a critical gelation concentration, entangle and associate to 
from three-dimensional networks with the ability to trap water (Elsawy et al., 2016). These provide 
excellent matrixes for neuronal cell attachments, differentiation and neurite growth. This was first 
established by developing self-complementary β-sheet peptides using L-amino acids, alternating in 





with functionalised motifs. For example, the hydrogel made from the β-sheet rich osteogenic growth 
peptide ALK, promoted the proliferation and osteogenic differentiation of mouse MC3T3-E1 cells 
(Horii et al., 2007). Similar results were seen with the β-sheet rich KLD-12 hydrogel providing an 
excellent scaffold for chondrocyte cartilage like extracellular matrix (Kisiday et al., 2002; Mankar et 
al., 2011). Although these examples are of self-assembling, β-sheet rich structures, XRFD is needed to 
confirm both peptides form amyloid.  
1.7.2 Applications in biotechnology – overview of other applications 
Table 1.3 provides some examples of applications of amyloid proteins in nanotechnology aside from 
cell culture scaffolds (Mankar et al., 2011).  
Table 1. 3. Examples of amyloid proteins in nanotechnology 
 
From the table, it is apparent to see there are several applications of amyloid proteins that do not 
display toxicity. Therefore, amyloid proteins serve as an extremely useful tool in developing novel 
biotechnological applications.  
 
Amyloid Protein Applications Reference 
Transthyretin 
Functionalised amyloid proteins 
for cell adhesion 
(Gras et al., 2008) 
GnRH 
Depot formulation of long 
acting drugs 
(Maji et al., 2008) 
Killer peptide 
Auto-delivery of therapeutic 
peptides 
(Magliani et al., 2011) 
α-Synuclein Hydrogel to trap enzymes (Bhak et al., 2010) 
Sup35p NM domain Nanowires (Yin et al., 2011) 
Hen egg white lysozyme 
amyloid fibrils  
Thin films (Knowles et al., 2010) 
β2-Microglobulin Nanoporous Matrix (Ahn et al., 2010) 
L-Diphenylalanine 
Hollow nanotubes for drug 
delivery 





1.8 Research Objectives 
The ability to form amyloid proteins under suitable conditions is an inherent property of all proteins 
and peptides (Dobson, 2004). Although much research has been focused on the structure and 
assembly process of amyloid proteins, little is understood about the factors determining the toxic 
nature of amyloid proteins.  
The oligomeric species has been identified as being neurotoxic in disease (Glabe & Kayed, 2006; 
Kayed et al., 2003; Kayed & Lasagna-Reeves, 2013; McLean et al., 1999) , however, we are still 
unclear as to what specifically determines oligomers to be toxic.  This raises questions such as, 'is it 
the ability to form oligomers?', 'is toxicity related to size or conformation?' and 'is internalisation 
required for amyloid toxicity?' Addressing these questions, combined with lessons learnt from non-
toxic functional amyloid proteins, will help us determine 'rules' that govern amyloid toxicity.  
To address these questions in the following chapters, we use models of disease-related and functional 
amyloid proteins to better understand their assembly process and relate this to cytotoxicity. By 
assessing factors such as primary sequence, size and conformation, we will gain a better 





Chapter 2: Methods 
2.1 Biophysical characterisation of amyloid proteins 
2.1.1 Introduction 
The structure of amyloid proteins has been extensively researched; we know amyloid proteins are 
insoluble fibrillar species which display a cross-β structure. This cross-β structure is attributed to the 
orientation of the β-strands which are perpendicular to the fibre axis with pairs of β-sheets being 
tightly bonded by interdigitating amino acid side chains (Serpell, 2000).  
In pathology, oligomers have been identified as the neurotoxic species (McLean et al., 1999). The 
structure of this toxic species has been difficult to characterise due to its transient nature. Despite this, 
much effort has been made to establish the structure of the oligomeric species. 
2.1.2 Techniques for amyloid structural characterisation 
Mounting structural information regarding amyloid fibrils has been established due to advances in 
biophysical techniques. There are now a number of techniques employed to elucidate the structure of 
amyloid proteins. For example, electron microscopy allows for the direct visualisation of amyloid 
morphology. This has long been considered a low resolution method, however with the development 
of cryo-EM, resolution is greatly improved (Langkilde & Vestergaard, 2009).  
Small angle neutron or X-ray scattering (SANS/SAXS) offers the advantage of medium resolution 
visualisation of any nanoscale particle. High resolution information can be obtained by X-ray 
diffraction patterns of crystals where the electron density provides a 'map' of all atom thereby provide 
structural information at atomic resolution. This can often prove difficult with amyloid proteins as 
crystallisation is a necessity for this technique and  requires  homogeneity of solution (Langkilde & 
Vestergaard, 2009). To obtain crystal structures of amyloid proteins, short amyloidogenic segments 
from the full length protein are used (Sawaya et al., 2007). Therefore, often the information obtained 
from this technique is usually taken to be a 'snapshot' of protein structure; in reality, the protein 





not be the most appropriate method for structural determination since some fibres and crystals formed 
from the same peptide may differ in structure (Marshall et al., 2010). Nevertheless, atomic resolution 
structural information obtained from X-ray diffraction is invaluable to understanding fibrillar amyloid 
structures.   
ssNMR has also been extremely useful in gaining an understanding of amyloid fibrils. This technique 
determines information regarding the identity and backbone conformations of (non) β-strand 
segments, the supramolecular organisation of β-sheets and interactions/contacts between amino acid 
side chains. ssNMR also provides an overall arrangement and symmetry of cross-β protofilaments 
(Tycko, 2011). Often combined with electron microscopy, ssNMR can be used to develop molecular 
models of amyloid.  
As following the assembly process of amyloid proteins is a major aspect of this thesis, we use three 
main biophysical techniques to probe for structural changes over time. These include transmission 
electron microscopy (TEM), circular dichroism (CD) and Thioflavin T (ThT) fluorescence. X-ray 
Fibre Diffraction (XRFD) is also used to detect for the characteristic cross-β structure of amyloid 
proteins. These techniques are also complemented with dot/western blotting and 
immunocytochemistry. 
2.1.3 Transmission Electron Microscopy 
Electron microscopy can be separated into two broad categories (Figure 2.1); transmission electron 
microscopy (TEM) and scanning electron microscopy (SEM). In TEM, electrons are projected 
through the sample to produce a two-dimensional image. SEM, produces a three-dimensional image 
by using a 2-3nm spot of electrons to scan the surface of the sample to generate secondary electrons 
from the samples itself. These are then detected by a sensor. A third category of electron microscopy 
combining both TEM and SEM is known as scanning transmission electron microscopy (STEM) and 






Figure 2. 1. Schematic representation of Transmission Electron Microscopy (TEM) and Scanning 
Emission Microscopy (SEM). In TEM, electrons are passed through the sample and provides a two-
dimensional 'shadow' image. SEM produces a three-dimensional image detected by a sensor. 
 
TEM has been used to visualise amyloid proteins for many years. It has the advantage of providing 
better resolution (Winey et al., 2014) than light microscopes as well as simple sample preparation for 
imaging, makes it a highly attractive and useful tool (Gras et al., 2011) . 
In TEM, electromagnetic lenses focus electrons into a thin beam which is then passed through the 
specimen. Depending on the density of the material present, some electrons are scattered and 
disappear. The un-scattered electrons hit a fluorescent screen at the bottom of the microscope which 
gives rise to what is known as a 'shadow image'.  
TEM is extremely useful for visualising the morphology of amyloid fibrils (e.g. ribbon-like fibrils or 
curved fibrils) as well as quantifying data such as fibril length. In order to achieve a good contrast and 
protect the specimen from radiation damage, samples are typically negatively stained using a heavy 
metal (Bremer et al., 1992). One of the most commonly used negative stains is uranyl acetate which 
forms a radiation-stable, electron dense coat over the sample. As the beam of electrons passes through 
the sample, electrons are absorbed by the stain and therefore the sample appears light and surrounding 





Visualising the assembly of amyloid proteins using TEM is an excellent tool in monitoring species 
formed during the assembly process and will also enable us to link structural morphology to 
cytotoxicity.  
2.1.4 Circular Dichroism (CD) 
CD is often used to probe for the secondary structure of a protein. The way in which this is achieved 
is through differential absorption of circularly polarised light by an optically active molecule, either to 
the left or right.  
As a beam of UV light has time dependent electric and magnetic fields, this beam is polarised by 
passing through prisms/filters, its electric field will oscillate sinusoidally in a single plane. These 
waves can be visualised as circles which rotate clockwise (R) or anticlockwise (L) and are 90 degrees 
out of phase with each other (Bulheller & Hirst, 2009). Asymmetric molecules absorb right- and left- 
handed circularly polarised light to different extents, as well diffract the waves by different indices. 
This results in a rotated plane of the light wave and the R and L vectors trace an ellipse. The light is 
therefore said to elliptically polarised (Greenfield, 2006).  
As a protein folds into its secondary structure, the chromophores of amides in the polypeptide 
backbone are specifically arranged and their optical transitions are shifted as a result of exciton 
interactions (Sreerama & Woody, 2004). This means each secondary structure has its own 
characteristic spectra. Table 2.1 provides the signal wavelength for each secondary conformation 
(Martin & Schilstra, 2008).  
Conformation Minima (nm) Maxima (nm) 





β-sheet -218 +195 






Figure 2. 2. CD spectra for α-helix, β-sheet and random coil secondary structure conformation. Taken 
from www.proteinchemist.com 
 
Usually, the secondary structure of proteins is measured in the far-UV region, (180-250nm), where 
the peptide bonds are measured. Near-UV CD of proteins (310-255nm) reflect the tertiary structure of 
proteins due to Trp, Tyr, Phe and Cys residues. However, a number of amino acid side chains absorb 
in the far-UV regions too, including Try, Trp, Phe, His and Met (Martin & Schilstra, 2008) .  
The α-helix -222nm arises from the n п* and the -208nm and +195nm is due to the splitting of the п 
п* transition where the 208nm represents the polarised component parallel to the helix and the 
195nm represents the perpendicular component. The positive and negative peaks for the β-sheet signal 
arise from the п п* and n п* transition respectively  (Bulheller & Hirst, 2009). The n п* 
transition is of lower energy and intensity and is polarised along the carbonyl bond. The п п* 
transition has a higher energy and intensity and is polarised between the oxygen and nitrogen (Figure 
2.2).  
2.1.5 Thioflavin T (ThT) fluorescence 
Thioflavin T is an amyloid binding dye first identified in 1959 (Vassar & Culling, 1959). Much 





fluorescence is attributed to the red shift upon binding to amyloid (Groenning, 2010). A strong ThT 
fluorescence signal at ~483nm is seen when excited at 450nm (Xue et al., 2017).  
The mechanism of ThT fluorescence is thought to be due to the central C-C bond connecting the 
benzothiazole and benzylamine rings (Xue et al., 2017). A vast amount of evidence suggests that ThT 
behaves as a ‘molecular rotor’; the C-C bonds allow the ThT benzothiazole and benzylamine rings to 
rotate freely (Biancalana et al., 2009) which quenches excited states causing low fluorescence. 
Binding to amyloid ‘locks’ the dye and immobilizes the rotation of the benzothiazole and 
benzylamine rings. This keeps ThT in its excited state and results in an increased fluorescence 
(Biancalana et al., 2009).   
The binding mechanism of ThT still remains unclear, however as the dye binds to amyloid fibrils of 
differing primary sequence, it is a structural feature that is most likely recognised by ThT. 
Conformationally, it is thought that unbound ThT preferentially remains in a non-planar 
conformation. There are two proposed conformations of ThT when bound to amyloid; it is thought to 
remain planar (Krebs et al., 2005; Lindgren et al., 2005) or significantly twisted (Biancalana et al., 
2009; Dzwolak & Pecul, 2005).  
The cross-β structure of amyloid fibrils gives rise to cross-strand ladder arrangement of side chains. 
These side chains have been shown to from channel-like motifs in which linear dyes, such as ThT, 
could bind (Biancalana et al., 2009). Using polarised fluorescence microscopy, it has been observed 
that the long axis of ThT is aligned in a parallel orientation to the fibre axis (Krebs et al., 2005). 
Another suggested mechanism for ThT binding to amyloid, is via hydrophobic interactions with ThT 
micelles formed at concentration higher than 4µM in water (Khurana et al., 2005).  Building on this, 
ThT may bind to large hydrophobic regions on amyloid proteins as excited dimers, termed as 
‘excimers’ (Groenning et al., 2007). Both these theories, however, do not take into account the 






2.2 Methods relating to chapters 3-6 
Unless stated otherwise, data presented in the results chapters are the average of three independent 
repeats.  
2.2.1 Identification of amyloidogenic regions 
The WALTZ algorithm (http://waltz.switchlab.org) was used to identify amyloidogenic regions for 
Aβ42, Aβ42-1 and AβS peptides. The primary sequence of each peptide was input in FASTA format 
into the WALTZ algorithm at pH 7. Data was output as a text file and replotted using R Studio. The 
algorithm was also used to explore the effects of amino acid substitutions within the two 
amyloidogenic regions of Aβ42 sequence, in order to abolish amyloidogenicity. There were several 
substitutions identified at positions 19 and 37 as reducing amyloidogenicity and two were selected 
based on previous assembly studies; F19S and G37D. This variant Aβ42 sequence will be referred to 
as vAβ42. 
2.2.2 Preparation of Aβ42 and primary sequence variant peptides 
Recombinant Aβ42 was purchased from rPeptide as 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) films. 
Aβ42-1 and AβS were purchased from Bachem in powder form and vAβ was purchased from JPT.  
0.2mg aliquots of peptide were solubilised in 200µl HFIP (Sigma-Aldrich) to disaggregate any 
preformed aggregates. The solution was then vortexed for 1 minute and sonicated in a 50/60Hz bath 
sonicator for 5 minutes. The HFIP was then dried off using a steady flow of nitrogen gas. 200μl of 
anhydrous dimethyl sulfoxide (DMSO) (Sigma-Aldrich) was then added and vortexed for 1 minute. 
The solution was then sonicated for 1 minute and then put through a buffer equilibrated 7K MWCO 
Zeba buffer-exchange column (Thermo Scientific) at 4°C. The protein solution was then kept on ice 
whilst the absorbance at 280nm was measured using a NanoDrop spectrophotometer. The 
concentration was calculated using the molecular coefficient of 1490 M-1cm-1; (A280/1490) x1000 x 
1000. Solutions were immediately diluted to 50μM in buffer and this was taken to be the new working 





temperature for 48 hours for AβF. For AβSon, the solution was incubated at room temperature for 48 
hours and then sonicated for 10 minutes on ice.  
Solutions were prepared in either HEPES buffer (10mM HEPES, 50mM NaCl, 1.6mM KCl, 2mM 
MgCl and 3.5mM CaCl2) or in 20mM Phosphate buffer (200mM Na2HPO4, 200mM NaH2PO4, 
diluted to 20mM with ddH2O), both at pH 7.4. 
2.2.3 Preparation of Alexa Fluor 488-conjugated Aβ 
Aβ42 was prepared as described above (Section 2.2.2), up to the addition of DMSO. As per the 
manufacturer’s instructions (Life Technologies), the Alexa Fluor 488 tag was prepared by adding 
10µl H2O to the Alexa Fluor TFP ester (kept on ice). This was added to the Aβ42 in DMSO with 10µl 
1M sodium bicarbonate (pH 8.3), mixed for incubated at room temperature for 15 minutes. From this 
step onwards, the sample was protected from light using aluminium foil. After this, the usual Aβ 
preparation method continued with the Zeba buffer exchange column. To take into account the 
absorbance of the dye, the following calculation was used for the concentration of the 488-tagged 
Aβ42 preparation: 
Protein concentration (M) = [A280 – (A494 x 0.11)]/ 1490 
For 488-AβO, the preparation was incubated for 2 hours at room temperature before being added to 
cells. The preparation was incubated for 48 hours at room temperature for 488-AβF and for 488-
AβSon, the preparation was incubated for 48 hours at room temperature and sonicated on ice for 10 
minutes.  
The labelling efficiency was not measured for this preparation of Alexa Fluor tagged-Aβ as it was 
assumed any unbound dye would be removed by the buffer exchanged column. It was also assumed 
that the final concentration of Aβ42 measured was all labelled with the dye. However, it would 
beneficial to investigate the labelling efficiency in the future to ensure the same level of labelling was 





The labelled peptide was only used for live cell imaging experiments. All structural characterisation, 
cell viability and immunocytochemistry experiments were conducted on untagged peptide.  
2.2.4 Preparation of functional amyloid peptides  
Both functional amyloid proteins were prepared at 1mg/ml in the appropriate buffer/ddH2O for 
experimentation. Due to the amyloidogenicity of both peptides, an accurate absorbance at 280nm was 
not possible. Using the molecular weight of GNNQQNY (836.81 Da) a stock concentration of 
1.12mM was calculated. For FEFKFEFKK (1249.47 Da) the stock concentration was calculated to be 
800.33µm. 
Solutions were prepared in either HEPES buffer (10mM HEPES, 50mM NaCl, 1.6mM KCl, 2mM 
MgCl and 3.5mM CaCl2) or in 20mM Phosphate buffer (200mM Na2HPO4, 200mM NaH2PO4, 
diluted to 20mM with ddH2O), both at pH 7.4. 
2.2.5 Transmission Electron Microscopy 
Aliquots of peptide samples, prepared as described above, were taken at progressive time points to 
monitor changes in morphology. 4μl of peptide was applied on the surface of Formvar/Carbon film 
coated 400 mesh copper grids (Agar Scientific) and allowed to absorb for 2 minutes before being 
blotted dry. The grid was then washed with 4μl of milliQ-filtered water and blotted dry. The grid was 
negatively stained using 2% (w/v) uranyl acetate for 2 minutes blotted and dried. This was repeated 
once more, and the grid was left to air dry before being imaged. All grids were examined and imaged 
using a JEOL JEM1400‐Plus TEM at 120 kV and images were captured using a Gatan OneView 4K 
camera (Abingdon, UK). FIJI software was used to measure the length of oligomers and sonicated 
fibrils; three images from three independent preparations were measured. 
2.2.6 Circular Dichroism 
Aliquots of peptide samples (prepared in 20mM phosphate buffer, pH 7.4) were taken at progressive 





0.5mm (Hellma) cuvette was used for AβS. For both GNNQQNY and FEFKFEFKK were prepared in 
water, a 0.1mm cuvette was used. Scans were taken between 180-280nm on a JASCO J715 
Spectropolarimeter at 20°C. Three spectra were averaged for each measurement. Spectral data were 
converted to molar ellipticity using the following equation: Mdeg x Molecular Weight / (10 x mg·ml-1 
x pathlength of cuvette x number of amino acids). 
2.2.7 Thioflavin T fluorescence 
As a measure of fibrillogenesis, the fluorescence of 10μM ThT in 50μM peptide was measured in a 
quartz 10mm cuvette. Aliquots of each peptide were taken at time points corresponding those for EM 
and CD. An emission scan between 460-600nm was performed in a Varian Cary Eclipse Fluorescence 
Spectrophotometer at a scan rate of 600nm/min and three spectra were averaged for each 
measurement. The sample compartment was kept at 21°C.      
2.2.8 X-Ray Fibre Diffraction 
X-Ray fibre diffraction (XRFD) patterns of partially aligned fibres formed by Aβ42-1 and AβS in 
water were obtained by Louise Serpell (Vadukul et al., 2017). XRFD patterns for aligned F9 fibres in 
20mM Phosphate buffer, washed three times with water and 10 minutes centrifugation at max speed, 
were obtained by Youssra Al-Hilaly. Briefly, 10µl droplets of each peptide were suspended between 
two wax-tipped 1.2mm O.D, 0.94mm I.D borosilicate capillaries (Harvard apparatus). These were 
incubated for 24 hours at room temperature in a parafilm sealed petri dish. X-ray diffraction patters 
were obtained using a Rigaku 007HFcuKa (λ 1.5419 Å) rotating anode generator with a Saturn 944+ 
CCD detector. Exposure times of 10–120 seconds were used with specimen to detector distances of 50 
or 100 mm. The images were displayed and examined using Mosflm. 
2.2.9 NMR 
NMR studies were conducted by Dr Iain Day. vAβ was prepared as described above at a 
concentration of 200µM in 10% v/v D2O standard. 1H NMR spectra were acquired every 30 minutes 





echo method provided solvent suppression and the temperature was regulated at 25°C. The spectra 
were processed with 1.5Hz line broadening, base line correction and Fourier transformation (Marshall 
et al., 2016). 
2.2.10 Dot blotting 
The primary antibodies 4G8 and 6E10 were purchased from Biolegend, A11 from Thermo Fisher and 
NU1 was kindly gifted to us from William Klein Lab (Lambert et al., 2007). The epitopes of each 
antibody are shown in Table 2.2. The anti-mouse and anti-rabbit HRP conjugated secondary 
antibodies were purchased from Cell Signaling and Promega respectively.  
 
Dot blotting was not possible for Aβ42-1, AβS, GNNQQNY and FEFKFEFKK as these do not have 
recognisable epitopes for our available antibodies.  
5μl aliquots of Aβ42 and vAβ were taken at progressive time points over a 7-day time period and 
spotted onto a 0.45µm nitrocellulose membrane and allowed to dry. The membrane was boiled with 
PBS for three minutes twice before being incubated in blocking buffer (10% Milk in 0.1% TBS-
Tween(T)) for 1 hour at room temperature. The blocking buffer was then replaced with primary 
antibody (NU1, 6E10 and 4G8 at a 1: 10,000 dilution. A11 at a 1:5000 dilution) and incubated 
overnight at 4°C. The membrane was washed three times with 0.1% TBS-T for 10 minutes per wash 
before being incubated with HRP conjugated secondary antibody (anti-mouse for NU1, 6E10 and 4G8 
Antibody Epitope 
NU1 
Conformational antibody specific to oligomers (Lambert et al., 
2007) 
A11 















at a 1: 10,000 dilution. Anti-Rabbit for A11 at a 1:5000 dilution) for 30 minutes at room temperature. 
Following another set of washes, the membrane was incubated with Enhanced Chemiluminescence 
(ECL) substrate (Bio-Rad) for three minutes before being developed on CL-Exposure Film (Thermo 
Fisher). 
2.2.11 Western Blotting and Immunoprecipitation 
Western blotting was not possible for Aβ42-1, AβS, GNNQQNY and FEFKFEFKK as these do not 
have recognisable epitopes for our available antibodies.  
2μg of Aβ42 and vAβ peptide in 4 x Laemelli Sample Buffer (Bio-Rad) containing 1:10 β-
mercaptoethanol (BME) were loaded on a 50μl 10 well 4-20% Mini-PROTEAN TGX Stain-Free gel 
(Bio-Rad). The gel was run in 1X running buffer (diluted from 10X Tris/Glycine/SDS stock, Bio-
Rad) at 100V. The gel was then transferred on to 0.45μm nitrocellulose membrane in 1X transfer 
buffer (diluted from 10X Tris/Glycine stock, Bio-Rad) for 2 hours at 25V. The membrane was 
incubated with blocking buffer (10% Milk in 0.1% TBS-T) at room temperature for 1 hour after 
which the 6E10 primary antibody (1: 10,000 dilution in blocking buffer) was applied for overnight at 
4°C. The membrane was the washed three time with 0.1% TBS-T for 10 minutes per wash after which 
the membrane was incubated with HRP conjugated anti-mouse secondary antibody (1:10,000 dilution 
in blocking buffer) for 30 minutes at room temperature. The membrane was washed again three times 
with 0.1% TBS-T before being incubated with ECL substrate for 5 minutes. The membrane was then 
developed on CL-Exposure Film. 
For immunoprecipitation, cells were incubated with 10µM Aβ for the required amount of time after 
which the media was replaced with fresh, Aβ-free media. The media removed, was kept at -80°C until 
ready to use. The cells were incubated for 7 days after which the new media was removed, and cells 
were lysed using RIPA buffer (Thermo Fisher) supplemented with phosphatase and protease 
inhibitors (1:100 dilution). The cell lysate was then collected in an Eppendorf tube and kept at 4°C for 
20 minutes after which it was centrifuged at max speed at 4°C for 15 minutes. DynaBeads Protein G 





placed on a magnet and the antibody was removed. The media removed and cell lysate samples were 
added to the beads and shaken at 800rpm for 45 minutes at room temperature. The samples were 
again placed on the magnet following this and the supernatant was discarded. The beads were washed 
three times with 0.025% PBS/Tween. For elution, 20µl of 50mM glycine (in H2O) and 10µl 4x 
Laemelli Buffer containing 1:10 BME was added to the beads and boiled at 80°C for 10minutes. The 
samples were placed on to the magnets once more and everything except the beads were loaded on to 
the gels. Western blotting was then carried out as described above using the 4G8 primary antibody 
(1:10,000) and an anti-mouse HRP conjugated secondary antibody (1: 10,000).  
2.2.12 Cell Culture  
Rats are housed in a specialised facility under Home office guidelines and sacrificed using Schedule 1 
procedures in accordance with Animals (Scientific Procedures) Act 1986, Amendment Regulations 
2012. Primary hippocampal cultures were prepared from either P0 or P1 rats. Initially, the 
hippocampus was dissected in ice cold Hanks' Balanced Salt Solution (HBSS) containing 0.1M 
HEPES. It was then washed in pre-warmed Basal Medium Eagle (BME) (Gibco) containing 0.5% 
glucose, 2% FCS, 1mM Na-Pyruvate, 0.01M HEPES (pH 7.35), Penicillin-Streptomycin, 1% B27 
supplement and 1% Glutamax. The hippocampus was then titrated using a 1ml pipette until the tissue 
was fully dissociated and then finally diluted further with the BME supplemented media. 
Approximately 40,000 cells were plated on Poly-D-Lysine (20μg·mL-1) and Laminin (20μg·mL-1) 
pre-coated coverslips and incubated at 37°C and 5% CO2. After 3-5days incubation, the cells were 
treated with 3.25μM cytosine arabinoside to stop astrocyte proliferation. Cells were used for 
experiments, 10-14 days after plating.  
2.2.13 Cell viability assay: ReadyProbes  
All peptides were prepared in 10mM HEPES as described. Aβ peptides were incubated at room 
temperature for 2 hours before being added to rat primary hippocampal cultures at a final 
concentration of 10μM.  GNNQQNY and FEFKFEFKK were added immediately after preparation at 





each Readprobes reagent (Life Technologies) was added to the wells. The NucBlue live reagent 
(excitation/emission at 360 and 460nm respectively) stains the nuclei of all cells. The NucGreen dead 
reagent (excitation/emission at 504 and 523nm respectively) stains only the nuclei of dead cells with 
compromised plasma membranes. Cells were incubated for 15 minutes with the reagents and then 
imaged using a Zeiss CO widefield microscope using the DAPI and FITC filters. 4-6 regions of 
interest were imaged per well and the percentage of dead cells were calculated as the number of green 
cells in the entire DAPI stained population. Astrocytes in the cultures were not counted. Cells were 
counted using the cell counter plug-in and astrocytes were excluded in the counting. The experiment 
was repeated 3 independent times. 
To assess whether the AβO internalisation is necessary to mediate cytotoxicity, cells were treated with 
10µM AβO for increasing lengths of time before being replaced with fresh, Aβ-free media. Cells were 
incubated for a total of 7 days before using the ReadyProbes assay to assess the measure of 
cytotoxicity.  
2.2.14 Immunofluorescent labelling and confocal microscopy 
The goat anti-mouse 488- and 555-Alexa Fluor conjugated secondary antibodies were purchased from 
Invitrogen. 
Primary hippocampal cells were treated with the peptide as desired for the required time before 
removing the media and immediately fixing the cells with 2% paraformaldehyde for 15 minutes.  This 
was then washed with wash buffer (25% Superblock (Thermo Fisher) in PBS) and cells were 
permeabilised with 0.3% Triton-X 100 for 10 minutes. 50µM glycine (in PBS) was then added to 
block unreacted aldehydes. Cells were then blocked with undiluted Superblock for 30 minutes, after 
which the 4G8 primary antibody (1:500 dilution in wash buffer) was incubated with the cells for 1- 
hour at room temperature. Following this a set of three washes for 5 minutes each using wash buffer 
were carried out.  Alexa Fluor 555 conjugated goat anti-mouse secondary antibody (1:500 dilution in 
wash buffer) was incubated with the cells for 1-hour followed by another set of washes. The 





Cell were imaged using a 63x1.2NA objective on a Leica SP8 confocal microscope. Emissions were 
collected using a 561nm emission laser line between 555-650nm on a PMT detector. Samples were 
imaged in a sequential manner.  
2.2.15 Live cell imaging  
Aβ42 peptide was prepared with a 488 Alexa Fluor tag as described above (Section 2.2.3).  Primary 
hippocampal neurons were plated on a PDL and Laminin coated 35mm glass bottom dish treated with 
3.25μM cytosine arabinoside after 3-5days of incubation to stop astrocyte proliferation. Cells were 
used for experiments 10-14 days after plating. The tagged 488-Aβ peptide was added to cells and 6 
regions of interest were imaged every 20 minutes for 15 hours on a Leica SP8 confocal microscope. 
Cells were maintained at 37°C and 5% CO2 for the duration of imaging. Cell were imaged using a 63 
x 1.2 NA oil objective and emissions were collected using a 488nm excitation laser line between 495 
and 540nm on a PMT detector. The FIJI software was used to string together images from the middle 





Chapter 3: Characterising the assembly and toxicity of the 
disease-related Aβ42 amyloid protein  
 
Chapter Overview 
Aβ42 deposits as extracellular plaques in Alzheimer's disease and is one of the key pathological 
hallmarks of the disease. The production of this amyloid protein, misfolding and subsequent self-
assembly has been the focus of many studies. Using a highly reliable and reproducible method of 
sample preparation, this chapter presents an extensive characterisation of Aβ42 self-assembly using 
several biophysical techniques. These include transmission electron microscopy (TEM), circular 
dichroism (CD) and Thioflavin T (ThT) fluorescence. This has been combined with conformation 
specific and anti-Aβ antibodies to identify assemblies present over a 7-day period using dot and 
western blotting. The toxicity of the oligomeric species has been assessed using a ReadyProbes assay. 
3.1 Introduction 
The enzymatic cleavage of Aβ is normally secreted as a peptide of between 39-40 amino acids in 
length (Selkoe, 1994). In AD, however, there is an increase in the secretion of the longer 42 amino 
acids. The additional two amino acids at the C-terminal of the Aβ means a higher propensity to self-
assemble into amyloid, possibly due to hydrophobicity, highlighting the importance of primary 
sequence in amyloidogenicity (Burdick et al., 1992). This, however, does not mean Aβ40 cannot form 
amyloid; extensive studies have established the formation of amyloid by Aβ40 (Lomakin et al., 1996; 
Schmidt et al., 2009; Villmow et al., 2016). In fact, the characteristic plaques deposited in AD are 
composed of both Aβ40 and Aβ42 (Fukumoto et al., 1996). The fibrillar species of Aβ42 was 
previously thought to be a causative factor of neurodegeneration, however, as there was a weak 
correlation seen with cognitive decline in relation to the amyloid plaque deposition (McLean et al., 
1999), this has since been revised. There are, in fact, arguments for the protective role of Aβ42 fibrils 
as the formation of these sequester available oligomers from the local environment and therefore limit 





The oligomeric species of Aβ has been identified as being neurotoxic due to the strong correlation 
between the concentration of soluble Aβ and cognitive decline (McLean et al., 1999). The oligomers 
of Aβ42 have been shown to be more detrimental than Aβ40 (Bitan et al., 2003; El-Agnaf et al., 2000; 
Ono et al., 2009); the work presented in this chapter will solely concentrate on the structural 
characterisation and toxicity of Aβ42.   
The assembly of Aβ42 follows a general pathway from monomers, oligomers, protofibrils and fibrils 
(Figure 3.1). 
 
Figure 3. 1. Schematic representation of Aβ42 assembly. Aβ42 assembles from soluble monomers to 
oligomers (the toxic species, pink box), to protofibrils and finally insoluble mature amyloid fibrils. This is 
a dynamic process. 
 
The formation of the oligomeric intermediary species in the pathway to amyloid fibrils, is nucleation 
dependent (Ferrone, 1999; Lomakin et al., 1996; Xue et al., 2008). The nucleation phase is the stage at 
which the monomer undergoes unfavourable self-association and forms a nucleus to facilitate the 
formation of fibrils. There is also thought to be a process of secondary nucleation whereby the surface 
of fibrils act as a catalyst on which monomers can bind and form new nuclei for fibril formation 
(Cohen et al., 2013; Linse, 2017).  
The preparation of Aβ42 in vitro, differs greatly from one research group to another. This poses a 
problem of reproducibility, sometimes even within a research group, as different species of Aβ42 are 
produced. The species used in experiments are often not characterised which offers an explanation as 





the same effects as Aβ42 oligomers (Kim et al., 2003). Moreover, due to the lack of a definitive 
definition, the term ‘oligomer’ covers a large range of sizes and this has led to arguments for different 
sizes being more or less toxic than others (Table 3.2) (Benilova et al., 2012; Larson & Lesne, 2012). 
Finally, as the sample population is always heterogeneous, the concentration of a particular species 
can vary greatly from one preparation to the next. Therefore, the oligomeric or fibrillar concentration 
being used in experiments may be inaccurately measured.  
To overcome this problem, we have established a preparation method that allows for reproducible and 
reliable sample preparation. After extensive characterisation over a 7-day period, we can confidently 
identify the species most prevalent in the population in vitro, at each time point following preparation 
and confirm the oligomeric species to be deleterious to cellular function.  
3.2 Aβ42 controlled assembly: overcoming factors affecting self-assembly 
There are several factors that affect the assembly process of Aβ; some examples are shown in Figure 









3.2.1 The effect of pH 
Physiologically, Aβ has been found in low pH organelles such as late endosomes (pH 4.9-6) (Huotari 
& Helenius, 2011) and lysosomes (Broersen et al., 2011; Selkoe, 1994; Wood et al., 1996), and it is 
known that acidic pH promotes the formation of amyloid fibrils (Burdick et al., 1992; Su & Chang, 
2001; Wood et al., 1996). 
Studies investigating fibril formation of various Aβ fragments over the range of pH 3-10, revealed 
that fibril assembly and disassembly was a function of pH. Table 3.1 summarises the main findings of 
a study using varying lengths of the first 28 residues in the Aβ sequence, to determine the effect of pH 
on assembly (Fraser et al., 1991). Specific residues necessary for electrostatic and hydrophobic 
interactions critical for fibril formation were also identified (Fraser et al., 1991). The findings of this 
study reveal that fibrils are only formed between pH 3-8, suggesting the requirement of the His 
imidazole and the Asp/Glu carboxylic acid side chains ionisation. This is due to the pKa values of 
these groups in this pH range; pKa 6.6 for His imidazole and pKa 3 for the carboxyl acid side chains 
of Asp and Glu. Maintaining these respective positive and negative charges is optimal for fibril 
formation.  
The same study highlighted the hydrophobic interactions between Leu17 and Ala21, therefore it was 
proposed during the self-assembly process, these electrostatic and hydrophobic interactions gives rise 
to an inter-sheet core which stabilises an anti-parallel arrangement of β-strands by residues 13-23 
(Fraser et al., 1991). This was later confirmed by NMR studies which identified a hydrophobic cluster 
at residues 17-21 (Hilbich et al., 1991) 
Truncating the first 16 residues has shown to drastically affect fibril stability (Brannstrom et al., 
2017). As all three histidines of the Aβ sequence are found within this region, the importance of these 
residues has not been overlooked. Using Surface Plasmon Resonance (SPR) to monitor the rate at 
which a monomer is incorporated onto a fibril and how long it is bound for, it is possible to monitor 
fibril stability. Single mutations of each of the histidines for alanine, as well a variant replacing every 





resulted in a 200-fold increase in fibril stability for each alanine variant, suggesting that the histidines 
only play a role in fibril stability at a neutral pH (Brannstrom et al., 2017). This suggests that although 
histidines play an important role in fibril stability, the protonation of their side chains is not critical in 
enhancing fibril stability as a function of pH (Brannstrom et al., 2017). Lowering the pH, has in fact 
been thought to facilitate fibril stability by a gain of function allowing a more rapid addition of 
monomers to fibrils (Brannstrom et al., 2014). 
 
More recent work has shown that the histidines may actually cause inhibition of fibril formation at a 
lower pH range due to the positively charged residues repelling each other in fibril forming structures. 
H6A, H13A and H14A mutants were monitored and it was revealed that while H6 does not affect 
fibril formation, H13 and H14 must be simultaneously protonated to inhibit fibril formation (Tiiman 
et al., 2015). It is likely, however, that the formation of fibrils is dependent on at least one His-
Asp/Glu salt bridge (Fraser et al., 1991). This suggests that although a lower pH could result in 
promoting the stability of fibrils, it may not enhance the rate of fibril formation. 
Although these studies are extremely important to understand the effect of pH on amyloid assembly, 
many did not consider the preparation of peptides (with the exception of Fraser et al, who pre-treated 
Peptide pH Morphology 
β(1-28) Low (<3) Fibril fragments 
Mid (3-7.5) Amyloid fibrils 
High (>8) No fibrils 
β(9-28), β(11-28), β(13-28) Low (<3) Small fibrils 
 
Mid-High (3-9) Amyloid fibrils 
High (10) No fibrils 
β(15-28) Low (<3) Ribbons 
Mid-High (3-9) Ribbons and Amyloid fibrils 
High (10) No fibrils 
β(17-28) Low (<3) Ribbons 
Mid-High (3-9) Ribbon fragments 
High (10) No fibrils 
β(19-28) <3 Amyloid-like fibrils 
>3 No fibrils 
Table 3. 1.Morphologies of amyloid fibres produced from various Aβ fragments at different pH. Adapted 






fragments with trifluoroacetic acid) (Fraser et al., 1991) . The results presented may be based on pre-
assembled structures rather than structures formed during assembly.   
pH is also thought to play an important role in the solubility of the peptide; the pH range at which the 
peptide is deposited may be due to the isoelectric point when the net charge is close to zero (Burdick 
et al., 1992). Aβ42 is considerably insoluble at a physiological pH due to the increased length of the 
hydrophobic C-terminal and is even more insoluble at a lower pH of 5 (Barrow & Zagorski, 1991).  
As previously mentioned, the formation of amyloid fibrils is a nucleation event which is concentration 
dependent. If the concentration of monomers is not high enough to form the nucleus for further 
addition of monomers, fibril formation does not occur. It has been shown by two groups that at a 
neutral pH, this critical concentration is ~100nM (Brannstrom et al., 2017; Hasegawa et al., 2002). 
This critical concentration is dramatically reduced, as much as 120 times, when the pH is lowered; 
another explanation for the formation of Aβ localised to acidic intracellular organelles such as 
endosomes and lysosomes (Brannstrom et al., 2017). This lowered critical concentration due to more 
acidic environment, also explains how there can be amyloid formation when the physiological 
extracellular Aβ concentration is only ~1nM (Jarrett et al., 1993). 
As one of our aims is to establish a protocol allowing for a 'controlled' assembly of Aβ, an acidic 
environment that would promote fibril formation and stability would not be favourable. Moreover, for 
an Aβ42 preparation that is physiologically relevant and can be used without disrupting optimal cell 
culture conditions, using only buffers at pH of 7.4 was selected for our protocol.   
3.2.2 Solvents and seeding 
The solvent used during the preparation of Aβ42 plays a critical role in the assembly process. As Aβ 
is often difficult to dissolve into physiologically relevant buffers, it is often first diluted into a solvent. 
Some common examples include DMSO, trifluoroacetic acid (TFA) and a mixture of TFA and 
acetonitrile (ACN) (Shen & Murphy, 1995). The solvent is thought to contribute to the toxicity 





less prominent if first dissolved in DMSO and least toxic if first dissolved in water (Busciglio et al., 
1992; Shen & Murphy, 1995).  This may be due to different solvents promoting different structures 
and aggregation states.  
The effect of various solvents on Aβ aggregation has been previously demonstrated.  For example, if 
the peptide is dissolved in DMSO, there is no β-sheet content detected (Shen & Murphy, 1995). This 
is thought to be due to the DMSO competing with the peptide carbonyl group for hydrogen bonding 
with the peptide amine groups (Shen & Murphy, 1995). In this way, DMSO destabilises the secondary 
structure. Although it has been shown that Aβ prepared in DMSO does form fibrillar species, it is 
100-fold more toxic than Aβ prepared in water (Zagorski et al., 1999). This is thought to be due to the 
slower assembly of Aβ in DMSO than in water (Mattson et al., 1992). 
One important reason for using solvents to dissolve Aβ, is to completely disaggregate any preformed 
aggregates and encourage a homogenous population of monomeric, unstructured peptide. This is due 
to preformed aggregates seeding further assemblies; introducing seeds can by-pass the lag phase of 
Aβ assembly completely by rapid secondary nucleation (Knowles et al., 2009; Xue et al., 2008). As 
the lag phase is an important step in the formation of the oligomeric species, it is extremely important 
that any seeds are removed.  
HFIP is the most commonly used organic solvent for amyloid preparation; a few examples are for Aβ 
preparations (Hilbich et al., 1991; Snyder et al., 1994; Wood et al., 1996), prion proteins (Gasset et 
al., 1992; Harrison et al., 1997) and IAPP preparations (Higham et al., 2000). Alcohols are often used 
as solvents; alkyl alcohols (or alkanols) are more effective in denaturing proteins than those with 
smaller alkyl groups which indicates the importance of the hydrophobic interactions in the 
denaturation process. Alcohols achieve this by weakening the nonlocal hydrophobic interactions and 
encouraging polar interactions of proteins (Thomas & Dill, 1993). The denaturing properties of HFIP 
are, however, limited. For example, HFIP was not found to be effective in dissolving β2-





hydrophobic interactions, it cannot dissolve mature, rigid fibrils (Broersen et al., 2011; Hirota-
Nakaoka et al., 2003).  
For this reason, an Aβ42 preparation where complete disaggregation (or as near to complete as 
possible) is critical, an extra step after HFIP solubilisation is necessary to ensure this. For this, DMSO 
is often used due to its polar nature and ability to abolish hydrogen bond networks. 
3.2.3 Temperature, Agitation and Concentration 
Temperature is another factor affecting the self-assembly process of Aβ. It has been well understood 
that the Aβ aggregation kinetics are enhanced as temperature is increased (Kusumoto et al., 1998). An 
effect of temperature has been shown with Aβ40, Figure 3.3A (Lin et al., 2008). This shows the 
different rates of fibrillogenesis at temperatures ranging from 30-45°C, the rate of fibrillogenesis 
increases with temperature.  In a protocol where we need to monitor assembly at early time points, a 
low temperature is essential in ensuring minimal fibril formation during the preparation process. 
Concentration is another factor that can drastically affect the lag phase of the assembly process 
(Hellstrand et al., 2010). Figure 3.3B shows there is a decrease in the lag time as the concentration 
increases. This means that fibrils are formed more rapidly at higher concentrations, and at a high 
enough concentration could even by-pass the formation of oligomeric species. The electron 
micrographs in Figure 3.3C and 3.3D demonstrate the importance of concentration in fibril formation. 
There are very few fibrils seen after 24 hours at 30µM and abundant fibrils seen at 24 hours at a 






Figure 3. 3. The effects of temperature and concentration on amyloid assembly. A) The effect of 
temperature on the fibrillogenesis of Aβ1-40 measured by ThT fluorescence. As the temperature 
increases, rate of fibrillogenesis also increases and there is a reduction in the lag phase. Taken from Lin et 
al, 2008. B) The effect of concentration on the lag phase of Aβ. As the concentration is increased, the lag 
phase decreases, suggesting a more rapid formation of fibrils. Taken from Hellstrand et al, 2010. C) 
Electron micrograph of Aβ42 prepared at 30 µM and D) 200µM (prepared in 10mM HEPES buffer pH 
7.4) at 24 hours. Few/no fibrils are seen at 30µM whereas at a higher concentration of 200µM, fibrils are 
abundant.  Scale bar shown at 0.5μm. 
 
It is thought that agitation also enhances aggregation due to fragmentation of existing fibrils and 
increasing sites for further fibril formation via secondary nucleation (Tiiman et al., 2013). It has also 
been suggested that agitation may lead to the formation of bubbles in the sample, which burst and can 
generate of hydroxyl and hydrogen radicals which induce further aggregation (Mahler et al., 2009). 
These factors have all been taken into consideration in our preparation method to ensure a consistent 





3.3 Results and Discussion 
3.3.1 The development of a highly consistent Aβ42 preparation protocol 
For reproducibility and reliability of experiments with Aβ42, it is important to characterise the species 
being used. As with all amyloid proteins, Aβ42 undergoes self-assembly and forms fibrils which 
display the characteristic cross-β structure detected by X-ray fibre diffraction (XRFD) (Serpell, 2000). 
The assembly process from monomer to mature fibrils (Figure 3.4) involves the formation of the toxic 
oligomeric intermediary species. One difficulty of working with the Aβ42 peptide has been a sample 
preparation that follows this assembly from monomers/oligomers into mature fibrils within a 
reasonable time frame. Without a protocol that controls for the several factors affecting self-assembly, 
every sample preparation composition in terms of the species most prevalent, will differ greatly.  It 
would be unexpected that the results of experiments where Aβ42 is predominantly oligomeric, would 
be the same as that of a preparation that is predominantly fibrillar.  
By controlling factors such as seeding, pH, temperature and concentration, it is possible to ensure a 
sample preparation that allows us to follow self-assembly within a 7-day period and also identify 
which species are most prevalent at each time point.  Below is a summary of our optimised 
preparation protocol.          
 
Figure 3. 4. Summary of our optimised Aβ42 preparation protocol. The factors affecting assembly which 






The preparation method has been adapted from a previous study which validated their approach of 
solubilising recombinant Aβ in a sequential manner followed by removal of all chemicals to eliminate 
any oxidation of the peptide (Broersen et al., 2011). Samples were prepared at 1mg/ml. Firstly, HFIP 
is used in order to disaggregate and any preformed aggregates. Concentrated HFIP has been 
previously shown to be able to remove preformed aggregates (Nichols et al., 2005). The solvent 
ensures the sample preparation is as homogenous as possible from the beginning, and also eliminates 
the issue of seeding. This is vortexed and sonicated to further break up any aggregates. The HFIP is 
then dried using a flow of nitrogen gas. The gas used must be oxygen free due to susceptibility of 
Aβ42 to oxidise at Met35 (Butterfield & Boyd-Kimball, 2005). The Aβ42 peptide is then re-
suspended in DMSO as a hydrogen bond acceptor to remove any water from the peptide surface 
through interactions of the S=O polar groups (Zheng & Ornstein, 1996).  To remove the DMSO, 
which has been shown to affect the assembly process of Aβ in a non-physiologically relevant manner 
(Shen & Murphy, 1995) the peptide is put through a buffer exchange column. The centrifuge is 
maintained at 4°C in order to prevent the peptide from aggregating. This also retains any species 
larger than 7 kDa, again ensuring the final preparation is as close to monomeric as possible. Once the 
sample has been collected, the absorbance at 280nm (A280) is measured and using the molecular co-
efficient of the peptide (Protparam) the concentration in micro-molar is calculated. This is then diluted 
immediately to 50μM which is taken to be the new working stock. 
3.3.2 Characterising the assembly of Aβ42 from monomers to mature fibrils 
After sample preparation, several imaging and biophysical techniques, including TEM, CD and ThT 
fluorescence, were used to monitor the assembly of Aβ42 over a 7-day period. To visualise the 
morphology of the structures formed over a 7-day period, TEM was used. The electron micrographs 
(Figure 3.6) are of un-tagged Aβ42 samples and each image is the most representative of all electron 
micrographs at each time point, obtained from three separate Aβ42 preparations. The electron 
micrographs show the presence of small spherical assemblies (blue arrows) from early time points. 
We identify these to be oligomers. By 2 hours, there are also some small rod-like structures which we 





confidently identify these slightly elongated structures as protofibrils; AFM measurements would be 
needed in order to measure the height of these and compared to what we identify to be oligomers and 
mature fibrils. By 24 hours, the fibrillar species (black arrows) seem to dominate the sample 
population which are abundant at 72 hours and 7 days. From these electron micrographs, we are able 
to visualise the assembly process from oligomers to protofibrils to mature fibrils. The presence of 
oligomers decreases as fibril formation increases suggesting these oligomers are assembling into 
fibrils. The presence of each of these species can be found at progressive time points due to the 
heterogeneity of the sample preparation as well as the dynamic nature of Aβ42 assembly. However, it 
is apparent that at each time point, one species predominates; oligomers are most abundant at time 
points earlier than 24 hours and Aβ42 forms mature fibrils at and after 24 hours.     
The diameter of visible oligomers from electron micrographs from three separate Aβ42 preparations 
at 2 hours was measured (Figure 3.5). Although some oligomeric species are likely to be too small to 
be visualised by TEM, this still provides useful information regarding the average size of larger 
oligomers present in the sample.  The diameter of these oligomers is also likely to be slightly smaller 
than measured due to the outline of the negative stain. The distribution shows there are a range of 
sizes up ~40nm with the majority measured at ~20nm. This is consistent with the previously reported 
diameter of oligomers (Cizas et al., 2010; Leung et al., 2017; Sakono & Zako, 2010).    
 
Figure 3. 5. Histogram to show the distribution of Aβ42 oligomer diameter (n=184, all oligomers counted 
from three separate Aβ42 preparations). The majority of oligomers were measured at ~20nm in diameter. 
50μM Aβ42 was prepared in 10mM HEPES buffer pH 7.4. Oligomers were measured from electron 






Figure 3. 6. Negative stain transmission electron microscopy images of Aβ42 over 7 days. Between T0 and 4hours, there are small spherical assemblies seen (blue arrows) which we 
identify to be oligomers as well structures that we suspect could be protofibrillar species (red arrows). Fibrillar species are visible by 24 hours (black arrows) which become more 
abundant over time. The peptide was prepared at 50µM in 10mM HEPES buffer pH 7.4, un-tagged and incubated at room temperature. Scale bar shown at 0.5μm. each image is the most 






Figure 3. 7. CD and ThT fluorescence of Aβ42 over a 7 days period. A) The CD spectra of Aβ42 (using a 1mm pathway cuvette) over 7 days shows a transition 
from random coil to β-sheet conformation. Between T0-4h hours there is a decrease in random coil conformation and by 24 hours there is β-sheet signal, 
concomitant with the appearance of fibrils in the TEM (Figure 3.6). The CD spectra is for one Aβ42 sample preparation, however, is representative of what was 
obtained from three separate Aβ42 preparation.  B) The average increase in β-sheet signal (218nm) of three separate Aβ42 preparation  over time is shown.. 
Error bars are expressed as ±SEM C) 10µM ThT fluorescence of three separate 50µM un-tagged Aβ42 preparations   over 7 days shows the typical sigmoidal 
curve for amyloid formation. There is a lag phase seen between T0-24hours after which there is the elongation phase followed by a plateau. 50μM Aβ42 was 





CD was used to monitor the secondary structure of Aβ42 at the same time points shown for EM 
(Figure 3.7A). The spectra shown in Figure 3.7A is from one Aβ342 sample preparation, however it is 
representative of the spectra obtained for three separate Aβ42 sample preparations. To show the 
variability within the three samples, error bars (expressed as ±SEM), have been included in Figure 
3.7B which shows the average β-sheet signal from three Aβ42 preparations at each time point. There 
is a clear transition from random coil (minima ~200nm) to β-sheet conformation (minimum at 218nm, 
maximum at 195nm) over a 7 day period. At T0, there is a strong random coil conformation which 
reduces between 2-4 hours. This reduction in random coil signal is most likely coupled with the 
increase in β-sheet signal (seen clearly in Figure 3.7B) suggesting there is a heterogenous population 
of unfolded and folded protein, with some oligomers adopting a β-sheet structure. By 24 hours, there 
is a clear β-sheet signal which becomes stronger at 48 hours up to 7 days. This is concomitant with the 
EM, in which there is the presence of mature fibrils (β-sheet rich structures) from 24 hours onwards. 
This is further confirmed by Figure 3.7B which displays the increase in β-sheet signal at 218nm over 
7 days; there is an increase in β-sheet signal up to 48 hours after which there is a plateau suggesting 
the sample population is primarily β-sheet rich. These data therefore confirm that there is a transition 
from disorder to order as fibril formation proceeds (Bacci et al., 2017). This order-dependent increase 
in β-sheet content has been previously seen by other research groups (Ono et al., 2009). Studies on 
Aβ40 assembly have previously shown a size and order dependent increase in β-sheet content of 
oligomers by CD (Ono et al., 2009). This supports the CD spectra presented in Figure 3.5 where there 
is a simultaneous decrease in random coil signal and increase in β-sheet signal between 2-4 hours i.e. 
disorder to order. 
A ThT fluorescence assay was carried out to monitor fibrillogenesis over the 7 days period (Figure 
3.7C). Aβ42 displays a low intensity signal even at the early time points suggesting some fibrillar 
species being present for dye binding. There is then a steep increase in signal intensity, concurrent 
with when the CD spectra display a β-sheet signal and mature fibrils are observed by TEM. The 
sigmoidal aggregation curve displayed by Aβ42 can be explained by the nucleation-dependent 





phase of polymerisation where a critical concentration of misfolded protein need aggregate into a 
nuclei (Ferrone, 1999). The steep increase in fluorescence intensity seen from 24-72 hours represents 
the elongation phase, where there is a rapid growth of fibrils by monomer addition to the nuclei.  The 
monomer ‘docks’ on to an aggregate reversibly and is then ‘locked’ in a number of steps, allowing it 
to become integrated onto the template for further elongation (Bacci et al., 2017; Esler et al., 2000). 
This is a time-dependent transition where the monomer becomes irreversibly associated with the pre-
existing template or ‘critical nuclei’ (Figure 3.8). This irreversible association has been proposed in 
the mechanism of amyloid plaque deposition in AD (Cruz et al., 1997).  
 
Figure 3. 8. A schematic representation of the monomeric dock-lock mechanism. The monomer added is 
shown in pink. Adapted from Bacci et al, 2017. 
 
Although it would be possible to obtain the kinetics of the elongation by calculating the slope of the 
curve, it was not deemed necessary to do so as we are not making comparisons of elongation 
rates/assembly under different conditions (e.g. temperature, concentration, pH); all experiments were 
conducted at 50μM under the same preparation conditions. Furthermore, although several studies have 
used ThT fluorescence in order to calculate elongation rates (Milto et al., 2013; Platt et al., 2008), it is 
difficult to obtain quantitative data from this method due to the molecular binding of ThT to amyloid 
fibrils not being fully known. This combined with the susceptibility to bind to impurities or 
amorphous aggregates means that although this type of fluorescence spectroscopy is a widespread and 
highly utilised method to monitor fibrillogenesis, it should ideally be combined with another method  
to obtain fully quantitative data (Arosio et al., 2015). One example of a better method to obtain the 
elongation rate would be by real-time monitoring of the changes in the number of molecules in the 





Studies using surface-based single fibril imaging have also been highly informative of the elongation 
phase. This phase occurs in a stepwise manner and alternates between a growth and arrest phase 
displaying a preferential direction of growth (Bacci et al., 2017; Watanabe-Nakayama et al., 2016). 
Little is known about the arrest phase of fibril elongation but it may relate to a ‘trapped’ state of fibril 
conformation which is not thought to require any disassembly to re-enter the growth phase (Bacci et 
al., 2017; Watanabe-Nakayama et al., 2016; Young et al., 2017). After the elongation phase, a plateau 
is reached (between 72 hours-7 days in the protocol presented in this Chapter) where fibrillisation has 
reached a steady state.  
Together, these biophysical data present a clear assembly of Aβ42 into amyloid fibrils, allowing us to 
pinpoint specific stages and the appearance of different species. To further consolidate this, a series of 
antibodies against different conformations and epitopes of Aβ42 were used. This also ensures that any 






Figure 3. 9. Aβ42 dot blot and western blot. The NU1 (1:10000 dilution) and A11 (1:5000) oligomer-
specific antibodies detected oligomers for up to 4 hours. The anti-Aβ 4G8 (1:10000 dilution) and 6E10 
(1:10000) antibodies with epitopes at the N- and C- terminal of the sequences respectively, were used to 
detect for Aβ42 over 7 days; the 6E10 signal is displayed up to 24 hours suggesting the epitope is buried 
during assembly after this time point. The 4G8 signal is displayed at all time points confirming the 
presence of the protein. The 6E10 antibody (1: 10,000 dilution) was used to detect Aβ42 in the western 
blot, 50µM Aβ42 was prepared in 10mM HEPES buffer pH 7.4 and incubated at room temperature. 
Aliquots were taken for each time point. 1 and 2µg of protein were loaded for dot blotting and SDS-
PAGE electrophoresis respectively. Both the dot blots and western blot was only carried out once and 





The dot blots shown in Figure 3.9 (top 4 panels), reveal that oligomer specific antibodies A11 (Kayed 
et al., 2007) and NU1 (Lambert et al., 2007) detected Aβ42 only up to 4 hours. The 6E10 antibody, 
which is raised against the N terminal of the Aβ42 sequence, displays a signal for up to 24 hours. This 
can be attributed to the epitope being ‘buried’ as Aβ42 continues to assemble. The 4G8 antibody is 
raised against the C terminal of the sequence and displays a signal at each time point over 7 days, 
confirming the presence of the protein.  
The Aβ42 sample preparation is expected to be heterogeneous. Therefore, although dot blots provide 
a useful tool to assess antigenicity of Aβ42, it does not tell us about the entire population of species 
present in the sample. To overcome this, we ran SDS-PAGE for samples at each time point and 
carried out a western blot using the 6E10 antibody (Figure 3.9, bottom). It is important to remember 
that the dot blot and SDS-PAGE can have different results because of the denaturation of the protein 
in the gel. This explains the detection of Aβ42 in the western blot by the 6E10 antibody, even though 
the epitope for this is buried in the dot blot. The effects of SDS on Aβ have been evaluated critically 
due to the artificial oligomerisation it may induce (Bitan et al., 2003). Despite this, combining these 
data with our robust biophysical characterisation is informative of the assemblies at each time point. 
There is a clear increase in the presence of larger assemblies at increasing time points. At T0 the Aβ42 
is mainly monomeric (4.5kDa), dimeric (9kDa) and trimeric (13.5kDa). At 2-4 hours we begin to see 
the presence of higher molecular weight species which migrate as a smear, still with the presence of 
the smaller assemblies. This can be explained by the assembly of larger oligomers as seen in Figure 
3.6. At 24 hours, there is an evident decrease in the signal for monomers, dimers and trimers, with a 
strong signal for larger assemblies and some fibrils being stuck in the well of the gel. This trend 
continues at 48 and 72 hours and by 7 days there is no signal for oligomeric species with fibrils only 
observed in the well.  
Both the dot blot and western blot were carried out once from one Aβ42 sample preparation, and 
therefore it was not possible to quantify the data. As a future objective, it would be beneficial to do a 





only one repeat was carried out in order to begin to get a preliminary understanding of the range of 
assembly sizes present in our sample preparation at each time point.  
The biophysical data combined with antibody-directed experiments confirm that using our sample 
preparation, Aβ42 is most oligomeric between 2-4 hours. After this time period, the sample 
preparation population is dominated by the fibrillar species.  
3.3.3 Aβ42 oligomers are cytotoxic 
 
 
Figure 3. 10. Aβ42 oligomer ReadyProbes cell viability assay. Rat hippocampal cultures were treated with 
10µM Aβ42 oligomers for 3 and 7 days. Examples of ReadyProbes for both time points have been 
included in the bottom panel. Cytotoxicity was measured as a percentage of dead cell in a culture and 
compared to buffer incubated cells. Aβ42 oligomers were significantly toxic at both 3days (43.2% ± 2.35, 
total number of cell =1619, number of dead cells = 703) and 7 days (66.3% ± 2.59, total number of cells = 
1172, number of dead cells=777) compared to buffer incubated cells (17.8% ± 3.06, total number of cells = 
1239, number of dead cells=221). One-way ANOVA with Tukey’s post hoc comparison where p= < 0.01 
(*), < 0.001 (**), < 0 (***). Error bars are expressed as ±SEM. Data shown here is the average of three 
separate Aβ42 preparations incubated with three separate hippocampal cultures. Aβ42 was prepared 





Having a protocol that produces a consistent preparation of Aβ42 allows us to confidently identify 
oligomers being most prevalent 2 hours after preparation. To confirm our oligomeric species is 
cytotoxic, we carried out a ReadyProbes assay in primary rat hippocampal cultures after incubation 
periods of 3 and 7 days with 10µM oligomeric Aβ42 (Figure 3.10). The assay labels the nuclei of all 
cells with a blue dye and all dead cells with a green dye. The percentage of green labelled cells of the 
whole neuronal population is taken as the measure of cell death. Examples of cells incubated with 
oligomers for both time points have been shown in the bottom panel of Figure 3.10. The average of 
three separate biological repeats (separate Aβ42 preparations and hippocampal cultures for each 
repeat) are shown in Figure 3.10. As expected, there was significant cell death seen at both these time 
points; ~44% (43.2% ± 2.35, total number of cell =1619, number of dead cells = 703) cell death after 
3 days and ~70% (66.3% ± 2.59, total number of cells = 1172, number of dead cells=777)  after 7 
days compared to buffer incubated cells (17.8% ± 3.06, total number of cells = 1239, number of dead 
cells=221). This confirms that our oligomeric species are cytotoxic. The deleterious effects of our 
Aβ42 oligomers have also been verified in SHSY5Y human neuroblastoma cells (Marshall et al., 
2016). Although a concentration of 10μM is not physiologically relevant, however, it allows for the 
accelerated effect of the peptide within a reasonable time frame and ensures that any negative results 
are not due to low levels of protein concentration. This concentration was chosen based on previous 
dose-response curve experiments conducted by other members of the lab group who assessed the 
cytotoxicity of Aβ42 oligomers at 1-, 5- and 10μM. 
Despite confirming our preparation method produces toxic oligomers, it is important to note that the 
preparation consists of only one Aβ length (Aβ42).  Physiologically there are many fragments of Aβ 
formed, all of which are likely to influence the assembly behaviour and toxicity of Aβ42. For 
example, it has been demonstrated that Aβ40 and Aβ42 directly interact to alter aggregation kinetics 
directly linked to the changes in Aβ 40/42 ratio seen in AD (Pauwels et al., 2012). Furthermore, using 
mass spectroscopy and ion mobility studies, it has been suggested that Aβ40 may inhibit the 





presented here suggest although other assemblies of Aβ may affect Aβ42 cytotoxicity, Aβ42 
oligomers alone are sufficient to cause cytotoxicity. 
There are several identified Aβ42 oligomers which vary in the levels of cellular dysfunction they 
cause. Some examples have been summarised in Table 3.2. 
Aβ42 Species  Effect  References  
Dimers/Trimers 
LTP impairment  
Little/No cytotoxicity  
(Shankar et al., 2007; Shankar et 
al., 2008; Townsend et al., 2006) 
A11 positive oligomers 
Cytotoxicity in Human cortical 
cultures and PC12 cells  
(Deshpande et al., 2006; Ladiwala 




(Lesne et al., 2013) 
Aβ-derived diffusible ligands   
Cytotoxic in primary hippocampal 
cultures 
(Lambert et al., 1998) 
Table 3. 2. Size and cellular dysfunction induced by previously identified oligomers. 
 
Using our protocol, we cannot specify the exact size of the toxic oligomeric species, however, we 
identify the toxic species to be pre-fibrillar with low ThT fluorescence, lacking significant β-sheet 
structure but reduced random coil signal by CD, and are A11/NU1 antibody positive.   
3.4 Conclusion 
Using extensive characterisation methods, we have established a reliable and reproducible protocol 
for the preparation of Aβ42. This allows for assembly from small monomeric/oligomer species to 
insoluble fibrils, to be monitored over a reasonable timeframe of 7 days. From the electron 
micrographs, it is possible to visualise the change in morphology of the peptide over 7 days. Small 
spherical species, which we identify to be oligomers, are most prevalent between 2-4 hours, whilst 
mature fibrils begin to dominate after 24 hours. The CD spectra shows a transition from random coil 
to β-sheet signal over 7 days. This data complements the appearance of fibril in the EM at 24 hours, as 





fluorescence monitored at the same time points, displays a typical sigmoidal curve for Aβ42 which 
represents the lag, elongation and steady phase of Aβ42 assembly (Xue et al., 2008).  Combining this 
with the dots blot and western blots signals displayed at each time point, we can confidently identify 
our sample population to be most oligomeric between 2-4 hours. Using this information, we verified 
our oligomeric species, 2 hours after sample preparation, to be cytotoxic utilising the ReadyProbes 
assay in rat primary hippocampal cultures. 
 
Although this chapter has provided a thorough characterisation of the assembly process and oligomers 
of Aβ42 produced from the sample preparation presented, there are several factors to consider in the 
critical evaluation of the techniques that were used and some of the conclusions reached. Firstly, the 
electron micrographs are representative of only 4μl of the entire sample preparation. Although the 
electron micrographs shown are representative of three independent Aβ42 sample preparations, it is 
possible the species visualised from the grids are not truly representative of the entire population. 
Furthermore, techniques such as cryo-EM or AFM measuring the height of the species, would provide 
more detailed and higher resolution information regarding the assemblies in the sample preparation. 
However, both these techniques were not readily available and therefore pursuing this would be a 
future direction for this project. The CD spectra presented in this chapter shows a transition from 
random coil to β-sheet signal over a 7 day period. Although the CD spectra between T0-4hours shows 
a reduction in random coil, there is most likely there is a simultaneous increase in β-sheet signal 
(shown in Figure 3.7B) that is being masked by the strength of random coil. In order to further 
analyse the ratio of random coil to β-sheet signal at each point, the DichroWeb online tool could be 
used. This would provide a better understanding the proportion of the sample preparation that is 
adopting a β-sheet conformation. Furthermore, CD only provides information regarding the secondary 
structure of the protein. Using a technique such as FTIR would provide further information regarding 
the anti-parallel/parallel packing of the β-sheets, again providing a better structural understanding of 






The sample preparations of Aβ42 presented in this chapter, and all subsequent chapters to follow, 
have been at a  pH of  7.4. This was due to the fact that the Aβ42 is being exogenously added to the 
cells and the extracellular Aβ42 in the brain would be at this pH.  Physiologically, however, it is 
thought that the production/accumulation of is in lysosomes/early endosomes which typically have a 
lower, more acidic pH. Therefore, it would have been beneficial and interesting to do similar 
characterisation at a more acidic pH environment to link the assembly to cytotoxicity. Based on the 
discussion above (Section 3.2.1), it would be reasonable to suggest that the kinetics of the assembly 
process would be enhanced, and the mature fibrils produced would be much more stable. 
 
 Finally, although the ReadyProbes assay is an extremely useful tool as a measure of cytotoxicity, it 
does not provide any information regarding any cellular dysfunction that may occur before cell death. 
As a further complementary technique to the ReadyProbes assay, an MTT assay to monitor any 
mitochondrial dysfunction would be one way in which to assess cell dysfunction before cell death. 
Furthermore, one of the biggest limitations of this preparation method is the inability to distinguish 
different categories of oligomers. Our identification of the oligomers being most prevalent at 2 hours 
does not specify a particular size as the main toxic species and therefore is a significant limitation of 
this kind of biophysical classification.  
 
Taking into consideration the critical evaluation presented above, the data presented in this chapter is 
important is still important two-fold; 1) we provide a thoroughly characterised and highly consistent 
Aβ42 preparation method, 2) the oligomeric species from our preparation method is cytotoxic and 
therefore representative of a disease-related amyloid protein.  Using the amyloidogenic Aβ42 as our 
disease-related amyloid model, we can gain a further understanding into what makes an amyloid toxic 
by comparing the cytotoxicity of assemblies formed from primary sequence variants of Aβ42, as well 





Chapter 4: Model peptides to investigate the importance of 
primary sequence in amyloidogenicity  
Chapter Overview 
The ability to form amyloid is an inherent property of all proteins and peptides (Dobson, 2006). Under 
suitable conditions, irrelevant of primary sequence, almost all peptides can form amyloid (Dobson, 
2004). There has been much research into how the amyloidogenicity of proteins is influenced by the 
primary sequence of peptides (Caputo et al., 1993; Frousios et al., 2009; Idicula-Thomas & Balaji, 
2005). Although several factors are involved in the formation of amyloid, the amino acid sequence of 
the protein is ultimately responsible for determining the propensity to form amyloid (Familia et al., 
2015). This chapter will address the ability of three Aβ42 primary sequence variants to self-assemble 
and in their cytotoxicity. This is compared to the assembly and toxicity of Aβ42 presented in the 
previous chapter.  
4.1 Introduction 
The cytotoxic effect of the Aβ42 peptide is believed to be linked to its ability to self‐assemble to form 
oligomers and amyloid fibrils (Kayed et al., 2003). It is the oligomeric species proposed to represent 
the toxic species leading to neuronal dysfunction and eventual cell death (Glabe & Kayed, 2006; 
Kayed et al., 2003).  
The lack of a suitable control peptide has been a big constraint in our fundamental understanding of 
Aβ42 assembly and toxicity.  Many studies examining the role of Aβ42 have utilised a buffer/vehicle 
solution, Aβ42-1 (reversed primary sequence) or AβS (scrambled amino acid sequence) as control 
peptides (Izzo et al., 2014; Jean et al., 2015). These Aβ42-1 and AβS “control” peptides are chosen 
because they are not expected to self‐assemble or to form toxic oligomeric species, despite sharing 
amino acid composition with Aβ42. However, the fibrillogenesis of these peptides and resulting 





assays as controls, the cytotoxic nature, or lack of, has not been studied in relation to their assembly 
state. 
A novel assembly impaired variant of the Aβ42 peptide, vAβ42, was designed to investigate the 
importance of primary sequence in amyloid self-assembly and cytotoxicity (Marshall et al., 2016). 
The effects of several amino acid substitutions within the amyloidogenic regions of wild-type Aβ42 
(16-22 and 36-42) were predicted using the WALTZ algorithm (Maurer-Stroh et al., 2010). These 
substitutions were then ranked by their predicted ability to abolish amyloidogenicity. A double 
substitution of phenylalanine for serine at position 19 (F19S) and glycine with aspartic acid at position 
37 (G37D) was the most promising and predicted to abolish amyloidogenicity completely. The 
importance of Phe19 and Gly37 as drivers of assembly has been extensively examined and is 
discussed below. It is therefore unsurprising that the WALTZ algorithm identified substitutions of 
these hydrophobic amino acids with polar, hydrophilic amino acids to abolish amyloidogenicity. This 
vAβ42 is presented in this chapter to serve as an additional model of primary sequence importance in 
amyloidogenicity and also as a more suitable experimental control for Aβ42.   
In this chapter, all three models, Aβ42-1, AβS and vAβ42, with similar yet varied primary sequences 
have been thoroughly characterised using a range of biophysical techniques. Linking the assembly 
process (or lack of) to the cytotoxicity of each of these models using a cellular viability assay in rat 
hippocampal cultures provides useful information regarding the importance of primary sequence in 














4.2 Results and Discussion 
4.2.1 WALTZ identified amyloidogenic regions in Aβ42-1, AβS and vAβ42 
The primary sequence of wild-type Aβ42 and the three variants are provided in Table 4.1. The vAβ42 
has two amino acid substitutions at F19S and G37D. Aβ42-1 is the reversed sequence of the wild type 
peptide and AβS is a scrambled sequence of the amino acids.   
 
The sequence of AβS is dependent on the company it is purchased from. Table 4.2 presents two Aβ42 
scrambled sequences available to purchase from several companies. The AβS sequence examined in 
this chapter has been purchased from Bachem.  
 









Table 4. 2. AβS sequences available from different companies. The sequence presented in this chapter has 
been purchased from Bachem. 
 
The WALTZ algorithm, which identifies amyloidogenic regions using a positional algorithm, was 
used to predict the propensity of each peptide to aggregate (Maurer-Stroh et al., 2010). The graphical 






Table 4. 1. The primary sequence of Aβ42 and the variant peptides, vAβ42 (substitutions shown in red), 






the trace for Aβ42-1 predicts a single region from 8-13 whilst both vAβ42 and AβS were predicted to 
have no amyloidogenic regions (Figure 4.1).  
 
 
Figure 4. 1. Traces produced using the WALTZ algorithm for Aβ42 and primary sequence variants. The 
trace for Aβ42 (blue line, black filled squares), shows two peaks indicating two amyloidogenic regions (16-
22 and 37-42). Aβ42-1 (dark grey line, asterix)  shows one peak suggesting an amyloidogenic region 
between 8-13 and no regions were identified for both vAβ42 (light grey line, unfilled black circle) and AβS 
(dark grey line, black filled diamonds). Traces were obtained from www.switchlab.org and replotted in R 
Studio. 
 
WALTZ is a web-based tool that uses a position specific scoring matrix to identify amyloid forming 
sequences. The rational of using this particular algorithm over the many others that are available is 
that due to the lack of extensively validated amyloid sequences, these sequence specific algorithms 
often cannot distinguish between β-sheet like amorphous aggregates and amyloid (Maurer-Stroh et al., 
2010; Morris et al., 2013). WALTZ overcomes this issue and was developed by exploring the 
sequence diversity of over 200 hexapeptide amyloid proteins, allowing users the ability to explore the 





importance of amino acid specific positioning in the formation of both disease and functional amyloid 
proteins (Maurer-Stroh et al., 2010).  
The hexapeptide sequences identified as being amyloidogenic regions are KLVFFA (16-21) and 
GGVVIA (37-42) in Aβ42 and MLGIIA (8-13) of the Aβ42-1 sequence. The Eisenberg group has 
previously identified and crystallised the KLVFFA and GGVVIA fragments (Colletier et al., 2011) . 
This was accomplished using a 3D profile method which scored six residue segments on their 
propensity to form steric zippers based on the profile of a canonical model (Colletier et al., 2011). The 
KLVFFA crystallised in three forms, all of which were in an antiparallel β-sheet ‘face-to-back’ 
stacking, via hydrophobic side chains giving rise to a dry interface (Colletier et al., 2011; Sawaya et 
al., 2007).  GGVVIA crystals display parallel β-sheets with a ‘face-back’ orientation (Sawaya et al., 
2007).  
As Aβ42-1 is not a naturally occurring peptide, there has been little/no characterisation of its primary 
sequence. It has previously only been used as an experimental control rather than a model to 
investigate the importance of primary sequence and therefore there is no literature exploring the 
amyloidogenicity of the MLGIIA fragment identified by WALTZ, even as a stand-alone hexapeptide. 
The naturally occurring, mirrored sequence of AIIGLM in the Aβ42 sequence, however, has been 
shown to form fibrils and crystals. This AIIGLM sequence is not identified by WALTZ in the Aβ42 
sequence, but is well known to be amyloidogenic using other algorithms (e.g. AWSEM-Amylometer) 
(Zheng et al., 2013).  This fragment forms a dry steric zipper interface with an anti-parallel β-sheet in 
a ‘face-back’ orientation. The interface packs in ‘knobs-into-holes’ as described by Crick in 1952 
(Crick, 1952). The Ile32 and Leu34 from one β-sheet form the ‘knob’ that will enter the hole, created 
by the presence of the glycine at position 33, between the Ile31 and Met35 of the partnering β-sheet. 
In the reversed sequence, this type of packing maybe be unchanged as the β-sheet parallel in-register 
arrangement seen in Aβ42 is unlikely to be disrupted.  
The WALTZ algorithm has highlighted the importance of amino acid position in amyloid propensity; 





showed the highest positional dependency (Maurer-Stroh et al., 2010). As all amino acids in the 
amyloidogenic regions of the Aβ42 sequence (with the exception of lysine) are highly hydrophobic, 
reversing the hexapeptide sequence would not drastically influence amyloid propensity solely based 
on this. A better explanation is offered by the positions of the residues in the hexapeptide fragments 
(Lopez de la Paz & Serrano, 2004). Positional mutations introduced into the STVIIE hexapeptide has 
provided a detailed understanding of the importance of amino acid position specificity. Table 4.3 
summarises the findings of different mutations at each position inducing the formation of amyloid as 
described previously (Lopez de la Paz & Serrano, 2004). 
 


























All amino acid substitutions 
resulted in amyloid except Leu 
and Glu 
 
Table 4. 3. Positional amino acid substitutions within the STVVIE hexapeptide which resulted in amyloid 







Despite positions 1 and 6 being able to accommodate almost any amino acid, position 5 is highly 
specific and restricted, with Ile, Phe and Tyr being strongly favoured (Lopez de la Paz & Serrano, 
2004). The MLGIIA fragment has an Ile at position 5, making it strongly amyloidogenic. Regions 16-
21 and 37-42 of the Aβ42-1 sequence are NSGVAG and HRFEAD respectively. The lack of one of 
three critical amino acids needed at position 5 and most likely weak positioning regarding 
hydrophobicity of each amino acid, are two possible reasons why these regions are not identified as 
being amyloidogenic despite the sequence for Aβ42-1 only being a reversal of Aβ42.   
AβS purchased from Bachem has no identified regions of amyloidogenicity by the WALTZ 
algorithm. WALTZ was also used to predict regions for amyloidogenicity for the alternate AβS 
sequence (Figure 4.2).  Both sequences show no regions of amyloidogenicity, despite having different 






Figure 4. 2. Traces produced using the WALTZ algorithm for two AβS sequences available for purchase 
from various companies. No peaks are shown suggesting no amyloidogenic regions in either sequence. 






The abolished amyloidogenic regions displayed in the vAβ42 graphical trace (Figure 4.1), is expected 
since WALTZ was utilised in designing the variant primary sequence (Marshall et al., 2016). 
Furthermore, both phenylalanine at position 19 and glycine at position 37 have been shown to be 
important drivers of assembly. Therefore, substitutions at these positions would likely impair 
assembly.  
Phenylalanine is an aromatic amino acid. The presence of aromatic amino acids has been identified in 
several amyloidogenic fragments of disease-related amyloid proteins. Examples of this include the 
FGAIL fragment (Tenidis et al., 2000) of the Islet amyloid polypeptide associated with Type II 
diabetes and the SFFSFLGEAFD fragment of Serum amyloid A which is associated with Chronic 
inflammation amyloidosis (Gazit, 2002). The interactions between two planar aromatic residues are 
attractive and non-bonded; these interactions are referred to as п-stacking. п-stacking has been found 
to be important in the process of molecular recognition and self-assembly in amyloid proteins by 
providing two key features for self-assembly (Gazit, 2002). Firstly, п-stacking provides a 
thermodynamic drive towards assembly and secondly, the specificity of the direction and orientation 
of the stacking, which is particularly important due to the highly structured morphology of amyloid 
(Gazit, 2002). There are four different types of п -stacking (Figure 4.3) that can occur; 1) parallel 
displaced 2) T-shaped 3) parallel staggered and 4) herringbone 
 
Figure 4. 3. Schematic diagram of possible п-stacking orientations. 1) Parallel displaced 2) T-shaped 3) 
parallel staggered 4) herringbone. Adapted from Gazit, 2002. 
 
In amyloid fibrils, it is thought that both  parallel displaced (Gazit, 2002) and T-shaped (Makin et al., 





interactions between β-sheets and also between hydrogen bonded strands (Makin & Serpell, 2005). As 
monomers of protein begin to assemble into fibrils, they are restricted by the geometry of two 
aromatic residues forming п-stacking. This is true for all further monomers that add on to form the 
mature fibril and therefore the entire assembly process is being regulated and restricted by the 
geometries of the stacking interactions (Gazit, 2002). Figure 4.4 shows a possible model for п-
stacking in a parallel and anti-parallel β-sheet arrangement.  
 
Figure 4. 4. п-stacking in Aβ42. Phenylalanine residues in parallel (Dark blue only) or anti-parallel (dark 
and light blue) β-sheet arrangements interact to form п-п interactions. These have postulated to be either 
parallel displaced or T-shaped in orientation. 
 
The importance of the two phenylalanine residues forming п-stacking in Aβ42 has been demonstrated 
in experiments where short phenylalanine rich fragments bound specifically to the length of the 
peptide. This inhibited addition of monomers and subsequent formation of fibrils (Tjernberg et al., 





needed for formation of amyloid fibrils and place the two monomers in the correct position for 
subsequent hydrogen bonding that is characteristic of amyloid fibrils. Several small, aromatic 
compounds have been shown to interact with amyloid proteins in a similar manner and inhibit the 
formation of fibrils (Gazit, 2005; Porat et al., 2006). The therapeutic potential of using these 
compounds to inhibit the formation of amyloid fibrils can be questioned as it is the oligomeric species 
identified as being cytotoxic (McLean et al., 1999). It would seem unlikely that neurodegeneration 
could be halted simply by inhibiting the formation of fibrils, however, it may be that the loss of 
neurons could be slowed down by reducing the number of fibrils that can act as either a 'pool' of 
oligomers or a site for secondary nucleation. On the other hand, inhibiting the formation of fibrils may 
increase the concentration of oligomers, driving further toxicity.  
Interestingly, Congo red dye (structure shown in Figure 4.5) which binds specifically to amyloid 
fibrils is a linear and amphiphilic molecule. There are two amino acid groups and a negatively 
charged sulphate group that comprise the hydrophilic part of the dye and a biphenyl group in the 
middle with a diazo group and two naphthalene groups (Wu et al., 2012). There is a strong presence 
of aromatic elements in this structure that are thought to facilitate the interaction of Congo red with 





Figure 4. 5. Structure of Congo red dye. The dye has a strong presence of aromatic residues which bind to 






Many mutations targeting the phenylalanine residues, Phe19 in particular, has demonstrated the 
critical role they play in amyloidogenesis. Examples of substitutions made at position 19, all of which 
negatively affect amyloidogenicity, include serine (Wurth et al., 2002), leucine (Cukalevski et al., 
2012), threonine (Esler et al., 1996), glycine (Hilbich et al., 1992) and isoleucine (Hilbich et al., 
1992). Substitutions made at Phe20, however, have still resulted in assembly. This has been observed 
with leucine (Cukalevski et al., 2012) and also with tryptophan (Pachahara & Nagaraj, 2015).  
One possible explanation for amyloid formation being greatly affected by mutations at F19 and not 
F20, is due to the role F19 has been hypothesised to play in nucleation (Cukalevski et al., 2012). 
Furthermore, using solid state NMR, contacts between F19 and L34 have been observed suggesting a 
turn conformation between this region of Aβ42 and also supports the notion that there is a 
hydrophobic collapse in the two most amyloidogenic regions of the sequence (Ahmed et al., 2010). 
Therefore, making a substitution at F19 with the polar residue serine, is expected to disrupt the normal 
п-stacking and fibril formation that is usually seen with wild type Aβ42 sequence. This is due to a 
combination of the small size of serine causing steric hinderance, and its hydrophilic properties 
disrupting the hydrophobic interactions usually buried within the protein.   
The glycine at position 37, substituted with aspartic acid, has also been shown to be critical in Aβ42 
assembly. Solid state NMR studies measuring amide exchange have identified solvent accessible turns 
at H13-Q15, G25-G29 and G37-G38. The β-sheet bend between G37 and G38 allows for the A42 to 
come into contact with the side chain of the M35 (Ahmed et al., 2010; Masuda et al., 2008). It has 
been suggested that this stabilizes the S-oxidized radical cation formed as a result of M35 oxidation 
by metal ions, by forming an S-O bond with an amide carbonyl oxygen or carboxylate anion on the 
A42. This has led to the assumption that there is the formation of intramolecular anti-parallel β-sheets 
at positions 35-42 in order to facilitate the S-O bond (Masuda et al., 2008). This results in a 
hydrophobic core being formed, long term oxidative stress and accelerated aggregation (Murakami et 








Figure 4. 6. The β-sheet bend between G37-38 in Aβ42 allows for the A42 to come into contact with the 
M35 side chains and stabilise radical cations which have been suggested to cause long term oxidative 
stress and aggregation of Aβ42 by the formation of intramolecular β-sheets. 
 
The C terminal of Aβ42 contains a Gly-XXX-Gly-XXX-Gly motif (also discussed in APP section). 
This is known as a glycine zipper (Kim et al., 2005) and is often found on the transmembrane domain 
of several bacterial channel proteins (Kim et al., 2005). This glycine motif can drive the formation of 
packing between two α-helical regions of two Aβ monomers and leads to the formation of cytotoxic 
membrane pores (Fonte et al., 2011). Substituting the glycine residues for leucine, especially at 
position 37, has been shown to drastically reduce Aβ42 toxicity in cell cultures and C.elegans (Fonte 
et al., 2011; Harmeier et al., 2009; Hung et al., 2008; Kim et al., 2005).  Taking into consideration the 
importance of glycine at position 37 in forming a solvent accessible turn, as well as the role it plays in 
α-helical packing of Aβ monomers, substituting G37 with a negatively charged, bulky amino acid 
such as aspartic acid will disrupt the turn and interactions that would usually occur in the wild type 
Aβ42 sequence. This is likely is due to the disruption of hydrophobic interactions and large size of 
aspartic acid causing steric hinderance.  
4.2.2 Aβ42-1 and AβS are amyloidogenic  
Using a range of biophysical techniques, the assembly and structure of the two control peptides were 
monitored until it was apparent that amyloid formation had reached a plateau. The peptides were 
prepared in an identical manner to the method developed in Chapter 3 for Aβ42 (Marshall et al., 





TEM was used to observe the morphology of untagged peptide assemblies over time (Figure 4.7). 
Electron micrographs are the most representative of three independent peptide sample preparations.  
For Aβ42-1 at T0, there are small aggregates (black arrows) which are identified as being prefibrillar 
oligomers. These are similar to those seen with Aβ42 (Marshall et al., 2016) at 4 hours and also seen 
by other groups with Aβ40 (Sarroukh et al., 2011). By 4 hours, there are obvious large fibrillar 
aggregates formed. These are not as ordered as fibrillar aggregates observed with Aβ42, however the 
presence of fibrillar species is seen at an earlier time point that for Aβ42.  It is evident that by 24 
hours Aβ42-1 forms fibrillar structures, although again these are less ordered in appearance than those 
formed by Aβ42 and are comparable to those seen with Aβ40 (Kok et al., 2009; Qiang et al., 2012). 
This may due to be only one amyloidogenic region being identified within the sequence. Furthermore, 
in Aβ42, the β-sheet packing is in register and anti-parallel. By reversing the sequence, the hydrogen 
bonding in this arrangement could be affected giving rise to less stable and ordered mature fibrils. 
Interestingly, AβS forms plaque-like fibrillar networks by 24 hours which are only observed with 
Aβ42 after 7 days (Figure 3.6 in Chapter 1) at the same concentration. As WALTZ predicted no 
amyloidogenic regions for AβS, this assembly was unexpected and highlights the importance of 
conducting experimental structural characterisation. It is possible the 200 hexapeptide used to develop 
WALTZ did not include sequences within the AβS sequence, however, it is more likely to be a 
limitation within the algorithm itself.  Despite no amyloidogenic region being identified, the presence 
of fibrils which display similarity to Aβ42, indicates that AβS is amyloidogenic. TEM suggests that 
not only does AβS aggregate but does so with a higher propensity than Aβ42. This raises the question 
of why rearranging the same amino acids in a different order increases the propensity to self-
assemble. As with Aβ42-1, AβS is not a naturally occurring peptide. However, as amyloidogenicity is 
an inherent property of all peptides under the correct conditions, perhaps the way in which the AβS 
was prepared (e.g. pH, salts in buffer, concentration) provided the optimal conditions to form 
amyloid. It is also possible that the arrangement of the amino acids may also lead to stronger 





Figure 4. 7. Negatively stained electron micrographs of Aβ42-1 and AβS over 24 hours. 50μM untagged peptides were prepared in 20mM Phosphate 
Buffer (pH 7.4) and incubated at room temperature. Aβ42-1 shows the presence of spherical aggregates (black arrows) at T0 which form clumps 
fibrils by 4 hours. AβS shows small fibrillar species at T0 (black arrows) as well as some possible small oligomers (red arrows), fibrillar networks by 
4 hours and these were much larger by 24 hours. Scale bars are shown at 200nm. The electron micrographs are the most representative of three 





To confirm both peptides can be classified as amyloidogenic proteins, X-ray fibre diffraction was 
used to confirm a cross-β molecular structure. The X-ray fibre diffraction patterns for both are shown 
below in Figure 4.8. The sample preparation was carried out by myself and the X-ray fibre diffraction 
data was collected by Louise Serpell.  
 
Figure 4. 8. X-ray fibre diffraction patterns for partially aligned fibrils formed by Aβ42-1 and AβS. X-ray 
fibre diffraction patterns revealed characteristic cross-β diffraction signals at 4.7 Å and at 10 Å. The 
sample preparation was carried out by myself, however, the X-ray fibre diffraction data was collected by 
Louise Serpell. This XRFD experiment was carried out once in order to confirm amyloid formation. 
 
The fibril samples were not aligned enough to provide details of structural similarities compared to 
Aβ42, however, the X-ray fibre diffraction patterns for the partially aligned fibres of both peptides 
display the characteristic signals at 4.6 Å and 10 Å for a cross-β structure. This confirms that both 










4.2.3 Aβ42-1 and AβS form mature fibrils with β-sheet rich secondary structure 
CD was used to investigate the secondary structure of both peptides over a 48-hour incubation time 
(Figure 4.9A and B). The spectra shown as the mean of three independent samples. Both control 
peptides show a strong β-sheet signal (minimum and maximum at 218nm and 192nm respectively) 
almost immediately after preparation. The spectrum for AβS is initially shifted slightly towards 
random coil, suggesting a mixed population, but displays a strong β‐sheet signal by 24 hours. The 
unchanged β-sheet signal seen for Aβ42-1, together with the electron micrographs suggests the small 
aggregates seen at T0 have already adopted a β-sheet structure. The change in β-sheet signal (218nm) 
over the incubation time are also shown (Figure 4.9 A and B, insets). There is a decrease in β-sheet 
signal from time zero to 4 hours, however, after this there is relatively little change in the spectra at 
increasing time points for Aβ42-1, with the molar ellipticity remaining at ~ -250deg.mol2/dmol up to 
48 hours. The initial decrease seen in might be explained by some of the fibril falling out of solution 
as aggregation progresses. An increase from -180deg.mol2/dmol at T0 to -500deg.mol2/dmol at 48 
hours is seen with AβS. Again, this could suggest a small population of random coiled conformation 
at early time points which quickly adopt a strong β-sheet signal. The TEM of AβS at T0 show small 
spherical structures (red arrows) that do not yet have a distinct appearance of a larger 
oligomers/protofibrils which may account for the slight shift to a random coil signal at the early time 
points. This is in contrast to wild‐type Aβ42 which transitions from random coil to β‐sheet over a 24 
hours period under the conditions used.  From TEM and CD, there seems to be an immediate 
assembly into β-sheet rich Aβ42-1 entities for Aβ42-1 and an extremely rapid assembly process 
including intermediary random coiled species for AβS.   
Fibrillogenesis was monitored using a ThT fluorescence assay (Figure 4.9C); both control peptides 
show a signal at 483 nm, which indicates the presence of ThT positive structures. The ThT 
fluorescence of both control peptides is shown over a 48-hour period. A typical spectrum for 
wild‐type Aβ42 (Figure 3.7C, Chapter 3) shows a lag phase before a steep increase in intensity, which 
then begins to plateau. This can be explained by nucleation-dependent fibrillisation; the lag phase is 





thermodynamically stable nuclei for fibril growth. Once a critical fibril concentration has been 
reached, secondary nucleation becomes the dominant nucleation process and the surface of these 
fibrils can act as a catalyst for the formation of oligomers and further proliferation into fibrils. This 
lag and elongation phase is not observed with either of the control peptides, consistent with the results 
indicating rapid assembly from TEM and CD. The lower intensity in ThT fluorescence at later time 
points may be attributed to the loss of peptide from solution as larger aggregates form. This is 
supported by the dense fibril morphology observed in the electron micrographs at 24 hours (Figure 
4.7). The ThT fluorescence spectrum for Aβ42-1 showed a very shallow increase in intensity, 
although fibrils are visible in the electron micrographs. Different peptide systems are difficult to 
directly compare using ThT fluorescence due to differential binding, however, it is clear that ThT 
intensity increases with incubation time. This suggests the peptides self-assemble to form amyloid 





Figure 4. 9. CD spectra and ThT fluorescence of Aβ42-1 and AβS over 48 hours. A) The CD spectra for Aβ42-1 (1mm cuvette) shows a β-sheet signal from T0. 
B) The CD spectra for AβS (0.5mm cuvette) shows a weak β-sheet signal at early points which shifts to a stronger signal by 24 and 48 hours. This increase in β-
sheet signal is more clearly seen in the graph inserted above the CD spectra showing the molar ellipticity at -218nm over time. Both CD spectra are means of 
the spectra obtained from three independent sample preparations. The insets show the mean increase in β-sheet intensity C) ThT fluorescence of both Aβ42-1 
and AβS show a slight increase in intensity over time. The average of three independent sample preparations for each peptide is shown.  Peptides were 





4.2.4 vAβ42 is assembly impaired 
As the vAβ42 is presented as a more appropriate, novel experimental control peptide, as well as a 
model to investigate the importance of primary sequence in amyloidogenicity, the characterisation 
was carried out over a 7-day period for a true comparison with Aβ42 (Chapter 3). This extensive 
biophysical characterisation is necessary to ensure that assembly for this peptide sequence is 
impaired, despite only a two amino acid substitution.  
As with Aβ42-1 and AβS, the vAβ42 peptide was prepared in an identical manner to Aβ42. CD, ThT 
fluorescence and TEM were used to investigate self-assembly. From TEM (Figure 4.10), no 
assemblies were visualised even at 7 days. The CD spectra for vAβ42 (Figure 4.11A) confirms that 
there is no secondary structure reorganisation and that the peptide remains in a random coiled 
conformation (minimum at 198nm) from T0 to 7 days. ThT fluorescence (Figure 4.11B) confirmed a 
lack of fibrillogenesis within the same timeframe, displaying negligible intensity at 483nm. Together, 
these results suggest vAβ42 does not assemble in the same time frame as Aβ42 (Marshall et al., 
2016). 
To further confirm lack of assembly into insoluble amyloid, solution state NMR was utilized to 
monitor changes in solubility over time (Pauwels et al., 2012).  Scans were taken every 30 minutes 
over 66 hours to monitor changes in shift positions and signal strength. Figure 4.11C. If there is a 
change in solubility, the signal disappears once the peptide assembles past than a certain size. Even at 
the high concentration of 200μM necessary for solution state NMR, the two traces at T0 and 66 hours 
are identical suggesting no changes in solubility (Marshall et al., 2016). The NMR trace of Aβ42 has 
been included as a comparison; the traces are T0 and 66hours are not identical and there is a loss of 
signal from the aromatic residues suggesting a change in solubility and structure. NMR results were 
obtained by Dr. Iain Day and the experiment was conducted once due to the high concentration and 





Figure 4. 10. Negatively stained electron micrographs of 50μM vAβ42 over 7 days. No assembly was seen in the time frame. Peptide was prepared in 10mM HEPES 
buffer pH 7.4 and incubated at room temperature. Scale bars are shown at 0.5μm. The electron micrographs are the most representative of all images obtained from 





  Figure 4. 11. CD, ThT fluorescence and NMR for vAβ42. A) CD spectra for vAβ42 displays a signal for random coil conformation from T0-7 days. This 
suggests the peptide remains unfolded and does not undergo any structural reorganisation. The spectra is representative of three spectra obtained from three 
separate sample preparations. B) ThT fluorescence for vAβ42 is negligible confirming a lack of fibrillogenesis. The graph is the average of three separate 
sample preparations. Error bars expressed as ±SEM. C) The NMR signal of vAβ42 remains unchanged over 3 days shown by the red circle on the bottom 
trace (T0 signal shown in the top trace, 3 day signal shown in the bottom trace) indicating that the peptide does not change structure in this time period. D) 
The NMR signal for the Aβ42 peptide is included for comparison and shows a loss in signal of the aromatic residues suggesting there is a structural change 
occurring and a change in solubility. The NMR experiment was performed by Dr. Iain Day. For CD and ThT, 50μM untagged peptide was prepared in 





Despite the biophysical characterisation presented above indicating impaired assembly of vAβ42, it is 
possible there may be small species (possible oligomers) that are undetected by TEM, with β-sheet 
secondary structure not detectable by CD or bind ThT. To examine whether vAβ42 forms small 
oligomers, antibodies directed at different conformations and epitopes were used.  
The  anti-Aβ antibodies used in this chapter and their epitopes are shown in Table 2.2 (Chapter 2). As 
the epitope for the N-terminal anti-Aβ 4G8 antibody, used in Chapter 1, overlaps with the F19S 
substitution in the vAβ sequence (18-23), this antibody is not expected to show reactivity with vAβ42. 
Dot blots (Figure 4.12A) were carried out and provide useful information regarding the antigenicity of 
vAβ42 as well as the species in present in the sample. However, as the assembly of amyloid is 
dynamic, the sample population is likely to be heterogenous. Therefore, SDS-PAGE and western 
blotting was also used separate the sample by size and detect any assembled strucutres. Samples of 
vAβ42 were collected at each time point and the 6E10 antibody was used to detect the peptide 









One repeat of both the dot blot and western blot were carried out and therefore quantitative analysis 
was not possible. Additional repeats for robust quantification would be a future direction.  
The dot blot (Figure 4.12A) using 6E10 antibody, the epitope for which is still conserved in the 
vAβ42 sequence (3-8), confirms the presence of the peptide at each time point. However,  NU1 shows 
no reactivity and only a faint signal is seen with A11. As both these antibodies are conformation-
specific for oligomers, this suggests there are no oligomeric assemblies formed over the course of 7 
days. The western blot (Figure 4.12B) using 6E10 detects only monomeric vAβ42 suggesting this 
peptide does not assemble into higher molecular weight structures over 7 days.  
Figure 4. 12. Antigenicity of vAβ42. A) Dot blots using 6E10 (1:10,000), A11 (1:5000) and Nu1(1: 
10,000) antibodies to detect for vAβ42 over 7 days. The 6E10 antibody confirms the presence of 
the peptide at each time point. A11 and Nu1 are oligomer specific conformational antibodies; 
there is a very faint signal displaced by A11 at later time points and no reactivity with Nu1 over 
7 days, suggesting no oligomeric species are formed.  B) Western blot using the 6E10 antibody 
shows that the vAβ42 runs as a monomer and does not assemble into higher molecular weight 
structures over 7 days.  The untagged peptide was prepared at 50μM in 10mM HEPES buffer 
pH 7.4 and incubated at room temperature. 1 and 2ug of protein was loaded for the dot blot and 
western blot respectively. Both the dot blot and western blot were carried out once, therefore 





The A11 antibody has been used extensively in several studies to differentiate between oligomeric 
and fibrillar species. As it is a conformational antibody with no specific epitope, A11 can be used to 
detect oligomers of a wide range of proteins including α-synuclein, HTT and SOD (Kayed et al., 
2003). The binding mechanism, however, has not yet been established and it is possible that the faint 
signal seen in the dot blot for vAβ42 is simply an artefact. Another possibility is that vAβ42 could be 
forming stable dimers at later time points that cannot be seen at the resolution of TEM. However, this 
seems to be unlikely as SDS-PAGE electrophoresis and western blotting reveal only a monomeric 
size from T0 to 7 days.  
Overall the biophysical and conformational specific antibody directed characterisation of vAβ42 
confirm that this sequence is assembly impaired and does not form β-sheet rich structures within the 
same time frame as Aβ42. This makes it an ideal and more suitable experimental control for Aβ42 
compared to Aβ42-1 and AβS. 
4.2.5 vAβ42, Aβ42-1 and AβS are not cytotoxic 
As all three peptides are both controls and models to explore the importance of primary sequence in 
amyloidogencity, their cytotoxic nature was investigated in rat primary hippocampal neurons. All 
three peptides were prepared in the same manner as Aβ42, which is most oligomeric after a 2 hour 
incubation period (Chapter 3).  After 2 hours of incubation at room temperature, 10μM of peptide was 
added to cells and incubated for 7 days, after which toxicity was assessed using a ReadyProbes assay. 
Although this concentration is not physiologically relevant, it allows us to rule out the possibility that 
negative results are not due to a low peptide concentration and also ensures effects are seen within a 
reasonable timeframe. ReadyProbes is a live/dead assay containing two reagents, one labelling the 
nuclei of all cells with a blue dye and a second that labels dead cells only with a green dye. An 











Figure 4. 13. Examples of ReadyProbes images. Zooms of images taken at 10X of hippocampal cultures 
incubated with 10μM (A) Buffer (B) AβS (C) Aβ42-1 (D) Aβ42 (E) vAβ42 at 7 days. Peptides were 
prepared at 50μM in 10mM HEPES buffer pH7.4 and incubated for 2hours before added to cells. The 
ReadyProbes cell viability assay was then carried out at 7 days. Scale bars shown at 50μM. 
 
The number of green cells were calculated as a percentage of the blue cells, to quantify toxicity 
(Figure 4.14, top left). As the density of cells plated remained constant, imaging and counting the 
same number of regions for each condition of treated cells provides a valid indication of cyototxicity. 
Data for Aβ42 have been included as a comparison for both structure and cytotoxic effects. DIC 
images (Figure 4.14, bottom panel) are useful to look at the morphology of the cells, although, it is 
not possible to comment on the viability of cells simply using these images. From the DIC images, it 
is possible to see that cells treated with three variants of Aβ42 for 7 days are plentiful with their cell 
bodies and axons still intact. Finally, EM  was used to confirm the morphology of the peptides being 












Figure 4. 14. Aβ42 variant peptides ReadyProbes cell viability assay. Rat hippocampal cultures were incubated with 10µM Aβ42, Aβ42-1, AβS and vAβ42 
for 7 days, after 2 hours of peptide incubation. The average of three independent experiments (three separate Aβ42 preparations and hippocampal 
cultures) is shown. Cytotoxicity was measured as a percentage of dead cell in a culture and compared to buffer incubated cells (10.21% ± 2.32, total 
number of cells = 558, number of dead cells=52). Aβ42 oligomers were significantly toxic compared to the buffer at 7 days cell (66.3% ± 2.59, total number 
of cells = 1172, number of dead cells=777) as was AβS (17.19 ± 1.49, total number of cells = 1627, number of dead cells=288) Both Aβ42-1 (14.06% ± 1.26, 
total number of cells = 719, number of dead cells=97) and vAβ42 (12.38% ± 2.81, total number of cells = 1245, number of dead cells=179)  were non-
cytotoxic. Unpaired parametric student’s t test where p= < 0.01 (*), < 0.001 (**), < 0 (***). Error bars are expressed as ±SEM. Electron micrographs of 
each peptide are shown (top, right. Scale bars at 2μm) as are the DIC images of cells incubated with each peptide after 7 days (bottom panel. Scale bars 





It is important to note that although cell viability assays are widely used to investigate cytotoxicity, 
the relationship to AD pathology may not be closely linked due to the various pathways involved in 
cell death and the specificity of the assay being used. Nevertheless, as the cytotoxicity of these control 
peptides in hippocampal neurons is being investigated, and not a model of AD pathology, the 
ReadyProbes assay is a valid approach. As described previously, Aβ42 causes 65% (66.3% ± 2.59, 
total number of cells = 1172, number of dead cells=777 , ‘***’) cytotoxicity after 7 days of incubation 
compared to the buffer only condition that showed only 10% cell death (10.21% ± 2.32, total number 
of cells = 558, number of dead cells=52). In comparison, AβS and Aβ42-1 demonstrated less potent 
toxicity than wild-type Aβ42 at the same time point and using the identical preparation conditions; 
17% (17.19 ± 1.49, total number of cells = 1627, number of dead cells=288, ‘*’) and 14% (14.06% ± 
1.26, total number of cells = 719, number of dead cells=97) respectively. Previous studies have also 
shown that Aβ42-1 (Yatin et al., 1999) and AβS (identical sequence to AβS used here from Anachem) 
(Izzo et al., 2014) are inactive in cellular assays.  
Electron micrographs of the peptides 2 hours after preparation offer an explanation for the difference 
in cytotoxicity. Aβ42 shows small spherical species, which we identify as oligomers. In contrast, 
electron micrographs of Aβ42-1 and AβS taken at the same time point show some larger aggregates, 
possible protofibrils and some fibrils. No assemblies were visible for vAβ42, which may explain its 
non-cytotoxic nature; all three peptides do not form visible oligomers in the same timeframe as Aβ42.  
It appears that reversed and scrambled variants of Aβ42 self-assemble to form fibrillar structures more 
rapidly than wild-type and these are much less toxic than oligomeric Aβ42. Previous work has linked 
internalisation of oligomers with toxicity and therefore one hypothesis for the reduced toxic nature of 
these peptides is that these structures are less able to enter the neurons (Chafekar et al., 2008; 
Marshall et al., 2016) and cause their downstream toxic effects due to their increased size. The 
inability for cells to take up AβS has been previously reported (Nath et al., 2012), as has the non-
apoptotic effects of Aβ42-1 (Gamba et al., 2011; Troy et al., 2000). The slightly significant cytotoxic 





hypothesised that some oligomeric species remains in the AβS population after 2 hours (black arrows 
in electron micrograph, Figure 4.8). If AβS was incubated for a shorter period of time before being 
added to neuronal cultures, it may exhibit slightly more toxicity due to the higher presence of 
oligomers.  
The vAβ42 peptide displayed no significant cytotoxicity (12.38% SEM± 2.81). Previous work 
adopting the MTT assay to monitor the metabolic function of hippocampal treated neurons, also 
confirmed no deleterious effect to cellular function by this peptide (Marshall et al., 2016) . Extensive 
functional characterisation was also carried out to confirm that vAβ42 has no effect on hippocampal 
synaptic function and does not disrupt the recall of consolidated long-term memory in Lymnaea 
stagnalis (Marshall et al., 2016). Together, these data shows the vAβ42 to be non-cytotoxic. This can 
be again linked to internalisation, which was not seen with this peptide (Marshall et al., 2016).  
Overall, the data presented on the cytotoxic nature of all three sequence variants of Aβ42, show them 
to be much less deleterious to cellular function than Aβ42.   
4.3 Conclusions 
In this chapter, we explored the importance of primary sequence in determining assembly propensity 
and its corresponding toxicity of Aβ42 related proteins.  
By characterising assembly of each Aβ42 variant (summarised in Figure 4.15) and relating this to 
toxicity, our findings suggest the toxic nature of these amyloid proteins is highly related to primary 
sequence. It is however, extremely, important to note that this is true for the peptides presented in this 
chapter using our preparation method. It is possible, using a different protocol of peptide preparation 
may not result in the same assembly or toxicity. Therefore, without exploring other methods of 
peptide preparation in a similar manner and relating assembly to cytotoxicity, we can only confidently 
state that primary sequence highly influences cytotoxicity due to the assembly process in our specific 
sample preparation. The influence of primary sequence in the propensity to form amyloid has been 





toxicity. The WALTZ algorithm predicted both control peptides to have fewer amyloidogenic regions 
than the wild-type; Aβ42-1 was predicted to have one amyloidogenic region, whereas AβS was 
predicted to have none. Despite this, both peptides show a high propensity to form amyloid with 
similar non-toxic behaviour in cells. Therefore, we can also make the conclusion that as a 
consequence of primary sequence, the ability to assemble into amyloid via oligomeric species, is an 
important factor influencing the cytotoxic nature of pathogenic amyloid proteins.  
The vAβ42 was predicted to have no amyloidogenicity, which has been confirmed by extensive 
characterisation. This peptide has also been shown to be non-toxic which is suggested to be related to 
impaired assembly due to the primary sequence. All three sequences do not assemble to form 
oligomeric species within the same timeframe as Aβ42 and therefore the species of each variant 
peptide added to our neuronal cultures were not oligomeric and non-toxic.  This supports the view that 
Aβ42 oligomers represent the toxic entity. Further experiments assessing cytotoxicity of Aβ42-1 and 
AβS after a shorter/no incubation to neuronal cultures would provide stronger evidence for this, as it 
would be likely some oligomeric species would be present (especially for AβS as suggested by CD). 
This toxicity may be related to internalisation of oligomers due to their size (discussed in-depth in 
Chapter 5). Furthermore, to understand better whether the process of self-assembly plays an important 
role in cytotoxicity the cells should be incubated with both Aβ42-1 and AβS immediately after 
preparation. This would allow us to add any oligomers that may be have been missed in the two-hour 
incubation and allow us to evaluate whether the assembly from oligomers to fibrils may mediate 
cytotoxicity. 
It has previously been reported that the uptake of aggregating amyloid proteins is sequence specific 
(Couceiro et al., 2015), and the cellular response to these proteins is thought to be highly dependent 
on aggregation propensity, size and charge. As the sequences of both Aβ42-1 and AβS peptides result 
in a higher propensity to aggregate than wild-type Aβ42, confirmed by structural characterisation 
presented above, the reported mechanisms of internalisation, which include dynamin‐mediated 





order of amino acids in Aβ42-1 and AβS may affect binding to receptors or assembly into specific 
oligomeric species that are required for toxicity.  
As a future direction, the internalisation of all three peptides should be looked at using techniques 
such as immunocytochemistry and live cell imaging. This would enable to gain a further 
understanding of whether the larger assemblies, or no assemblies in the case of the vAβ42, are not 
causing significant cytotoxicity due to internalisation.  
Although both Aβ42-1 and AβS have been used in many studies as experimental controls for 
Aβ42, the data presented in this chapter suggest their validity should be questioned. If conclusions are 
to be made regarding the effects of amyloidogenic proteins, it is desirable for controls to be sequence 
related but ideally show no propensity for self-assembly. The structural characterisation presented 
here confirms that the F19S and G37D substitutions are able to disrupt self-assembly and thereby 
render the sequence to be non-toxic in primary hippocampal cultures. Therefore, the sequence-related, 
non-aggregating variant of Aβ42, vAβ42, serves as a more suitable control. To critically evaluate and 
continually develop experimental controls in this way will ultimately aid our understanding of the 
mechanisms involved in AD. 
Overall, the Aβ42 variant models presented in this chapter provide support for the importance of 
primary sequence in determining amyloid toxicity. This due to the subsequent assembly process; the 
ability to assemble in a process allowing for the formation of intermediary oligomeric species is a 
factor determining amyloid toxicity.  
Finally, relating this work to disease-related mutations within the Aβ sequence that affect the 
assembly process and relating this to cytotoxicity would be future direction of this work. For example, 
the Arctic FAD mutation where there is a substitution of the glutamic acid with a glycine at position 
22, is thought to enhance the fibrillisation of Aβ. A similar characterisation of this sequence, 





relating this to cytotoxicity in primary hippocampal cultures, would begin to relate the conclusions 




Figure 4. 15. Schematic diagram to summarise the assembly process of three Aβ42 variants. Aβ42-1 
assembles from small aggregates which are β-sheet rich, into protofibrils and mature fibrils. AβS 
assembles rapidly from monomers/ small oligomers to fibrils and the vAβ42 is assembly impaired, 







Chapter 5: Implications of size, conformation and internalisation 
in amyloid toxicity  
Chapter Overview 
Having established the importance of primary sequence in the role of amyloid toxicity using Aβ42 
variants, we sought to determine the importance of the size and conformation of Aβ42 assemblies. 
The ReadyProbes cell viability assay was utilized to assess the cytotoxicity of Aβ42 oligomers (AβO), 
Aβ42 fibrils (AβF) and sonicated fibrils (AβSon) in rat primary hippocampal cultures. The data 
presented in this chapter also uses a combination of immunocytochemistry and live cell imaging to 
investigate the localisation and internalisation of each of these species in primary hippocampal and 
SHSY5Y cultures. In this way, we linked the importance of size, conformation and internalisation (or 
lack of) to cytotoxicity.  
5.1 Introduction 
The plaque deposits in AD brains are composed of cross-β sheet units arranged into amyloid fibrils of 
the Aβ peptide (Benilova et al., 2012).  Although it has been reported that cognitive decline seen in 
AD patients correlates poorly with plaque deposition (McLean et al., 1999), there is mounting 
evidence to suggest that these may play a role in disease process due to the dystrophic neurons, 
activated microglia and reactive astrocytes (Bezprozvanny, 2009; Meyer-Luehmann et al., 2008) 
surrounding plaques areas. Plaques have also been implicated as reservoirs of oligomers which may 
facilitate further toxicity (Kayed et al., 2007; McLean et al., 1999; Verma et al., 2015; Walsh et al., 
2002b) . 
The relationship between amyloid structure and toxicity has been the focus of much research, and it is 
generally accepted that Aβ exerts its deleterious effects due to the self-assembly process (Broersen et 
al., 2010; Pike et al., 1991; Pike et al., 1993; Williams & Serpell, 2011). This is supported by the data 





The amyloid cascade hypothesis identifies the Aβ42 oligomeric species as the primary culprit of 
toxicity (Hardy & Higgins, 1992). Focus on oligomers has been heavily influenced by the correlation 
between cognitive decline and soluble Aβ (McLean et al., 1999). The lack of a universal definition for 
the term 'oligomer' and the many different preparation methods used, has led to several oligomeric 
species being identified as neurotoxic (Reviewed in Table 3.2). This serves as support for the theory 
that rather than one size or species in particular being responsible for the toxic nature of Aβ42, it is 
more feasible toxicity of Aβ42 is somewhat linked to conformation (Broersen et al., 2010) 
5.1.1 Oligomeric and Fibrillar Aβ42 
The factors affecting amyloid assembly and the variability of different preparation methods have been 
discussed in Chapter 1. The result of this has been the identification of several species as being 
cytotoxic (Benilova et al., 2012; Broersen et al., 2010).  
From the data presented in Chapter 4, Aβ42 is the only primary sequence that forms intermediary 
species on the pathway to becoming amyloid fibrils. This was also the only peptide to exhibit 
cytotoxicity in rat primary hippocampal cultures (Vadukul et al., 2017) and SHSY5Y cells (Marshall 
et al., 2016). The toxicity is therefore, at least in part, related to the ability to form these intermediary 
oligomeric species. A specific understanding of why these oligomers are toxic, however, is not fully 
understood- is it related to size or conformation?  
As there are several conformations the term ‘oligomer’ can encompass, simply stating oligomers are 
toxic is not sufficient to gain an understanding regarding what makes an amyloid protein toxic. There 
is still much debate as to which conformational changes are needed to move from one phase to the 
next during the assembly process of Aβ, in which there is the lag phase followed by the elongation 
phase (Ferrone, 1999). Generally, it is accepted that Aβ begins as a randomly coiled (unstructured) 
monomer which then becomes ‘activated’ as a critical nucleus for further monomer addition and 





The initial steps of Aβ assembly are thought to include an equilibrium of randomly coiled, α-helical 
and β-sheet species monomers (Bartolini et al., 2007; Benseny-Cases et al., 2007; Broersen et al., 
2010). It is thought that only those species with β-sheet conformation can facilitate the elongation into 
fibrillar oligomers and mature fibrils (Broersen et al., 2010) (Figure 5.1) 
 
Figure 5. 1. Schematic diagram of conformational changes that occur during Aβ42 assembly. There is the 
equilibrium of β-sheet, random coil and alpha helix monomer which assemble into anti-parallel β-sheet 
oligomers and protofibrils. These then assemble into parallel β-sheet mature amyloid fibrils. Adapted 
from Broersen et al, 2010. 
 
Many groups have reported the oligomeric species as being β-sheet rich structures (Cheon et al., 2007; 
Kayed et al., 2007; Stroud et al., 2012). Although this is in contrast to the data presented in Chapter 3 
where we identify toxic oligomers to lack a significant secondary β-sheet rich structure by CD, it is 
likely that 1) both conformations co-exist and certain percentage of our oligomeric species is β-sheet 
rich with the random coil signal dominating due to the majority of the sample remaining unstructured 
and 2) oligomers can be both prefibrillar or fibrillar, with the β-sheet rich oligomeric species 
identified by other groups being the fibrillar oligomeric species. Fourier-transform infrared (FTIR) 
spectroscopy and NMR studies have shown pre-fibrillar Aβ42 oligomers lack a parallel β-sheet 
structure found in fibrillar oligomers and mature amyloid fibrils, and have an anti-parallel packing of 
β-sheets (Verma et al., 2015; Yu et al., 2009; Yu & Zheng, 2011).  The oligomeric species can 
therefore be split into two broad categories; prefibrillar (anti-parallel β-sheets) and fibrillar (parallel β-
sheets). 
Mature Aβ amyloid fibrils possess a hairpin secondary structure with an exposed N terminal (Tycko, 





which is thought to be further stabilised via a salt bridge between Asp23 and Lys 28 (Kahler et al., 
2013; Roychaudhuri et al., 2009). These fibrils are highly ordered and stable with their hydrophobic 




5.1.2 Conformation-specific antibodies 
The ability to differentiate between different aggregation states based on conformation has been the 
focus of much research (Kahler et al., 2013; Kayed & Glabe, 2006; Kayed et al., 2007; O'Nuallain & 
Wetzel, 2002). The development of conformation specific antibodies that recognise mature fibrils and 
soluble fibrillar oligomers, serves as evidence for establishing the importance of conformation in 
amyloid toxicity (Kayed et al., 2007). For example, the OC antibody does not recognise randomly 
coiled monomeric or pre-fibrillar oligomers, thereby confirming oligomers do not display a 
conformation dependent epitope found in fibrils (Kayed et al., 2007).  The ability of these 
Figure 5. 2. Schematic representation of the Aβ42 β-turn loop linking two parallel β-sheet 






conformation specific antibodies to bind to specific fibrillar structures, despite differences in primary 
sequence, could be due to the steric zipper side chains. These are found in fibrils formed by large 
number of amyloid forming sequences and could be the recognised generic epitope (Glabe, 2008).  
Furthermore, the A11 antibody specific for oligomers does not bind mature fibrils, fibrillar oligomers 
or fragmented fibrils. This further suggests  prefibrillar and fibrillar oligomers are structurally distinct 
(Kayed et al., 2007). Co-incubation of A11 with Aβ oligomers has been shown to suppress toxicity 
suggesting that although these oligomers may be different in size (and possibly shape), there could be 
a common feature rendering them toxic (Broersen et al., 2010). 
To directly link structure (i.e. size and conformation) to amyloid toxicity, we used our highly 
consistent preparation of Aβ42 to obtain and assess the toxicity of the fibrillar species. This was 
compared to the already established cytotoxicity of AβO. To probe further into the importance of 
structure in amyloid toxicity, the effect of sonicated fibrils was also monitored. Sonicating the fibrils 
not only allows us to compare the effects of size, but also conformation. As we define our oligomers 
to be a pre-fibrillar species, investigating the effects of sonicated fibrils, which we presume will retain 
their fibril-like β-sheet rich conformation, will allow us to determine whether this is a requisite of 
amyloid toxicity.  
5.2 Results and Discussion 
5.2.1 Establishing the biophysical properties of AβO, AβF and AβSon 
Before being able to determine the cytotoxicity of AβO, AβF and AβS, we first confirm their 
structural properties. In order to do so, we used TEM and CD in combination with western blotting. 
Using our highly consistent and reliable preparation of Aβ42 (Marshall et al., 2016), we confidently 
identify the sample to be most oligomeric 2 hours after preparation and fibrillar by 48 hours.  
For sonicated fibrils, it was important to first optimise conditions so fibrils were fragmented to a size 
as close to oligomeric as possible. These small, fibrillar oligomers will be referred to as oligomer-like 
to differentiate them from oligomers assembled from soluble Aβ42. This allows us to compare similar 





Figure 5.3B-D shows the EM of fibres sonicated for 5-, 10- and 20-minutes.  From this, it is apparent 
that sonication for longer than 10 minutes disrupts the integrity of the fibrils beyond the size of what 
we could classify as oligomers-like, whereas 5 minutes was not long enough for sufficient 
fragmentation. 10 minutes was therefore selected as the appropriate length of time for sonication. This 
sonication optimisation was carried out on one independent sample preparation of Aβ42 to ascertain 
the appropriate sonication time . From electron micrographs, the length of sonicated fibrils (n=544) 
were measured to assess the range of assembly sizes present (Figure 5.3E). From the histogram 
(Figure 5.3E), we can conclude the majority of sonicated fibrils are between 30 and 90nm in length. 
Fewer fibrils of increasing lengths are counted, with the longest fibril measured at ~800nm (n=1). 
Therefore, we are confident AβSon has been significantly fragmented. 
The oligomer-like species is difficult to clearly identify in electron micrographs, however, a zoom of 
the AβSon electron micrograph has been included (Figure 5.3B); the black arrow points to an example 
of an oligomer-like structure. The ability of sonication to produce species similar to oligomers has 
been previously shown in hen egg white lysozyme (Harte et al., 2015) and the prion protein (Lee et 
al., 2011). The diameter of these oligomer-like structures was measured (n=101) (Figure 5.3F) and 
compared to AβO (Figure 3.5, Chapter 3), shown as a boxplot (Figure 5.3G).  The median diameter 
size of ~20nm are similar for both oligomer and oligomer-like species formed by sonication. 
Sonication must be carried out on ice due to the likelihood of the fragmented fibrils driving assembly 
due to fragmentation or secondary nucleation (Cohen et al., 2011).  It was not possible to measure the 
length of AβF as these were indefinite in length or quite often bundled together and therefore difficult 






Figure 5. 3. Optimisation of Aβ42 sonicated fibrils (AβSon). Aβ42 fibres (A) were sonicated at the maximum setting for (B) 5-, (C) 10- and (D) 20 minutes on ice. 
Fibres were not sufficiently sonicated by 5 minutes whilst 20 minutes disrupted the integrity of fibrils beyond what could be classified as oligomer-like. 10 minutes 
sonication provided fibrils of varying length including those similar in size to oligomers. The optimisation was carried out on one independent sample preparation 
of Aβ42. Once optimised, quantification was conducted on three independent sample preparations. Quantification of Aβ42 sonicated (E) fibres (n=544) (10mins) 
confirm the majority of fibrils were between 30-90nm in length and (F) ~20nm in diameter  (G) A boxplot to show the range of diameters in oligomer and oligomer-
like species. Scale bar shown at 200nm. 50µM untagged Aβ42 was prepared in 10mM HEPES buffer pH7.4 and incubated for 48 hours at room temperature to 





To gain further insight into the size of each species, we carried out SDS-PAGE electrophoresis and 
western blotting (Figure 5.4).  
 
 
The anti-Aβ monoclonal antibody 6E10 was used to detect the size of each species. As expected from 
our previous data, AβO displayed bands corresponding to monomeric, dimeric and trimeric species as 
well as higher molecular weight species which migrate as a smear (Marshall et al., 2016). AβF fibrils 
are stuck in the well of the gel, with the presence of some higher molecular weight species. There are 
no bands for lower molecular weight species, confirming that our AβF sample is larger in size than 
AβO.  Importantly, AβSon shows bands for monomeric, dimeric, trimeric species as well as higher 
molecular weight species and some fibrils stuck in the well of the gel. This ensures that our AβSon 
Figure 5. 4. Western blot of AβO, AβF and AβSon samples using 6E10 (1:10,000 dilution) was used 
to detect the size of assemblies present in each species. AβO migrate as monomers (4.5kDa), 
dimer/trimers (9kDa/13.5kDa) and a smear of higher molecular weight species. AβF show no lower 
molecular weight species with some fibrils stuck in the well of the gel. AβSon shows a mixture of all 
species from monomers to fibrils stuck in the well. 50μM untagged Aβ42 was prepared in 10mM 
HEPES buffer pH7.4 and incubated for 2 hours at room temperature for AβO, 48hours for AβF 
and these were sonicated on ice for 10 minutes for AβSon. As only one repeat was carried out in 





Figure 5. 5. CD spectra for 50μM AβO, AβF and AβSon. The signal for AβO shows a random coil signal 
(minimum at -198nm) and the signal for AβF and AβSon shows a β-sheet signal (minimum at -218nm, 
maximum at -198nm). Samples were prepared in 20mM Phosphate buffer pH 7.4 and measured in a 1mm 
pathway cuvette. Error bars expressed as ±SEM. The average of three independent sample preparations 
are shown.  
sample is indeed representative of some species similar in size to that of our oligomeric sample. 
Previous studies have shown a large overlap in the sizes of prefibrillar and fibrillar oligomers (Kayed 
et al., 2007) suggesting that distinct conformations of the same size do indeed exist. (Glabe, 2008).  
As only one repeat was carried out in order to get an idea of the range of assemblies present, 
quantification was not possible. Again, this would be a future direction as more repeats would allow 
for quantification and a more robust conclusion reached regarding the assemblies sizes in each of the 
preparations. 
Next, we characterised the secondary structure of each species using CD (Figure 5.5). The average of 








The oligomeric species shows a dominant signal for random coil (minimum at ~198nm) whereas AβF 
and AβSon both display a signal for β-sheet (minimum at ~218nm, maximum at ~198nm). This 
confirms that at the secondary structural level, the oligomeric species is conformationally distinct 
from the fibrillar species. The sonicated fibrils retain their β-sheet signal despite being close to 
oligomeric in size. It is important to note that as previously stated, the random coil signal is most 
likely masking some β-sheet signal in the AβO sample. The difference in conformation between AβO 
and AβSon may be that of the anti-parallel/parallel β-sheet packing found in the samples. This cannot, 
however, be deduced from the CD spectra and would techniques such as FTIR to further investigate 
this.  
5.2.2 AβO but not AβF or AβSon is cytotoxic 
Having confirmed the structural and size differences of AβO, AβF and AβSon, we carried out a 
ReadyProbes live/dead assay to assess the cytotoxicity of each species. Rat primary hippocampal 
cultures were incubated with 10μM of each species for 3 days. It was not possible to incubate the cells 
with the peptides for 7 days as with our previous toxicity assays due to the fibrils growing over the 
cells. This made cells incubated with AβF extremely difficult to count at longer time points.  
As shown in Figure 3.10 (Chapter 3), AβO displayed ~43% cell death (43.2% ± 2.35, total number of 
cell =1619, number of dead cells = 703). AβF and AβSon (Figure 5.6) displayed ~18% (18.1% ± 2.12, 
total number of cells = 783, number of dead cells=142) and ~20% (19.5% ± 2.09, total number of 
cells = 425, number of dead cells=83) cell death respectively compared to buffer incubated cells 
(17.8% ± 3.06, total number of cells = 1239, number of dead cells=221, ***). The average of three 
independent experiments where three separate sample preparations were incubated with three separate 
hippocampal cultures are shown. and an example of the ReadyProbes images for each condition is 
shown in the top panel.  The right hand panel in Figure 5.6 shows the most representative electron 
micrographs of each sample from three separate sample preparations, confirming the species being 







Figure 5. 6. AβO, AβF and AβSon ReadyProbes cell viability assay. An example of each Readyprobes 
condition is shown in the top panel. Rat hippocampal cultures were treated with untagged 10µM AβO, 
AβF and AβSon (prepared in 10mM HEPES buffer pH7.4) for 3 days. Cytotoxicity was measured as a 
percentage of dead cell in a culture and compared to buffer incubated cells. AβO were significantly toxic 
(43.2% ± 2.35, total number of cell =1619, number of dead cells = 703). AβF (18.1% ± 2.12, total number 
of cells = 783, number of dead cells=142) and AβSon (19.5% ± 2.09, total number of cells = 425, number 
of dead cells=83) showed no significant cytotoxicity compared to buffer incubated cells (17.8% ± 3.06, 
total number of cells = 1239, number of dead cells=221). Unpaired parametric student’s t test where p= < 
0.01 (*), < 0.001 (**), < 0 (***). The average of three independent experiments where three separate 
sample preparations were incubated with three separate hippocampal cultures are shown. Error bars are 
expressed as ±SEM. Negative stain electron micrographs for AβO, AβF and AβSon are included to ensure 
the correct species were added to the neuronal cultures. Scale bars shown at 0.5μm. 
 
The difference in AβO and AβSon toxicity may be explained by the difference in conformation; AβO 
lacks a significant β-sheet signal and has a reduced random coil signal by CD, whereas this is not the 
case for sonicated fibrils. Despite AβSon being similar in size to oligomers (Figure 5.3 and 5.4), and 
the sample preparation covering a large range of sizes, these are non-toxic to hippocampal cultures. 
The AβF, which display a strong β-sheet structure, are also non-toxic and display a similar percentage 





effect on the neuronal culture which can be attributed to both species being β-sheet rich. The AβO, 
which lacks significant β-sheet structure by CD, exerts significant toxic effects.  
It is also interesting to note that these results implicate the self-assembly mechanism to be important 
in cytotoxicity; the oligomers self-assemble into mature fibrils and this process influences their 
toxicity. However, the fibrils are already fully assembled and are non-cytotoxic. As a future direction, 
it would be interesting to investigate whether sonicated fibrils continue to assemble to further 
establish the importance of the self-assembly process in cytotoxicity.  
Together with the biophysical characterisation of each species, the data presented thus far are in 
support of conformation, and not necessarily size, as a determinant of amyloid toxicity.  
5.2.3 AβO, AβF and AβSon display differing internalisation in primary hippocampal 
cultures 
Having established that the oligomeric species, and not the fibrillar or sonicated fibrils are cytotoxic, 
we determined whether this was due to internalisation. The role of size in internalisation has been 
investigated and it has been postulated that oligomers can induce toxicity as they are small enough to 
be internalised (Chafekar et al., 2008; Lambert et al., 1998; Marshall et al., 2016).  
We first used immunocytochemistry and confocal imaging to visualise Aβ42 in rat primary 
hippocampal cultures. Neurons were treated with the peptide for 30 minutes, 4 hours, 24 hours and 3 
days to monitor changes in localisation and internalisation over time (Figure 5.7). The anti-Aβ 4G8 
antibody, which detects all Aβ42 species, was used with an Alexa Fluor-555 secondary antibody to 
probe for Aβ. Zooms for each image are shown in Figure 5.8. Images shown are the middle slice 
taken from a Z-stack. Internalisation over time of each species has been quantified using FIJI software 
(Figure 5.9). All three species of Aβ bind to the neuronal projections and cell body (Figure 5.7). At 30 
minutes, AβO displays a punctate staining whilst AβF and AβSon also display some ‘clumps’ which 
we presume are large aggregates. These are smaller in AβSon, again confirming we have successfully 
fragmented our Aβ fibrils at the time of adding it to the cells. There does not seem to be any (or very 





At 4 hours, there is some internalisation seen with AβO (white arrows). This is not seen with AβF or 
AβSon, which are still bound to neurons and the cell body. Although AβSon appears to follow a 
similar distribution to AβF at this time point, the fluorescence is brighter than that of AβF. This could 
be due to there being more epitopes exposed to antibody in the AβSon sample; these could be buried 
in AβF (Marshall et al., 2016).    
At 24 hours, it is apparent that oligomers have been internalised (white arrows). The AβF and AβSon 
appear much ‘clumpier’ which is likely due to the Aβ aggregating into larger entities. There does 
appear to be some internalisation seen here which can be explained by 1) the heterogeneity of the 
sample preparation means some oligomers will inevitably be present and 2) oligomers may shear off 
the ends of these fibrils (Verma et al., 2015; Walsh et al., 2002b). In inability to distinguish between 
oligomers and fibrils due to the limitations in resolution of confocal microscopy (~250nm) is a 
notable criticism of approach to investigate internalisation of different assemblies sizes/conformation. 
In order to overcome this, using super-resolution microscopy, which has ~20nm resolution (roughly 
the size of our oligomers) would be a future direction and one way in which to obtain more robust and 
clear data.  
Finally, by 72 hours, the AβF and AβSon ‘clumps’ have disintegrated/degraded and are not 
internalised. This is specific only to the images shown in Figure 5.7 and we cannot disregard the 
possibility that these disintegrated fibrils may be internalised at a later time point in cells that have not 
yet died. This disintegration can be explained by the reported instability of amyloid fibrils at pH7.4; it 
has been shown that β2-microglobulin fibrils dissociate into non-toxic native monomers at this pH 
(Tipping et al., 2015). The oligomers also become slightly ‘clumpier’ and fewer cells were identified 
as having internalised AβO at this time point.  This could be due to the fact that cells which have 
already died due to internalisation of oligomers (~40% according to our toxicity assay) cannot be 
imaged. It is also possible that the larger aggregates seen could be due to Aβ42 released into the 










Figure 5. 7. Immunolabelled neurons incubated with 10μM untagged AβO, AβF and AβSon (prepared in 10mM HEPES buffer pH 7.4)  for 30 minutes, 
4-, 24- and 72- hours. Cells were fixed and labelled with 4G8 antibody (1:500) and Alexa Fluor-555 secondary antibody (1:500 dilution). White arrows 
point to clear AβO internalisation seen by 4 and 24hours which is seen to a lesser extent with AβF and AβSon. Scale bars are shown at 20μm. Zooms of 












The images shown are representative of three separate repeats (separate Aβ preparations and 
hippocampal cultures) at each time point. Aβ was prepared without a tag for this set of experiments.  
The buffer incubated control at the longest time point of 72 hours is show in Figure 5.9. No 
endogenous Aβ signal was detected in buffer incubated cells, as was expected. This is likely to be due 
to either the 4G8 antibody unable to detect endogenously expressed Aβ or more likely, due to very 
low levels of Aβ expressed until 21 days, as has been reported previously (Bertrand et al., 2011). The 
lack of significant endogenous Aβ is beneficial to assess internalisation of Aβ species as this allows us 
to confidently conclude that it is the exogenously incubated with the neurons that is being 
internalised. It would have useful to have a secondary antibody control to ensure no non-specific 
binding is occurring. 
 









Emissions from coverslips of antibody bound Aβ42 were collected using a 561nm emission laser line 
between 555-650nm on a PMT detector. In order to quantify internalisation, the intensity within the 
cell body was measured. To  ensure any Aβ42 bound to the membrane of the cell was not measured as 
being internalised, only intensity inside on the cell membrane was measured. An example of this is 
shown in Figure 5.10.  Although this approach seemed reasonable due to the clear visibility of the cell 
membrane, using a marker for the cell membrane would have been a more thorough way in which to 
ensure only Aβ42 inside of the cell body was quantified.  
From Figure 5.10, there is a clear increase in intensity seen with time for AβO. This increase is 
steepest between 30 minutes to 24 hours, suggesting internalisation is most active during this time. 
There is little change in intensity between 30 minutes and 24 hours seen in cells incubated with AβF, 
however, after 24 hours there is a steep increase in intensity suggesting internalisation. This could be 
due to depolymerisation of fibrils to act as a source of fragmented fibrils and fibrillar oligomers (Jiang 
et al., 1994; Martins et al., 2008). AβSon show a steep increase in internalisation between 30 minutes 
and 4 hours, which decreases over time. This may be explained by sonicated fibrils driving further 
assembly via secondary nucleation and therefore reducing the presence of shorter fibrils/oligomer-like 
species that may be internalised. The ability of nanoscale fibrils produced from fragmentation to be 
internalised has been previously reported for β2-microglobulin (Jakhria et al., 2014), however were 
shown to have no cytotoxic effects. This is in line with AβF and AβSon showing some internalisation 
but displaying no cytotoxicity in the ReadyProbes assay (Figure 5.6).  
The internalisation of AβO in 14, 16, 15 and 10 cell was quantified at 30 minutes, 4 hours, 24 hours 
and 72 hours respectively. For AβF, 13, 9, 8 and 11 cells were quantified at 30 minutes, 4 hours, 24 
hours and 72 hours respectively. To quantify the internalisation of AβSon, 9, 6, 11 and 6 cells were 
measured at 30 minutes, 4 hours, 24 hours and 72 hours respectively. These were all the cells that 






Figure 5. 10. Quantification of Aβ42 internalisation using FIJI software. . Cells were incubated with AβO, 
AβF and AβSon for progressive time points before being fixed and labelled for Aβ42 to visualise 
localisation and internalisation. Internalisation was quantified in the middle of the Z stack for all cells 
from three independent experiments. A) An example of how internalisation was quantified is shown by 
the image on the left. The red outline is on the membrane of the cell and intensity within the yellow 
outline was quantified. This was to ensure any Aβ42 bound to the cell membrane was not measured as 
internalisation. B) Quantification. There is a clear increase in internalisation seen with AβO, an initial 
increase in internalisation at 4 hours with AβSon, which then plateaus from 24 hours. AβF shows a slight 
increase in internalisation from 30 minutes to 24 hours, after which there is a steeper increase in intensity 
suggesting increased internalisation. Error bar are expressed as ±SEM. The internalisation of AβO in 14, 
16, 15 and 10 cells were quantified at 30 minutes, 4 hours, 24 hours and 72 hours respectively. For AβF, 
13, 9, 8 and 11 cells were quantified at 30 minutes, 4 hours, 24 hours and 72 hours respectively. To 
quantify the internalisation of AβSon, 9, 6, 11 and 6 cells were measured at 30 minutes, 4 hours, 24 hours 
and 72 hours respectively. C) The average percentage toxicity of three experiments plotted against the 
average internalisation (fluorescence) at 3 days. Both AβF and AβSon displayed similar levels of toxicity 
and internalisation, whereas AβO had a much higher average internalisation measured and displayed 
greater cytotoxicity. 
 
In order to establish the relationship between the quantified internalisation and cytotoxicity of each of 
these species (Figure 5.10C), the average internalisation (i.e. the average fluorescence intensity) was 
plotted against the mean toxicity (shown in Figure 5.6). This was done from the fluorescence intensity 





not used to assess cytotoxicity at any other time point, this was the only time that could be used to 
directly link internalisation of each of the species to toxicity and although we have AβO toxicity for 
7days, the internalisation was not monitored up to this time point. From the graph we can begin to 
suggest that due to an increased internalisation compared to AβF and AβSon, AβO displays greater 
cytotoxicity. Ideally, we would have ReadyProbes for each of the time points quantified for 
internalisation, which would allow us to establish the link between increased internalisation and 
cytotoxicity over time rather than just one-time point.  
In order to monitor the same cells over a 15-hour time period, live cell confocal imaging was used. As 
mentioned, one major limitation of using confocal microscopy to assess the internalisation of different 
assemblies formed from the same protein, is resolution of the microscope (~250nm). This does not 
allow us to distinguish between different assemblies (e.g. oligomers which are roughly 20nm). 
Ideally, super- resolution microscopy which has a resolution of ~20nm would allow us to begin to 
identify the internalisation of different assemblies with better confidence.  In the following analysis of 
the images from the live cell imaging, we suggest the punctate staining corresponds to smaller 
oligomeric species whereas the larger, dense staining is most likely aggregated Aβ.  
Live cell imaging over a 15-hour time frame is a reasonable time frame allowing us to maintain the 
cells in a healthy environment and still gain valuable information regarding the early internalisation of 
each Aβ species. The peptide was conjugated with an Alexa Fluor-488 tag which has been previously 
shown not affect assembly (Soura et al., 2012). However, this study only confirmed the ability of the 
tagged Aβ42 to form fibrils by EM; therefore, a thorough characterisation of the tagged peptide over 
time to confirm the kinetics or oligomers do not differ from the untagged peptide is still needed and 
would be a future set of experiments to be conducted.  
Figure 5.11 show snapshots of cells incubated with each Aβ species over 15 hours; AβO are evidently 
internalised and there are very few large aggregates or ‘clumps’ seen. AβF incubated cultures show 
large Aβ aggregates from the time it is added. There is some internalisation seen, however, the 





experimental limitations, AβSon internalisation could only be followed for 8 hours, however, there is 
clear internalisation seen by this time point.  
The quantification of internalisation from live cell imaging is also shown in Figure 5.11. As the 
experiment was only carried out once, in this instance the n number was taken to be the total number 
of cells quantified per condition. Quantification was carried out for every hour over 15hours by 
drawing within the membrane of the cell and measuring the fluorescence intensity, in the same way as 
shown in Figure 5.10A. 12, 3 and 1 cell(s) were quantified for AꞵO, AꞵF and AꞵSon respectively. 
There is a clear increase in internalisation with time seen with AꞵO, however this is not as prominent 
with AꞵF. Although this may be due to fibrils not being able to be internalised, it may also be due to 
fibrils being internalised at later points and therefore conclusions other than the fact that fibrils are not 
internalised to the same extent as AꞵO in this timeframe, cannot be reached. As only one cell was 
quantified for AꞵSon internalisation over 8 hours, it is not possible to comment on the amount of 
internalisation seen. From these preliminary data, however, it does seem as though there is an increase 
in internalisation over time from the cell live imaging quantification.  
 The time frame in which internalisations differs to that shown from the immunolabelling shown in 
Figure 5.9 and 5.11. However, this could be due to the Alexa Fluor tag influencing uptake properties, 
or perhaps the cells which internalise Aβ at these early time points have already died and therefore are 
not present to image at our later time points by immunolabelling. It may also be that some cells 
internalise Aβ with higher affinity than others (Chafekar et al., 2008) or that the Alexa Fluor tagged 
method is more sensitive.  
Together, the confocal and live cell imaging presented here confirm AβO are internalised by primary 
neuronal cultures. This internalisation is not as pronounced in AβF and AβSon incubated cells 
(although these samples inevitably also have some oligomers present), which may be due to the 
difference in conformation of these structures and AβO. Notably the difference in β-sheet packing 
(anti-parallel/parallel) may influence uptake. Although some AβSon fibrils are similar in size to AβO, 





factor in internalisation. Due to time constrictions, live cell imaging for each of the Aβ species was 
recorded only once. For this reason, each cell within the experiment was quantified and this has been 
expressed as the n number. Further repeats are needed in order to make reliable and concrete 
conclusions regarding the internalisation of Alexa Fluor-488 tagged AβO/AβF/AβSon.  
It was also not possible to plot the toxicity against internalisation as shown for the immunolabelled 
cells (Figure 5.10C) for tagged-Aβ in neurons as this was only monitored over a 15 hour time period 





Figure 5. 11. Snapshots of live cell confocal imaging. Cells were incubated with 10μM Alexa Fluor-488 tagged AβO, AβF and AβSon and imaged every 20 
minutes for 15 hours. There is evident internalisation of AβO over the course of 15 hour (suggested by the punctate staining shown by white arrow in the 
inset). There is less prominent internalisation seen with AβF, which due to the punctate staining, is believed to be the internalisation of oligomeric species. 
Live cell imaging was only possible over 8 hours for AꞵSon and some internalisation was seen. Scale bars shown at 50μm (AβSon zoom shown at 20μm). The 
quantification of internalisation at every hour over 15 hours is shown by the graph in on the right. Internalisation of oligomers was quantified from 12 cells, 






5.2.4 Internalisation is a requirement for cytotoxicity 
Having established AβO is internalised by primary hippocampal cultures, we questioned whether this 
was a requirement of cytotoxicity. In order to do so, we once again utilised the ReadyProbes assay as 
a measure of cell death after incubation with oligomers for increasing lengths of time. To remove Aβ 
from the culture after the required incubation period, we replaced the media with fresh, Aβ-free 
media. The percentage of cell death was measured after 7 days after initial addition of AβO. 
 
Figure 5. 12. Immunolabelled neuronal cells incubated with untagged AβO (prepared in 10mM HEPES 
buffer pH7.4) for 4 hours and  24 hours followed by a media change to remove soluble Aβ. Cells were 
fixed and labelled after the media change using the primary 4G8 antibody (1:500 dilution) and Alexa 
Fluor-555 secondary antibody (1:500 dilution). White arrows show internalisation at both time points, 
although this is more prominent at 24 hours. Scale bars shown at 20μm. This immunolabelling was only 
carried out once in order to establish if there was a difference seen in the staining after a media change.  
 
We first used immunocytochemistry in order to establish whether the removal of Aβ with a media 
change did indeed remove extracellular AβO. Again, we used the 4G8 anti-Aβ antibody with an 
Alexa Fluor-555 secondary antibody (Figure 5.12). Cells were incubated with AβO for 4- and 24- 
hours, followed by a media change after which they were ‘rested’ for ~1 hour before being fixed and 
stained. Following media change after 4 hours of incubation (-4 hours), there is very little punctate 
staining in the extracellular space to indicate the presence of oligomers. The staining seen is the AβO 





indicating the media change only removes soluble Aβ from the extracellular space. Following media 
change after 24 hours of incubation (-24 hours), the majority of Aβ present is ‘clumped’ which is as 
expected; although Aβ is added as oligomers, it will continue to aggregate over time. There is also 
more internalisation of AβO seen at 24 hours, consistent with the data presented above. We can begin 
to conclude from the difference in staining at both points that by removing the media, unbound 
soluble (and not high molecular weight or fibrillar Aβ) is removed from the extracellular space. 
However, this immunolabelling was only carried out once to establish a whether a difference in 
staining is seen which would allow us to directly monitor the effect of AβO internalisation.  
To further confirm replacing the media with fresh, Aβ-free media removes soluble Aβ from the 
cellular environment, we compared the amount of AβO in the media removed and lysates of treated 
cells.  We immunoprecipitated Aβ from the media removed and cell lysate at both time points, and 
conducted SDS-PAGE electrophoresis, followed by western blotting using the 4G8 antibody. 
From the western blot (Figure 5.13, left) we can see there is less AβO in the cell lysate than in the 
media removed at 24 hours. Comparing this to the amount of AβO seen after 7 days, there is an 
increased amount seen in the lysate than at 24 hours. There is also less AβO in the media removed at 7 
days compared to 24 hours. This has been quantified and shown in Figure 5.13, right.  
 
Figure 5. 13. Western blot of immunoprecipitated Aβ42 in the cell lysate and media removed at 24 hours 
and 7 days (left hand side), detected using 4G8 (1:10000 dilution). The amount of soluble Aβ42 was 
quantified (right hand side); there was more detected in the media removed than in the cell lysate at 
24hours and in contrast, there was more in the cell lysate and less in the media removed at 7 days. Cells 
were treated with 10µM untagged AβO prepared in 10mM HEPES buffer pH7.4. This experiment was 







This data informs us that 1) there is increased internalisation with time and 2) removing the media 
removes soluble Aβ from the neuronal cultures. This experiment was carried out only once due to 
time constraints and therefore reliable quantification was not possible. However, combined with the 
immunolabelling shown in Figure 5.12 these data together suggest there is the removal of 
extracellular AβO by a media change.   
Next, we established the cytotoxicity of treating cells with AβO for increasing amounts of time before 
being removed from the extracellular space (Figure 5.14). The cytotoxicity of AβO at 7 days shown in 
Chapter 3, has been included for a comparison, ~70% (66.3% ± 2.59, total number of cell =1172, 
number of dead cells = 777, ‘***’). Cells were incubated with 10µM AβO for 2 hours, 4 hours and 24 
hours before replacing the media and thereby removing Aβ from the environment. Cell viability was 
measured 7 days after initial incubation with AβO. Cells incubated for 2- or 4-hours with AβO before 
being replaced with fresh media, displayed no significant cytotoxicity (17.7% ± 2.13, total number of 
cells =595, number of dead cells = 105 and 25.7% ± 24.6, total number of cell =599, number of dead 
cells = 154 respectively) compared to buffer incubated cells, which also had a media change 15.63% 
± 1.91, total number of cell =1152, number of dead cells = 180  at 7 days. Cells incubated with AβO 
for 24 hours before being replaced with fresh media, displayed significant toxicity at 7 days (41.3% ± 
4.22, total number of cells =602, number of dead cells = 249, ‘***’).  
Combining this with internalisation, toxicity seems to be linked to the amount of AβO internalised 
into the cell.  This is consistent with the hypothesis that cells are capable of degrading and clearing 
misfolded protein from their environment up to a certain point. However, once a certain threshold is 
reached, the cell becomes overwhelmed and can no longer cope with misfolded protein burden.  
(Chen et al., 2011; Valastyan & Lindquist, 2014). Our findings suggest this threshold is reached 
around 24hours, as at this point the cells can no longer recover from the amyloid insult. Removing 
AβO after 2- and 4-hours does not allow for this threshold of internalisation to be reached and 






Figure 5. 14. ‘Is internalisation a necessity for cytotoxicity? -ReadyProbes cell viability assay. Rat 
hippocampal cultures were treated with 10µM untagged AβO, (prepared in 10mM HEPES buffer pH7.4) 
for increasing amounts of time before being removed and replaced with Aβ-free media. Cytotoxicity was 
measured 7 days after initial addition of AβO. Cytotoxicity was measured as a percentage of dead cell in a 
culture and compared to buffer incubated cells which also had a media change (15.63% ± 1.91, total 
number of cell =1152, number of dead cells = 180). AβO were significantly toxic (66.3% ± 2.59, total 
number of cell =1172, number of dead cells = 777) at 7 days. Cells incubated with AβO for 2- (17.7% ± 
2.13, total number of cells =595, number of dead cells = 105) and 4 hours (25.7% ± 24.6, total number of 
cell =599, number of dead cells = 154) displayed no significant cytotoxicity at 7 days. Cells incubated with 
AβO for 24 hours (41.3% ± 4.22, total number of cells =602, number of dead cells = 249) displayed 
significant cytotoxicity at 7 days. One-way ANOVA with Tukey’s post hoc comparison  where p= < 0.01 
(*), < 0.001 (**), < 0 (***). The average of three independent experiments (three separate AβO 
preparations and three independent hippocampal cultures are shown in this Figure). Error bars are 
expressed as ±SEM. 
5.3 Conclusions 
Having established Aβ42 is the only primary sequence out of three variants characterised that forms 
intermediary oligomeric species, we sought to determine whether the toxicity mediated by these 
oligomers was due to size and/or conformation. Gaining an understanding of this will further aid us in 
deciphering the determinants of amyloid toxicity. A schematic diagram summarising the data 
presented in the chapter is shown in Figure 5.15.  
We first thoroughly characterised the size and conformation of AβO, AβF and AβSon. Samples were 
prepared using our highly consistent, thoroughly characterised preparation of Aβ. AβO displayed a 
predominantly random coil conformation by CD, although it is likely this is masking some β-sheet 





however, did display a wide range of assemblies (detected by western blot) some of which 
corresponded to the size of AβO. This therefore allows us to evaluate the importance of size and 
conformation- the sonicated fibrils displayed a strong β-sheet conformation and were a similar size to 
oligomers (lacking a predominant β-sheet structure by CD).  
The ReadyProbes assay used to measure the cytotoxicity of each species confirmed only AβO were 
significantly toxic after 3 days. AβF and AβSon showed no significant cytotoxicity; as AβSon is a 
similar size to AβO, we can conclude toxicity of Aβ is not mediated by size. The difference in 
conformation of both AβO and AβSon suggests conformation influences toxicity.  
Unfortunately, the conclusions reached regarding internalisation from these data are preliminary and 
further repeats are necessary to reach concrete conclusions. Furthermore, due to the limitation in 
resolution of the microscope, it is difficult to ensure that species we believe to be internalised are 
indeed what we identify to be oligomers and fibrils.  However, in order to begin linking the above 
data with internalisation, we report that AβO are internalised by 4 hours of incubation with cells. The 
same level of internalisation is not observed with AβF or AβSon which could be indicative of 
conformation-specific internalisation of Aβ42. The endocytosis of β-sheet rich structures is thought to 
be an important feature of several disease-related amyloid proteins, e.g. α-synuclein (Desplats et al., 
2009), however, the anti-parallel arrangement of β-sheets of Aβ42 oligomers described in the 
literature (Cerf et al., 2009), could influence its toxic nature compared to the in register, parallel 
arrangement seen in fibrils. Furthermore, selective uptake of oligomers and not fibrils has been 
reported previously in HeLa and differentiated SK-N-SH cell lines, consistent with our data (Chafekar 
et al., 2008).  The uptake of β2-microglobulin fragmented fibrils, has however been reported and 
although these were shown to be non-toxic, they did exert cellular dysfunction by disrupting 
lysosomal membrane protein trafficking and inhibit lysosomal protein degradation (Jakhria et al., 
2014).  It is therefore reasonable to hypothesise that although AβSon is not cytotoxic (Figure 5.6), it 
may affect normal cellular functioning. As a future direction, an MTT assay to evaluate cell metabolic 





Furthermore, by 72-hours, the images shown in Figure 5.7 and 5.8 show the nuclei of the cells 
incubated with AβF and Aβson, to be rounded. This suggests that the cells are damaged, even though 
AβF and AβSon are non-cytotoxic as assessed by the ReadyProbes assay (Figure 5.6). This is again in 
line with previously reported effects of fragmented β2-microglobuin fibrils on cell functioning 
(Jakhria et al., 2014). Furthermore, from the data presented in this section (Figure 5.7 and 5.8, clearly 
seen at 24 hours), it seems that the internalisation of AβO causes the entire cell to change in 
morphology and become rounded. Although internalisation is seen to a lesser extent in cells incubated 
with AβF and AβSon (Figure 5.10), as future work, analysis of the morphological changes induced by 
incubating neurons with each of the Aβ42 species (e.g. overall morphology of cell, shape of nuclei, 
nuclear membrane integrity etc) and linking this to internalisation, would provide useful information 
regarding the effect of structure/conformation on cellular dysfunction.  
Similar data are presented in Figure 5.16, where the same experiments presented above were 
conducted in the SHSY5Y cell line. This was to ensure robust conclusions of the data presented in 
this Chapter and that these data are not specific to primary neuronal cultures only. Data presented in 
Figure 5.16 was obtained and analysed by Astrid Nardecchia (undergraduate student) and I was 
Astrid’s laboratory supervisor for her project. We first had to determine the concentration dependent 
cytotoxicity of AβO in these cells (Figure 5.15, top left); 10μM was too low to see significant 
cytotoxicity over 7 days, however, 20μM required a large volume of AβO therefore making it 
uneconomical. 15μM AβO was therefore decided upon. Next, the cytotoxicity of 15μM AβO, AβF 
and AβSon at 3 and 7 days was established (Figure 5.15, top right). Only AβO at 7 days (69% ±SEM 
3.4) displayed significant toxicity compared to buffer incubated cells, consistent with data presented 
in Figure 5.6. Immunolabelling was used to monitor internalisation at 3 and 7 days (Figure 5.15, 
bottom) and showed AβO and AβSon internalisation. AβO internalisation has been previously shown 
in this cell line (Soura et al., 2012). Again, this is consistent with the data presented in primary 








Figure 5. 15. AβO, AβF and AβSon toxicity and internalisation at 3 and 7 days in SHSY5Y cells. The 
concentration dependent cytotoxicity of AβO was first established (top left). This was carried out once in 
order to decide the concentration to use for the ReadyProbes assay and therefore statistical analysis was 
not possible. Cytotoxicty was assessed using the ReadyProbes assay. 15 μM AβO, AβF and AβSon were 
incubated with cells for 3 and 7 days Only AβO at 7 days displayed significant cytotoxicity (69%, ‘***’) 
compared to buffer incubated cells. The average of three experiments are shown. One-way ANOVA with 
Tukey’s post hoc comparison where p= < 0.01 (*), < 0.001 (**), < 0 (***). The average of three 
independent experiments (three separate AβO preparations and three independent hippocampal cultures 
are shown in this Figure). Error bars are expressed as ±SEM. Internalisation of each species was 
monitored at 3 and 7 days (bottom panel); AβO and AβSon show internalisation, this is not seen with 
AβF. Data was obtained, analysed and presented by Astrid Nardecchia. 
 
There are many proposed mechanisms of oligomer internalisation, some examples include clatherin 





receptor mediated e.g. LDLR and LRP1 receptors as well as RAGE (Yan et al., 1996), and lipid raft 
mediated internalisation (Saavedra et al., 2007). Each of these are likely to play a role in the 
accumulation of oligomers within neuronal cells. There is a threshold of oligomer internalisation after 
which the cell is unable to efficiently clear/degrade Aβ (Domert et al., 2014) and therefore no longer 
recover. Some mechanisms of Aβ degradation clearance are outlined in Table 5.1. All of these are 
thought to be affected in AD. 
Table 5. 1. Mechanisms of Aβ degradation and clearance. 
 
Together, our data strongly suggest that conformation rather than size influences AβO mediated 
cytotoxicity. The accumulation of intracellular oligomers must reach a certain threshold after which 
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Figure 5. 16. Schematic diagram summarising the data presented in this chapter. AβO which has a random-coil conformation, are internalised and have cytotoxic 





Chapter 6: Characterising the assembly and cytotoxicity of the 
GNNQQNY and FEFKFEFKK functional amyloids 
Chapter Overview 
Functional amyloid proteins feature throughout nature and have been exploited as nanomaterials, 
neither of which display cytotoxicity. To better understand how these amyloid proteins avoid toxicity, 
the Sup35 prion protein fragment GNNQQNY and the hydrogel forming FEFKFEFKK (F9) are 
presented in this chapter as models of functional amyloid proteins. The assembly process of both 
peptides was monitored using biophysical techniques including transmission electron microscopy 
(TEM), circular dichroism (CD) and ThT fluorescence. The cytotoxicity of these peptides has been 
assessed using the ReadyProbes assay. By characterising the assembly and toxicity (or lack of) of 
functional amyloid proteins in this way, lessons or 'rules' can be determined to avoid amyloid toxicity.  
6.1 Introduction 
Functional amyloid proteins are a feature in many living organisms (Table 1.2, Chapter 1). In these 
examples, the amyloid state is the native fold of the protein and is critical to perform function. The 
Sup35p prion protein [PSI] found in Saccaromyces cerevisiae (yeast) plays a role in termination of 
mRNA translation in wild type cells. (Kushnirov et al., 2000). However, it can also behave as an 
amyloid forming prion [PSI+] to prevent translational termination (due to a loss of function); this 
allows for stop codon read-through and C-terminal extension. From this, there is phenotypic diversity 
created (Bertram et al., 2001). Prion proteins are self-propagating and transmissible therefore the 
Sup35p amyloid forming protein allows for the transmission of genetic information; the cytoplasmic 
amyloid is reversible and heritable leading to a particular phenotype being passed from mother to 
daughter cells upon division. This non-Mendelian inheritance is facilitated by cytoduction which 
involves the fusion of donor and acceptor cell cytoplasm, without nuclear fusion (Conde & Fink, 
1976). The amyloidogenic fragment of the Sup35p protein, found in N-region prion determining 
domain, has been identified as the GNNQQNY sequence. It was one of the first amyloidogenic 





The use of amyloid proteins in the development of biomaterials is vast both in vitro and in vivo. They 
are often used as scaffolds for 3D cell cultures and tissue engineering (Szkolar et al., 2014; Tang et 
al., 2014; Wan et al., 2016). Hydrogels have also been used as a vehicle for localised drug delivery in 
regenerative medicine. The F9 peptide is a short, hydrogel forming peptide which are three- 
dimensional networks of entangled fibrous structures. They are able to form these structures due to 
non-covalent interactions in response to external factors such as pH and temperature (Morris et al., 
2017). The F9 peptide is an amphipathic peptide with alternative hydrophobic and hydrophilic 
residues which assembles into β-sheet rich assemblies above a certain concentration. This is known as 
the critical gelation concentration (CGC) (Elsawy et al., 2016).  
GNNQQNY and FEFKFEFKK peptides were used as models of non-toxic amyloid peptides which 
have a functional role in yeast and a designed bionanomaterial respectively. Their assembly was 
characterised using CD, ThT and TEM. ReadyProbes assay was used to assess the cytotoxicity the 
resulting amyloid. 
6.1.2 Structure of GNNQQNY 
The crystal structure of GNNQQNY was solved by the Eisenberg group (Nelson et al., 2005). This 
peptide was previously shown to form amyloid fibrils when dissolved in water and used at a 
concentration of 400µM (Balbirnie et al., 2001). At higher concentrations of 10-100mM (Balbirnie et 
al., 2001; Langkilde et al., 2015; Nelson et al., 2005; Sawaya et al., 2007), this peptide forms 
elongated microcrystals which allows for X-ray diffraction studies. Electron diffraction examination 
of GNNQQNY microcrystals showed three important features; firstly, the β-sheets are tightly packed 
with hydrogen-bonded neighbouring side chains, secondly, the β-sheets were anhydrous and finally, 
the β-sheets were parallel (Diaz-Avalos et al., 2003). Although this provides important information 
regarding the packing of the peptide, conclusion about the interactions of the side chains and 
backbone cannot be made.  The Eisenberg group were the first to crystallise GNNQQNY (pdb code 
1YJP) (Nelson et al., 2005) and established that the strands in one sheet are anti-parallel to those in 





chains extending form a strand fit between the side chains extending from two strands of the 
partnering sheet (Nelson et al., 2005). The crystal structure of GNNQQNY suggests that a tight dry 
steric zipper between a pair of β-sheets is a fundamental feature of amyloid fibrils. This steric zipper 
is best described as polar side chains of the dry interface (i.e. no water molecules between two β-
sheets) being tightly interdigitated with the three same polar side chains of the partnering sheet 
(Nelson et al., 2005). The side chains of the dry interface do not form hydrogen bonds with each 
other, but rather form van der Waal interactions due to their complementing shapes. This suggests the 
β-sheets to be the stable structural unit of the cross-β spine. Though there is a lack of hydrogen bonds 
within the dry interface of GNNQQNY, there are 11 hydrogen bonds formed with two neighbouring 
molecules in the same sheet. These 11 are made up of five backbone hydrogen bonds, four amide 
stacks (hydrogen bonds between pairs of Asn or Gln residues) and two hydrogen bonds between the 
backbone amide nitrogen to the Asn2 side chain oxygen. It is the amide stacks that force the 
GNNQQNY molecules to stack in a parallel and in register manner in their respective sheets. There is 
also a wet interface formed which is lined with water molecules, completely separating GNNQQNY 
molecules (~15Å). 
In 2007, a second crystal structure was solved (pdb code 20MM) (Sawaya et al., 2007) which 
although shared similarities to the first, also displayed significant differences. The two crystals can be 
separated into monoclinic and orthorhombic structures. The monoclinic form has been described 
above. The orthorhombic form has a much less defined wet interface and the N3 and Y7 residues 
from one molecule interact with the Y7 and N3 on a different molecule. There is also no interaction of 
the tyrosine side chains in the sheet-spacing direction (Sawaya et al., 2007).  










Historically, hydrogels were formed from high molecular weight polymers (Hirst et al., 2008), 
however the properties of amyloid forming peptides make them highly attractive as alternatives. Their 
high stability, and combination of hydrophobicity and charges residues enable them to bind to both 
macro and small molecules and cells (Ahmed, 2015). Low molecular weight gelators have also 
recently been developed and can be triggered to form gels using several triggers. An example of this 
are hydrogels formed  using the functionalised dipeptide 2NapFF (Colquhoun et al., 2017) .  
There are a number of factors that contribute to the gelation properties of peptides and these can be 
adapted to provide different functionalities of the hydrogel. Hydrogel scaffolds should ideally have 
certain characteristics including ease of handling under physiological conditions, uniformity at nano, 
micro and macroscopic levels as well as the possibility of being able to design gels to match the cell 
type. Traditionally, synthetic hydrogels were formed by covalently cross-linking polymers, however 
due to the toxic nature of some cross-linking reagents, their biological applications were limited. 
Supramolecular hydrogels can be formed without the need for cross-linking, using self-assembling 
peptides via number of non-covalent interactions. These include van der Waals, electrostatic and 
hydrophobic interactions (Dou & Feng, 2017). The weaker non-covalent interactions in 
supramolecular hydrogels allows for smart responses to external stimuli and thereby allowing for 
manipulation of characteristics such as pore size of fibrillary network as cells migrate through them.  
There are four main families of self-assembling peptides used to form hydrogels; 1) short peptide 
derivatives; 2) α-helix/coiled-coiled; 3) amphiphilic peptides and 4) β-sheet peptides. Specific amino 
acids and peptide derivatives are gelators, with intermolecular hydrogen bonds between amide bonds 
as the gelation driving force (Bakota et al., 2013). Generally, amino acid and peptide derived gelators 
are often designed to have both hydrophobic and hydrophilic groups. This is due to the hydrophobic 
side chains shielding amide groups from water to form hydrogen bonds and hydrophobic central cores 
(van Bommel et al., 2004). Charge and pH are important factors in designing peptides to form 





form flat, straight fibrils by the insertion of a diproline peptide between two β-sheet forming strands 
consisting of alternating lysine and valine residues. Under basic conditions, lysine has no charge 
which allows for its folding into a β-hairpin where one face is lined with the hydrophobic valine 
residues and the other with the hydrophilic lysine residues (Schneider et al., 2002). The subsequent 
self-assembly is due to lateral hydrogen bonding between β-hairpin and also due to hydrophobic 
interactions between the valine rich faces of the folded peptide (Schneider et al., 2002). When the pH 
was lowered to below the pKa of the lysine chains (i.e. protonating the lysine residues), intrastrand 
repulsion between partnering lysine residues and the unfolding of individual β-hairpins occurred. This 
led to hydrogel formation (Schneider et al., 2002).  
Amyloidogenic sequences have also been shown to form hydrogels which have been used in number 
of biological applications. For example, amyloid fibrils have been shown to support cell adhesion and 
growth (Reynolds et al., 2014). For this reason, their application in tissue engineering in vitro and in 
vivo has been extensively developed. A recent example was shown in exploiting the self-recognition 
motif of α-synuclein to promote the differentiation of mesenchymal stem cells without the addition of 
growth factors. In vivo, human mesenchymal stem cells were transplanted with the hydrogel in mice. 
The hydrogel was shown to contain the cells at the transplant site and provided support for neuronal 
differentiation as well as improved survival (Das et al., 2016).   
A similar effect was seen with hydrogels formed from peptides based on the aggregation of the C-
terminal of Aβ42, GGVVIA, which has previously shown to form a hydrogel. (Jacob et al., 2015; 
Lakshmanan et al., 2013). This hydrogel was shown to be non-toxic in the SHSY5Y neuroblastoma 
line (Jacob et al., 2015). The KLVFF fragment of the Aβ peptide has also been shown to form a 
hydrogel when prepared in concentrated phosphate buffered saline. This highlights the importance of 
the electrostatic charges between the lysine residues and the salts in the buffer (due to the screening of 
the lysine side chains), which are thought to enable the aggregation of β-sheets into hydrogels 
(Krysmann et al., 2008). Each of these hydrogels showed recovery after disruption (e.g. by vortexing), 
suggesting if these should be injected as a method of drug delivery for example, any occurring 





of drugs into the gel matrix and subsequent release at a diffusion rate that is dependent on the 
diffusion coefficient of the drug (Hoare, 2008). 
The F9 peptide has been recently characterised in vivo as a therapeutically relevant self-assembling, 
β-sheet rich hydrogel (Morris et al., 2017). From the study, positron emission tomography and 
fluorescence labelling assessed the pharmacokinetics, bio-distribution and excretion of the hydrogel in 
healthy mice and found it to be a highly promising biomaterial for drug delivery with no toxicity of 
the hydrogel detected (Morris et al., 2017). This non-toxic hydrogel forming F9 peptide will be used 
as a second model of functional biomaterial amyloid in this chapter.  
6.2 Results and Discussion 
6.2.1 GNNQQNY and F9 form fibres with a high propensity 
In order to confirm both peptides formed fibrils, 1mg/ml of each peptide was dissolved in water or 
10mM HEPES buffer. It was necessary to confirm assemblies formed in 10mM HEPES buffer for cell 
viability assays. The GNNQQNY peptide (Pepceuticals) and F9 peptide (kindly provided by the 
Saiani group, Manchester) assembly morphologies were examined using TEM (Figure 6.1). It is 
evident GNNQQNY fibrils are abundant at T0 and 24 hours in both water and 10mM HEPES buffer. 
This is consistent with immediate fibril assembly observed over a range of concentrations from 
0.5mg-10mg/ml (Marshall et al., 2010). Similar abundance of fibrillar species is seen with F9 at both 
time points, shown in Figure 6.2. Previous reports have demonstrated the ability of GNNQQNY to 
form fibrils and crystals in a concentration dependent manner (Balbirnie et al., 2001; Nelson et al., 
2005). Here, we have used the relatively low concentration of 1mg/ml for GNNQQNY in an attempt 
to monitor the assembly process. Although we cannot visualise the gradual formation of fibrils over 
time, Figure 6.1D shows an example of crystals that were observed at 24 hours suggesting crystals are 
formed from fibrils. This is consistent with previous reports of GNNQQNY crystal formation 
(Marshall et al., 2010).  
The cross-β structure of GNNQQNY fibrils has been previously shown (Balbirnie et al., 2001). To 





used (Figure 6.2E) and the XRFD pattern was collected by Y. Al-Hilaly. F9 displays a XRFD pattern 
consistent with a cross-β structure, previously not shown. The XRFD pattern shows a 4.7 Å reflection 
on the meridional axis consistent with hydrogen bonded beta-strands oriented perpendicular to the 
fibre axis. The equatorial reflection at 10.8Å arises from the spacing between associated beta-sheets. 
This will be determined by the size of the side-chains and is consistent with the phenylalanine content 
(Fandrich & Dobson, 2002). More detailed information of the structure could not be obtained from the 
XRFD pattern due to the way in which the fibres entangle to form large networks.  
 
 
Figure 6. 1. Negatively stained electron micrographs of GNNQQNY prepared in water and 10mM 
HEPES buffer. Prepared in water at T0 (A) and 24 hours (B) and in 10mM HEPES buffer pH 7.4 at T0 
(C) 24 hours (D) show assembly into fibrils. Scale bars shown at 200nm. Representative images from 










Figure 6. 2. Negatively stained electron micrographs and XRFD pattern of the F9 peptide in water and 10mM HEPES 
buffer.  Prepared in water at T0 (A) and 24 hours (B) and in HEPES buffer (C) and (D), F9 forms abundant fibrils. Scale 
bars shown at 200nm. Electron micrographs are representative of three separate peptide preparations (E)  
The F9 XRFD pattern shows the characteristic cross-β structure typical of amyloid peptides The XRFD experiment was 





Due to the rapid formation of fibrils, an accurate concentration could not be obtained using the A280 
as a result of scattering. For these peptides, the theoretical molar concentration at 1mg/ml was 
calculated using their molecular weight; 1.12mM for GNNQQNY and 800µM for F9. 
Having confirmed both peptides form amyloid fibrils, we next prepared both using the protocol 
presented for Aβ42 in Chapter 3. This was done with a view to control and follow assembly of the 
peptides into amyloid fibrils.  
Figure 6.3 below shows electron micrographs of the GNNQQNY and F9 peptide following buffer 
exchange spin column method. Very little assembly is shown in these electron micrographs, even 
after a 24-hour incubation period.  
 
Figure 6. 3. Negatively stained electron micrographs at T0 and 24 hours of the GNNQQNY and F9 
peptides prepared using the same protocol as described in Chapter 3. Little/no assembly is seen for either 
peptide following the buffer exchange spin column method. 1mg/ml of each peptide was dissolved in 
HFIP, sonicated for 5 minutes before drying the HFIP with nitrogen gas. The peptides were then 
resuspended in DMSO before being put through a 10mM HEPES equilibrated buffer exchange column. 
Scale bars shown at 200nm. This sample preparation was carried out once as it was clear this spin column 





In this protocol, HFIP is used to disaggregate any preformed aggregates. As it is possible HFIP may 
not be having this effect, TEM was used to visualise the GNNQQNY and F9 peptide dissolved in 
HFIP. From Figure 6.4 it is clear that HFIP does not disaggregate GNNQQNY and F9 fibrils, and due 
to this the fibrils are most likely getting trapped in the spin column. This also demonstrates the 
unusually high stability of these fibrils. 
 
 
Figure 6. 4. GNNQQNY and F9 dissolved in HFIP at T0. Scale bars shown at 200nm. This was carried 
out once as it was apparent that HFIP does not disaggregate fibrils.  
 
From this, we can conclude both peptides form amyloidogenic fibrils with a high stability and are 
resistant to solvents and due to this, the buffer exchange spin column method of peptide preparation 
cannot be utilised. Therefore, for all subsequent data presented in the chapter, peptides were dissolved 
in water or HEPES buffer as appropriate.  
To determine a lag phase in which ThT negative (non-fibrillar) assemblies were present, the ThT 
fluorescence of both peptides was monitored. The assembly of GNNQQNY has been proposed to 
occur in three stages. Firstly, there is the rapid formation of parallel β-sheets by β-strands (Nelson et 
al., 2005) which in the second stage, slowly form pair-of-sheets structures with a characteristic dry 





specific patterns of bonding and therefore polymorphism (Nelson et al., 2005). These can then behave 
as the nucleus for subsequent fibril formation. Using structure-based energetics, the Eisenberg has 
argued that the nucleus must be made up of ~4 GNNQQNY molecules requiring a ~3 molecule 
transition state complex, for subsequent fibril formation. The formation of this nucleus is likely to 
occur relatively slowly due to the need of amide side chains acquiring the appropriate rotamers for 
interdigitation with partnering β-sheets, and also due to the dehydration needed to allow for the dry 
amide-hydrogen bonds (Nelson et al., 2005).  The decrease in entropy during this step is thought to 
act as a barrier to fibril formation. Physiologically, the Sup35 gene encodes the release factor 3 
(eRF3). Under normal conditions the Sup35p, in the non-prion conformation [PSI-], functions together 
with eRF1 to release polypeptide chains. The frequency with which there is a conformational switch 
from [PSI-] to the prion [PSI+] is proportional to the level of [PSI-]. Once this seed has been 
established, the formation of fibrils occur rapidly (Liebman & Derkatch, 1999). A fourth stage of 
crystal formation from these fibres has been more recently proposed (Marshall et al., 2010) which 
may affect ThT binding. 
By using ThT fluorescence, we aimed to monitor this lag-dependent cooperative formation. 
 
 
Figure 6. 5. ThT fluorescence of GNNQQNY over 24 hours show no lag or elongation phase. The peptide 
was incubated with 10μM ThT at 1.12mM stock concentration. This was carried out once in order to 
establish if there was an increase in fluorescence seen over 24 hours as this was not the case, no further 





From Figure 6.5, we can conclude that due to the rapid assembly of the peptide, it is not possible to 
monitor assembly following a lag and elongation phase using ThT fluorescence. However, this does 
complement the TEM data to confirm the formation of fibrils.  
ThT fluorescence of F9 at stock concentration and 50μM was observed at T0.  A dilution to 50µM 
was used as at the stock concentration of 800μM, ThT positive assemblies were already present at T0. 
This is consistent with the TEM (Figure 6.1). Dilution of these fibrils may allow us to monitor any 
assembling F9 into mature fibrils over time. However, as seen in Figure 6.6, both concentrations 
displayed similar fluorescence intensities at T0, in fact, a slightly higher intensity is seen with the 
diluted sample. This is possibly due to more binding sites being available to the dye; at higher 
concentrations, the characteristic fibrillar tangles may limit these binding sites.  ThT fluorescence of 
50µM F9 was monitored up to 24 hours (Figure 6.6B) to identify whether there was a lag phase 
followed by elongation phase, as is seen with Aβ42. No increase in fluorescence intensity was seen 
over 24 hours further suggesting immediate assembly into fibrils by the entire sample population.  
 
Figure 6. 6. F9 ThT Fluorescence. A) ThT fluorescence of 50µM (purple) and 800µM (blue) F9 at T0 
(prepared in 10mM HEPES buffer pH 7.4, incubated at room temperature) Both display similar 
fluorescence (B) ThT fluorescence of 50 µM F9 over 24hours. There is no increase seen in intensity over 
24 hours suggesting assembly of the peptide is immediate. This was carried out once in order to establish 
if there was an increase in fluorescence seen over 24 hours as this was not the case, no further repeats 





The differences in ThT fluorescence intensities for GNNQQNY and F9 can again be explained by the 
tangled nature of the F9 peptides ‘burying’ sites for the dye to bind to. Combining the TEM, ThT 
fluorescence and CD spectra, it is evident that even at relatively low concentration both peptides 
assembly rapidly into β-sheet rich structures.  
6.2.2 Secondary structure of GNNQQNY and F9 
As with peptides presented in the previous chapters, CD was used to probe for the secondary structure 
of GNNQQNY and F9. From the electron micrographs for both peptides, we are confident fibrillar 
structures are seen at T0 and 24 hours. Therefore, the secondary structure was monitored for these 
times only.  
Figure 6.7 displays the CD spectra for GNNQQNY.  
 
Figure 6. 7. GNNQQNY secondary structure by CD. CD (solid line) and 90° rotation (dash-dot line) 
spectra GNNQQNY at T0 (grey) and 24 hours (pink). Without flow and at this low concentration, it is 
difficult to obtain a true LD spectrum with the characteristic positive peak at 195nm, however, at 24 
hours the CD and rotated spectra display different spectra, suggesting there is LD contribution. The inset 
shows a small peak seen at 278nm (shown in inset) in the 24 hours CD spectra, which is due to the 
splitting of a peak in the aromatic region of the peptide. The peptide was prepared at 1mg/ml in water 
and CD spectra were obtained using a 0.01mm pathlength cuvette. The spectra shown are the mean  of 
three separate peptide preparations and each displayed a spectra indicative of LD contributions. Error 





The CD spectra do not display the characteristic spectra expected for β-sheet rich structures. There is 
no strong signal seen at T0, which could be due to the low concentration of the peptide. From the 
electron micrographs, it is more likely however, that the fibrils are oriented in a manner that does not 
allow for the chromophores to create oscillations of circularly polarised light. As there could be 
contribution of Linear Dichroism (LD) due to the inherent orientation of the fibrils, the cuvette 
containing the GNNQQNY sample was rotated by 90° and spectra were collected at same 
wavelengths. In LD, it is the differential absorbance of light polarised in a parallel and perpendicular 
manner to an orientation axis that is measured. The signals in the subsequent spectra are due to the 
aligned samples showing directional dependence. Therefore it is reasonable to consider that the CD 
spectra obtained at 24 hours, with positive peaks seen at 204nm and 235nm, may be due to LD 
contributions arising from the regular and ordered arrangement of the assemblies (Bulheller et al., 
2007).  
The 90° rotated spectra at T0 shows a small positive signal at 235nm and a small negative signal at 
204nm. This could be due to fibrils at T0 that are not fully aligned to give a definite LD signal. At 24 
hours, smaller peaks are seen at the same positions as the CD spectra, confirming that there is some 
contribution by LD. Furthermore, the tyrosine residue in this peptide is expected to contribute 
significantly to the CD spectra which can be intensified due to the coupling transitions of close 
proximity of aromatic residues (Sreerama et al., 1999). This can be seen in the peaks arising at 235nm 
can be attributed to the close proximity of the tyrosine residues undergoing exciton coupling. There is 
also a small peak seen at 278nm (shown in inset) which is due to the splitting of a peak in the 
aromatic region of the peptide. The second peak is expected to be at 286nm, as has been observed in 
previous studies (Marshall et al., 2010). The importance of aromatic residues in the assembly of Aβ42 
has been discussed (Chapter 3). Similarly, the behaviour of the aromatic tyrosine residue in the 
assembly process of GNNQQNY has been established (Marshall et al., 2010). Previous studies on the 
crystals of GNNQQNY have shown there is a strong positive LD signal at 195nm due to the пп* 
amide transition dipole moment being oriented perpendicularly to the β-strands which is consistent 





signal from crystals observed by 24 hours in the electron micrographs (Figure 6.1D), a Couette flow 
and tilt to orient the long axes of the crystals with the direction of flow, as well as high concentration 
of peptide, are needed. It is likely that this 195nm peak has shifted to 204nm in the CD spectra shown 
above due to LD, confirming the formation of cross-β structure from β-sheet rich fibrils.  
The folding of GNNQQNY into β-sheet rich structures has been previously described from solved 
crystal structures (Nelson et al., 2005) and therefore we are convinced of the secondary β-sheet 
structure of the fibrils and crystals shown in the electron micrographs (Figure 6.1). The elongated 
morphology of fibrils (and crystals) is attributed to the hydrogen bonded addition of GNNQQNY β-
strand molecules was found to occur at growing β-sheets (Nelson et al., 2005).    
The F9, which also rapidly forms fibrils (Figure 6.2), posed a similar problem of an LD rather than 
CD spectra (Figure 6.8). As with GNNQQNY, a characteristic β-sheet spectra was not seen with the 
F9 peptide. At T0, the CD spectra displays a small negative signal at ~218nm and positive peak at 
roughly 198nm which suggests a β-sheet rich structures due to the transition of   пп* and n п 
respectively. There is also, however, the presence of a negative signal at roughly 198nm which is 
likely due to LD artefacts similar to those seen with GNNQQNY. By 24 hours, the CD spectra shows 
a negative peak at 222nm due to nп* transition and two positive peaks at 192 and 198nm. The 
222nm negative peak in the CD spectra of F9 has been previously observed and is attributed to the 
aromatic phenylalanine residues (Elsawy et al., 2016). It is interesting that although there is no change 
in fibril morphology viewed in electron micrographs, the CD spectra changes from T0 to 24 hours. 
This suggests there is a change occurring within the structures. The 90° rotation LD spectra at 24 
hours (dotted black line) displays a characteristic β-sheet spectrum. Although it was not possible to 
replicate the CD spectra, the LD spectra shown above is consistent with data previously presented by 
the Saiani group (Elsawy et al., 2016). This would suggest that the CD spectra is due to LD artefacts 
that have led to a shift in the spectra. Using the rotated spectra, we can confidently identify the F9 
peptide to be β-sheet rich. This has also been previously confirmed by FTIR spectroscopy where two 
strong absorption peaks at 1624 and 1524 cm-1 were shown, corresponding to an extended β-sheet 






Figure 6. 8. Secondary structure of F9 by CD. CD spectra for F9 peptide at T0 and 24hours are shown in 
the left hand spectra. The 90° rotation spectra at 24 hours is also shown in the right hand specta. The 
peptide was prepared at 1mg/ml in water and spectra were obtained in a 0.01mm pathlength cuvette. The 
spectra shown for CD at T0 and 24hours are representative of spectra seen from three independent 
peptide preparations, error bars expressed as ±SEM. The β-sheet signal seen at 24hours with a 90° 
rotation, however, was only obtained from one sample preparation.  
  
Due to the alternating hydrophobic and hydrophilic resides in the F9 peptide, the peptide is thought to 
self-assemble into anti-parallel β-sheet fibrils. These have both a hydrophobic and hydrophilic face 
and in order to avoid contact with water, the hydrophobic faces of β-strands pair to from β-sheet fibres 
with hydrophobic residue side chains buried in the core (Elsawy et al., 2016). A schematic of this is 






Figure 6. 9. Schematic representation of the extended β-sheet conformation of the F9 peptide. Taken from 





The importance of phenylalanine aromatic residues in the F9 peptide to form β-sheet structures has 
been demonstrated by another group (Elsawy et al., 2016). Disruption of the phenylalanine packing 
resulted in the loss of β-sheet structure as measured by FTIR (Elsawy et al., 2016). This further 
demonstrates the importance of primary sequence in amyloidogenicity; as the F9 peptide is rich is 
aromatic residues, this is likely a factor influencing amyloid forming propensity.   
6.2.3 GNNQQNY and F9 functional amyloid peptides are non-cytotoxic 
 
 
Due to their functional properties, both peptides were expected to be non-toxic. In order to investigate 
this, we utilised the ReadyProbes assay as a measure of cytotoxicity (Figure 6.10). Peptides were 
prepared in 10mM HEPES and incubated with primary hippocampal cultures at a final concentration 
Figure 6. 10. GNNQQNY and F9 ReadyProbes cell viability assay. 10μM incubation of both 
GNNQQNY (14.54% ± 1.98, total number of cells =1025, number of dead cells = 149) and F9 
(11.2% ± 4.4, total number of cells =215, number of dead cells = 24) peptides show no significant 
toxicity compared to buffer incubated neurons (9.8% ± 1.7, total number of cells =929, number of 
dead cells = 91) . Examples of the ReadyProbes images show the morphology of cells incubated 
with the peptides look healthy and similar to those incubated with buffer only with very few/no 
green labelled cells. Unpaired parametric student’s t test where p= < 0.01 (*), < 0.001 (**), < 0 
(***). Error bars are expressed as ±SEM. The averages of three separate peptide preparations in 





of 10µM. Due to the rapid assembly of the peptides, they were added to cells immediately after 
preparation. Cells were incubated with the peptide for 7 days, after which cytotoxicity was measured. 
No significant cytotoxicity was displayed by the F9 peptide (11.2% ± 4.4, total number of cells =215, 
number of dead cells = 24) and GNNQQNY (14.54% ± 1.98, total number of cells =1025, number of 
dead cells = 149) compared to buffer incubated cells (9.8% ± 1.7, total number of cells =929, number 
of dead cells = 91). The morphologies of the assemblies added to the cells can be seen in Figures 6.1C 
and 6.2C. Despite no incubation period, both peptides are added as mature fibrils due to their high 
propensity to aggregate. The non-toxic properties of these mature fibrils, is consistent with that of the 
AβF presented in Chapter 5. These data supports the hypothesis that the ability to form oligomeric 
species is extremely important in determining the cytotoxic properties of amyloid proteins. 
The lack of cytotoxicity by the GNNQQNY and F9 peptides is unsurprising for several reasons. 
Firstly, as previously discussed (Chapter 5), internalisation is a likely factor influencing amyloid 
toxicity. From the electron micrographs (Figure 6.1 and 6.2), it seems unlikely that the GNNQQNY or 
F9 fibres would be internalised by hippocampal neurons due to their size. Furthermore, immediately 
after preparation, there are no oligomeric species detected by the biophysical techniques presented 
above, confirming the high efficiency with which both peptides from amyloid.  
Although the absence of oligomers to mediate cytotoxicity may serve as an explanation for the non-
cytotoxic behaviour seen in the ReadyProbes assay, both peptides would be expected to assemble in 
the characteristic nucleation-dependent pathway of amyloid formation (Xue et al., 2008). An example 
of functional amyloid proteins forming oligomers has been seen in acrosomes of sperm cell, which 
react positively with the A11 oligomer specific conformational antibody (Guyonnet et al., 2014). 
Furthermore, computational simulations as well as de novo [PSI+] have suggested the ability of 
GNNQQNY to form oligomers (Qi et al., 2012; Sharma et al., 2017; Zhang et al., 2007). These 
studies often do not take into account experimental procedures and data so their validity is somewhat 
limited. Therefore, it is possible that functional peptides do form oligomers, however spend very little 
time in this conformation on the pathway to forming mature fibrils. Using SAXS, a recent study has 





(Langkilde et al., 2015). They observed the presence of only two species, monomers and fibrils, in the 
sample solution at all time points monitored and postulate the elongation phase to proceed via 
monomer addition (Langkilde et al., 2015). The lack of oligomeric intermediates formed is attributed 
to the GNNQQNY monomers fluctuating between different conformations, some of which are 
extended β-like conformations and can serve as the site for fibril elongation. Therefore, in this case, 
an oligomeric intermediate is not needed to drive amyloid assembly (Langkilde et al., 2015; Strodel et 
al., 2007). This supports our hypothesis that it is the ability of an amyloidogenic protein to form 
oligomers that contributes to its cytotoxic properties. A possible way to reconcile this finding with 
that of the Eisenberg group, who have proposed a nucleus is made up of ~4 GNNQQNY molecules, is 
due to several segments of a monomer needed to form an intramolecular nucleus (Nelson et al., 2005).  
This rapid assembly is also seen with the Aβ42-1 and AβS sequences which from larger aggregates 
faster than Aβ42 and display a drastically reduced cytotoxicity (Chapter 4, Figure 4.14) (Vadukul et 
al., 2017).  Lastly, shown by a previous group, the natural amino acid composition of the F9 peptide 
along with its in vivo metabolic profile made it highly unlikely to be cytotoxic (Morris et al., 2017). 
This further highlights the importance of primary sequence in amyloid toxicity.  
Cell viability assays assessing the cytotoxicity of several functional amyloid proteins have shown the 
ability of these proteins to cause cellular dysfunction. For example, amyloid fibrils formed from 
glucagon, α-helical corticotropin-releasing factor, glucagon-like peptide 2 and urocortin 3 were shown 
to decrease cell viability in primary neurons (Maji et al., 2009). Another example is seen with the 
disruption of PMEL fibril formation by a three amino acid insertion in the transmembrane domain of 
the glycoprotein precursor. Ordinarily, PMEL assembles into fibrils at a rate that is order of 
magnitudes faster than that of Aβ40 (Fowler et al., 2007). This mutation causes oligomerisation of the 
transmembrane domain which subsequently alters the assembly of PMEL to form toxic oligomers 
(Kerje et al., 2004; Watt et al., 2011). This supports the notion of oligomers being the toxic species as 
well as the need to reduce/'by-pass' oligomer formation by rapid fibril formation, to avoid toxicity.  
Lastly, it is important to note that mediating cell death could be a functional role for amyloid proteins 





inducing regulated necrosis (Li et al., 2012). Therefore, it is only the misfolding of proteins into a fold 
not native to its function that mediates toxicity.  
Finally, disease-related amyloid proteins are deposited as either extracellular plaques or intracellular 
inclusions (Sipe et al., 2016). This suggests a failure to clear or degrade the misfolded protein. This is 
not the case with functional amyloid. There are several examples of the disassembly of functional 
amyloid proteins seen at physiologically relevant pH; PMEL and hormone fibrils are disassembled 
into monomers and not oligomers again avoiding toxicity. This also removes the possibility of fibrillar 
oligomers being 'shed' from the end of mature fibrils (Tipping et al., 2015) and causing deleterious 
effects to the cell. The [PSI+] amyloid forming prion conformation of Sup35p, containing the 
GNNQQNY fragment, is thought to be in part disaggregated into monomers by the over-expression of 
chaperone heat shock protein 104 (Paushkin et al., 1996; Romanova & Chernoff, 2009), highlighting 
the importance of tightly controlled assembly and disassembly in functional amyloid proteins and 
avoiding cytotoxicity. The disaggregation of F9 peptide hydrogels injected into mice as method of 
drug delivery has been recently monitored. The hydrogel is gradually disaggregated in vivo followed 
by renal excretion, showing no subsequent toxicity (Morris et al., 2017) 
The non-toxic nature of the two functional amyloid peptides presented in the chapter, can be linked to 
their rapidly forming amyloid fibril structure. In doing so, the formation/quantity of toxic oligomeric 
species is kept below a cytotoxic threshold. Using these lessons learnt from both functional amyloid 
peptides, we postulate the time spent in the oligomeric species before forming mature fibrils 
influences the toxic nature of amyloid proteins. 
6.3 Conclusions 
Using lessons learnt from the assembly of functional amyloid proteins, which do not display 
cytotoxicity, we can gain valuable information regarding factor determining amyloid toxicity. In this 
Chapter, we have used the GNNQQNY and F9 peptide as our models of functional amyloid. Using 
biophysical techniques such as TEM, CD and ThT fluorescence we can conclude there is extremely 





The cross-β structure of GNNQQNY has been previously reported (Nelson et al., 2005), however 
using XRFD, we show for the first time that the β-sheet F9 peptide also displays this characteristic 
feature of amyloid proteins.   
Using the ReadyProbes assay, we show both peptides do not display cytotoxicity. Possible reasons for 
this have been discussed above, however, the most likely reason is due to the rapid formation of fibrils 
and therefore minimum time spent in oligomeric conformation. This does not necessarily implicate 
driving disease-related proteins into amyloid fibrils would sequester toxicity as disassembly of 
functional amyloid into monomers in normal physiology is also key in avoiding toxicity. It is 
therefore reasonable to conclude that avoiding the formation of oligomers during assembly and 




Chapter 7:  Discussion 
Amyloid proteins feature in several diseases (Table 1.1), have a functional role across many 
organisms (Table 1.2) and have also been exploited for their properties as functional materials (Table 
1.3) (Gras et al., 2008). The oligomeric species of disease-related amyloid protein have been 
identified as neurotoxic (Glabe & Kayed, 2006), however, functional amyloid proteins do not appear 
to induce cellular dysfunction (Jackson & Hewitt, 2017; Pham et al., 2014). This raises the question of 
which factor(s) make pathogenic peptides deleterious to cellular function. In order to answer this 
question, the assembly process of disease-related and functional amyloidogenic peptides were 
thoroughly characterised and linked to cytotoxicity in primary hippocampal cultures.    
Several factors such as primary sequence, amyloidogenicity, size and conformation have been 
investigated using a wide variety of biophysical techniques. These have been combined with 
molecular techniques including western blotting, dot blotting, immunolabelling and live cell imaging 
where possible, for robust characterisation of assemblies and to probe for localisation of peptides 
incubated with neurons. In order to establish the cytotoxic effect of assemblies, the live/dead 
ReadyProbes assay was used as a measure of cytotoxicity. The limitations of this approach has been 
discussed in the appropriate chapters however, despite this, using a wide variety of complementary 
techniques in this way has proven to be invaluable in order to the overarching aim of investigating 
factors that determine amyloid toxicity (Marshall et al., 2016).  
Aβ42 is the amyloid protein deposited extracellularly as plaques in AD brains. The self-assembly of 
this peptide has been heavily researched, with several groups establishing the formation of oligomers, 
protofibrils and mature fibrils (Lomakin et al., 1996; Roher et al., 1996; Tjernberg et al., 1999). This 
assembly follows the characteristic nucleation-dependent polymerisation pathway of amyloid proteins 
(Xue et al., 2008). Here, we have established a consistent and reliable protocol for the preparation of 
recombinant Aβ42 from monomer to mature fibril (Broersen et al., 2011; Marshall et al., 2016).  
This is important for two reasons. Firstly, it provides the ability to follow assembly over a reasonable 




been previously lacking and often the structure and morphology of the Aβ42 species being used in 
experiments is not characterised. As shown in Chapter 5, the oligomeric and fibrillar species of Aβ42 
display differing cytotoxicity and this therefore serves as an explanation for inconsistent results in 
Aβ42 experiments. It is important to note here, however, that the lack of toxicity of fibrils and 
sonicated fibrils has only been established within the timeframe of our experiment. It is possible that 
these may take longer than 7 days to exert their cytotoxic effect. To ensure reliable and comparable 
results regarding Aβ42 mechanisms of pathology from one research group to the next, the same 
preparation method should ideally be used. However, the use of different preparation methods is 
potentially extremely valuable in understanding how different assembly conditions affect the 
pathological properties of the peptide. This is particularly true for the pathogenic properties of 
oligomers. As the term 'oligomer' covers a wide range of sizes (Table 3.2) and possibly conformation 
(Kayed et al., 2010), a continued review of the preparation methods of Aβ oligomers, the size and 
structure of aggregates formed and their cytotoxic effects from a vast number of groups would 
provide a large collection of data to gain a further understanding of oligomer pathogenic properties.  
This preparation method has allowed us to investigate the importance of primary sequence in amyloid 
toxicity. Using a range of biophysical and antibody-directed techniques, we can identify the 
oligomeric species to be most prevalent in population after 2 hours. We therefore have a disease-
related amyloid model that assembles into a toxic species, in a time frame suitable for 
experimentation. Using the same preparation method, we characterised the assembly of three primary 
sequence variants of wild-type Aβ42 and investigated their cytotoxic nature after an initial 2-hour 
incubation period. The vAβ42 peptide with two amino acid substitutions showed an impaired 
assembly and remains monomeric for 7 days. The importance the F19S and G37D substitutions have 
been discussed in Chapter 3 and were identified by the WALTZ algorithm to abolish amyloidogenic 
regions found in the wild-type sequence (Marshall et al., 2016). Several studies have identified 
various amino acid substitutions that impair assembly, however, we have taken this a step further and 
established the effect of this on the cytotoxic nature of the peptide. The same characterisation for 




than the wild-type sequence. Therefore, we can conclude, using our preparation method, the 
propensity with which amyloid fibrils are formed relies heavily on the primary sequence of the 
precursor protein. All three variants did not form oligomers within the same time frame as the wild 
type sequence and displayed drastically reduced cytotoxicity. This indicates that it is 1) the ability to 
form oligomers and 2) the time spent in an oligomeric conformation that influences the pathogenic 
properties of amyloid proteins. It is entirely possible that this may not be the case if the peptides were 
prepared using a different protocol which would result in an altered/different self-assembly process. 
Therefore, the conclusions reached regarding the importance of primary sequence in Chapter 4, can 
only be made for the preparation method used here. Using this approach, the processing of APP 
discussed in Chapter 1 that results in several different lengths of Aꞵ being produced, could be 
structurally characterised and provide insights into the altered self-assembly process seen in disease.  
The second reason our preparation method is important is due to the nucleation-dependent 
polymerisation mechanism of amyloid proteins. Whilst some experiments use techniques such as 
photo-induced cross linking of unmodified proteins (PICUP) (Ono et al., 2009) or reverse phase 
purification (Sato et al., 2006b) for assessing structure and cytotoxicity of Aβ, it has been shown that 
a crude preparation of Aβ containing a heterogeneous population of monomer and oligomer species 
was more toxic than purified peptide (Jan et al., 2011). This has been attributed to the critical role 
nucleated polymerisation plays in cytotoxicity. Oligomer/protofibrillar toxicity was abolished when 
the population of monomers were removed by sub-fractionation, and re-introduction of monomers 
recovered cytotoxicity leading to the conclusion that the interaction of monomer-oligomer was critical 
for toxicity (Jan et al., 2011). This implicates that it is the ability to assemble into fibrils via 
oligomeric and larger aggregates that renders a peptide toxic which has been supported by the data 
presented in Chapter 6 where both functional amyloid proteins did not form detectable oligomers on 







Table 7.1 summarises the biophysical characterisation and cytotoxic properties of each peptide, which 
supports the implication that it is the ability to form oligomers that influences amyloid toxicity. From 
the table, we can see that it is only Aβ42 which shows cytotoxicity. It is also the only peptide that is 
initially unfolded by CD (Figure 3.7, Chapter 1) and also fibrils visualised by TEM. This suggests 
soluble protein must be present in order for nucleation-dependent polymerisation to occur and form 
oligomers that display cytotoxicity. The vAβ42 does not form oligomeric species and therefore the 
lack of cytotoxicity was expected; by introducing the F19S and G37D substitutions, we impaired the 
ability of the peptide to assemble into amyloid.  This is further supported by the data presented in 
Chapter 5 where fibrillar Aβ showed no significant cytotoxicity. This fibrillar sample showed no 
monomeric, dimeric or trimeric species in the population (Figure 5.2, Chapter 5) and therefore very 
little nucleated polymerisation is expected to be occurring. The AβSon has been shown to be 
structurally identical to AβF but fragmented in size. Therefore, although oligomer-like sized species 




Fibrils seen in 
TEM? 
ThT positive? 
Initially unfolded by 
CD? 
Cytotoxic? 
Aβ1-42 ✓ ✓ ✓ ✓ 
vAβ1-42   ✓  
Aβ42-1 ✓ ✓   
AβS ✓ ✓   
GNNQQNY ✓ ✓   




are present, shown in Figure 5.2 (Chapter 5), these may at a low enough concentration to avoid the 
cytotoxicity as a consequence of nucleation-dependent polymerisation. In this case it is most likely 
secondary nucleation that is occurring (Cohen et al., 2013; Linse, 2017).  
A similar explanation can be used for the non-cytotoxic effects of the two functional peptides 
presented in Chapter 6. From the structural characterisation, both peptides form amyloid fibrils 
extremely rapidly with no oligomeric species being detected. This high propensity to form fibres is 
likely due to the primary sequence of the peptides. Due to rapid fibre formation, only fibrillar species 
were incubated with the cells. Again, this lack of oligomeric species, immediate fibril formation and 
non-cytotoxic behaviour suggests the imperative influence the time spent in an oligomeric 
conformation plays in the amyloid toxicity. 
During the assembly of Aβ42, there is a conformational rearrangement from randomly coiled soluble 
protein, anti-parallel β-sheet pre-fibrillar oligomers and parallel β-sheet mature fibrils (Figure 3.7, 
Chapter 1). It is important to distinguish between pre-fibrillar and fibrillar oligomers (Kayed et al., 
2010) as these are most likely structurally distinct. We identify the lower molecular weight species in 
the AβSon to represent fibrillar oligomers. Although there is a difference in secondary structure of 
AβO (prefibrillar oligomers) and AβSon (fibrillar oligomers) detected by CD (Figure 5.5, Chapter 5), 
to get a deeper understanding of the β-sheet packing in an anti-parallel or parallel manner, FTIR 
spectroscopy would need to be utilised. However, as the anti-parallel β-sheet arrangement of 
oligomers has been extensively reported in the literature (Cerf et al., 2009; Colletier et al., 2011; Gu et 
al., 2014), we assume our prefibrillar oligomers to have an anti-parallel β-sheet conformation which 
seems to be an important determinant of amyloid toxicity.  
Overall, from this structural characterisation, we can conclude that the primary sequence of peptides 
greatly influences the propensity with which amyloid fibrils are formed using the preparation method 
presented in this thesis. This significantly determines the time spent in an oligomeric conformation 




To further investigate whether it is size, conformation or internalisation (or all three) that mediates 
cytotoxicity of AβO, the cytotoxicity and internalisation of AβF and AβSon were assessed. Both AβF 
and AβSon displayed no significant toxicity. Although this was expected for AβF, it was thought that 
the possible fragmentation to a size similar to that oligomers (AβSon) may cause cytotoxicity. This, 
however, was not the case. Analysis of species visualised by TEM combined (Figure 5.3, Chapter 5), 
combined with the western blot (Figure 5.5, Chapter 5) confirmed that AβSon does indeed have 
species similar in size to AβO. The secondary structure of AβO was shown to be randomly coiled, 
although some β-sheet signal is expected to be present, and AβSon showed a strong β-sheet structure. 
As AβSon displayed no significant cytotoxicity despite being similar in size to AβO, conformation is 
implicated as an important factor in amyloid toxicity. Additionally, the β-sheet packing in AβO is 
expected to be anti-parallel and in AβSon, parallel. This further emphasises the importance of 
conformation. Furthermore, Aβ42 shows a transitional change from randomly coiled to β-sheet 
structure after 2 hours, which again serves as evidence for the importance in nucleation dependent 
polymerisation from soluble to insoluble species in mediating cytotoxicity.  
The data presented in Chapter 5 also supports the notion that internalisation is necessary to mediate 
cytotoxicity. However, the conclusions regarding internalisation of each of the Aβ species are limited 
due to the resolution of the microscope and the heterogeneity of the sample. Furthermore, additional 
repeats for quantification of internalisation at each time point are needed and it would be useful to 
obtain data from the ReadyProbes assay at the same time points in order to establish a relationship 
between internalisation and cytotoxicity. From the data obtained, however, oligomers are internalised 
whereas this is to a lesser extent with AβSon fibres, and little internalisation is seen with AβF. AβSon 
internalisation is most likely due to the smaller species present in the sample population, although 
internalisation of larger β2-microglobulin sonicated fibrils has been previously observed (Jakhria et 
al., 2014). Nevertheless, sonicated fibrils are smaller in size than mature fibrils and this therefore 
suggests size is important in the internalisation process of amyloid proteins. Despite some AβSon 




important factor in amyloid toxicity and it is the anti-parallel packing of β-sheets and/or presence of 
random coil conformation in oligomers that mediates this.  
Together, the data presented here has used several models of amyloid proteins in order to determine 
factors that make pathogenic amyloid deleterious to cellular function. We show that the ability to 
from oligomeric species and the time spent in this conformation greatly influences amyloid toxicity. 
Furthermore, although size influences internalisation into primary hippocampal neurons, once 
internalised it is conformation that is a determining factor of cytotoxicity.  
Concluding Statement  
 
‘What makes pathogenic amyloid proteins deleterious to cellular function?’ In answer to this question, 
the data presented in this thesis suggests it is the ability to form oligomers with anti-parallel β-sheet 
packing, the time spent in this conformation and the intraceullar accumulation of these oligomers 








All peptide sequences characterised in this thesis have provided invaluable information regarding 
factors that make an amyloid protein cytotoxic. Similar characterisation of assembly and cytotoxicty 
of other disease-related amyloid proteins in this way, α-synuclein or tau for example, would further 
establish the important factors contributing to amyloid toxicity.  
Establishing a high resolution structure of Aβ42 oligomers using cryo-EM would further build on the 
structural characterisation presented here and in the literature. A recent example of this has been 
shown by the cryo-EM structure of tau filaments (Fitzpatrick et al., 2017). This study provided cryo-
EM maps and identified filament cores made up to two identical protofilaments adopting a combined 
cross-β/β-helix structure and identified this as the seed. Cryo-EM is a particularly attactive technique 
as it does not require crystallisation and allows for the visualisation of 3D structures at near-atomic 
resolution. This technique has been previously used to dissect the structure of Aβ42 fibrils (Gremer et 
al., 2017; Miller et al., 2010; Schmidt et al., 2015; Zhang et al., 2009). To use this technique for Aβ42 
oligomers, would provide a fundamental understanding of the strucutral features that drive assembly. 
Furthermore a true high resolution structure of oligomers of different sizes would provide an 
explanation for the varying levels of cytotoxicity. Furthermore, using super-resolution microscopy it 
would also be extremely useful to monitor the aggregation of pathogenic amyloid peptides once 
internalised into cells. 
Building on the data presented in Chapter 4, assessing the cytotoxicty of the Aβ42-1 and AβS 
peptides added to cells immediately after preparation (instead of after a 2 hour incubation period), will 
help confirm their reduced cytotoxicity (Figure 4.14) is due to a lack of oligomeric species. The 
sample prepararions at T0 may be more oligomeric than at 2 hours and therefore more cytotoxic. 
Additionally, observing the internaliation of these peptides would also further add to our conclusions 




peptides is seen, this would provide one explanation for the lack of cytotoxicity observed in the 
ReadyProbes assay.  
In Chapter 5, we established the non-cytotoxic effects of AβSon. The next step would be to separate 
the mixture of assemblies by size using low speed centrifugation. This would separate the higher 
molecular weight assemblies present in the sample from the lower molecular weight assemblies, 
essentially providing an ‘oligomer enriched’ supernatent. Establishing the cytotoxicity of this would 
remove the possbility that significant cytotoxicity is not observed in AβSon incubated cells due to the 
lower concentration of oligomer-like species being added, compared to AβO. However, it would be 
expected that these fibrillar oligomer-like species or higher molecular weight fraction would not be 
cytotoxic  due to their parallel β-sheet packing. One difficulty of this, however, would be establishing 
the correct concentration of the oligomer-enriched supernatent and higher molecular weight fraction. 
A possible way in which this could be overcome, would be by calculating the concentration of the 
supernatent using the A280nm intensity and subtracting this from the initial sample preparation 
concentration. Theoretically, this would provide the concentration of the higher molecular weight 
fraction of the centrifuged sample. Amino acid analysis would also be beneficial in establishing an 
accurate concentration.  
It would also be an interesting direction to use similar characterisation of the Aβ sequence containing 
mutations found in FAD. This would provide us with a better understanding as to why some 
mutations cause rapid fibrillisation (e.g. the Dutch mutation) or why more oligomeric species are 
detected in other mutations (e.g. Iowa). It would also provide us with whether these mutations altered 
the kinetics of aggregation or simply produce a larger amount of Aβ42 and therefore more oligomers 
are detected.  
As discussed in Chapter 5, analysis of the morphologyial changes that occur as a result of Aβ42 
internalisation, would be an extremely interesting future direction. By intially increasing the n-number 
of cells imaged, analysis of  factors such as the overall cell morphology and nuclei shape, would begin 




tomography would allow to view the ultra structure of cellular compartments and assess the 
morphological consequences of these as a result of internalised amyloid. Comparing the results of 
AβO, AβF and AβSon using these approaches, will allow us to further determine the effects of size, 
structure and internalisation in amyloid induced celluar dysfunction.   Furthermore, an MTT assay to 
monitor cellular dysfunction would also investigate deleterious effects of AβSon and AβF, despite the 
ReadyProbes assay confirming it is not cytotoxic.    
Interestingly, α-synuclein has been shown to be cytotoxic in its fibrillar form (Pieri et al., 2016). This 
may be due to the uptake of these fibrils and propagation to other cells in a prion-like mechanism 
(Freundt et al., 2012). Transmission of the amyloidogenic tau protein has also been demonstrated 
(Kfoury et al., 2012; Liu et al., 2012). It is therefore likely cell-to-cell transmission of amyloid 
proteins also play an important role in mediating toxicity (Braak & Del Tredici, 2011a; Guo & Lee, 
2014; Jucker & Walker, 2013). Using technqiues such as microfluidic devices to mimic neuronal 
networks (Wu et al., 2016), we could establish the whether propagation is specific to certain primary 
sequences, size or conformation, or similar by-product of normal cell functioning.  
Continuing to address factors that make pathogenic amyloid proteins deleterrious in this way, will 
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